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Summary
Spinal muscular atrophy (SMA) is a common and devastating genetic disease
characterized by degeneration of spinal alpha motor neurons and muscle atrophy. SMA is
caused by homozygous deletions or rarely other mutations of the SMN1 gene, resulting in
a functional loss of the Survival of Motor Neuron (SMN) protein. SMA severity is
determined by a nearly identical copy gene, SMN2, which encodes an identical SMN
protein but produces only ~10% correctly spliced transcripts. Rarely, individuals with
SMN1 deletion are fully asymptomatic, suggesting a protection by other modifying genes.
Identification of these modifiers would allow us to better understand the cellular pathways
affected by SMN deficiency and to develop new therapies.
Here, we report a novel modifier of SMA, Neurocalcin delta (NCALD), that showed a
reduced expression in SMN1-deleted asymptomatic individuals as compared to other
affected family members or unrelated SMA patients. NCALD is a neuronal calcium sensor
mainly expressed in CNS. Further preliminary studies in vitro and in non-mammalian SMA
animal models (C. elegans, zebrafish) have shown that NCALD knock-down ameliorates
SMA-related symptoms. Therefore, we proceeded to study the protective effect of NCALD
suppression in SMA mouse models. First, we followed a strategy of generating an
inducible Ncald knock-down mouse. We identified efficient shRNA sequences that
suppressed NCALD expression and cloned them into the targeting vector, which was
integrated into mouse embryonic stem cells by electroporation. This approach was
discontinued when an Ncaldko/ko mouse line became available at the Jackson Laboratory.
Next, we crossed the Ncaldko allele heterozygously with a severely affected SMA mouse
model and performed extensive phenotypic analysis. Reduced NCALD expression
improved many characteristics related to SMN deficiency, such as axonal length of
cultured motor neurons, size of acetylcholine receptor (AChR) clusters at the
neuromuscular junction and spinal motor neuron circuitry as assessed by the number of
glutamatergic inputs on motor neuron soma. However, due to very low SMN levels, other
internal organs were impaired, which resulted in early death of the SMA mice irrespective
of their NCALD levels. Therefore, we hypothesized that increasing peripheral SMN levels
is needed for the modifier to fully exert its function. Indeed, in SMA-Ncaldko/wt mice injected
with a suboptimal dose of SMN-ASO (antisense oligonucleotides), all characteristics listed
above were reproducibly improved; additionally, also the muscle fiber size was increased.
Unexpectedly, also in this intermediate model the survival of the SMA-Ncaldko/wt+ASO mice
was not rescued, presumably because NCALD is mainly expressed in neurons and unable
to counteract SMN deficiency in other inner organs. Currently, we are performing further
studies of NCALD suppression in an even milder SMA model, which shows only a motoric
impairment but without a shortened lifespan; this model resembles better the phenotype
Xof asymptomatic individuals, who all carry four SMN2 copies and would hypothetically
develop a milder SMA type without compromised survival. Indeed, first results show that
mild SMA mice have an improved motoric behavior upon reduced NCALD levels.
Finally, we anticipated that NCALD suppression would be eligible for a combinatorial
therapy using a mix of ASOs to increase SMN and simultaneously downregulate NCALD.
In collaboration with Ionis Pharmaceuticals (USA), a walk along the Ncald gene was
performed to identify the most efficient Ncald-ASOs. In our laboratory two ASOs were
subsequently tested by intracerebroventricular injections in neonatal mice. While we
achieved a satisfying NCALD knock-down, we encountered some toxicity issues;
therefore, the therapeutic potential of NCALD suppression requires further examination
considering its biosafety and clinical efficiency.
XIZusammenfassung
Zusammenfassung
Spinale Muskelatrophie (SMA) ist eine häufige verheerende genetische Erkrankung, die
durch die Degenerierung von Alpha-Motoneuronen im Rückenmark sowie die Atrophie
von Muskeln gekennzeichnet ist. Die Ursache von SMA sind homozygote Deletionen oder
in seltenen Fällen andere Mutationen vom SMN1-Gen, die zu einem Funktionsverlust des
Survival of Motor Neuron (SMN) Proteins führen. Das Schweregrad der Erkrankung wird
durch ein beinahe identisches Kopiegen bestimmt, SMN2, jedoch werden nur etwa 10%
der SMN2 Transkripte korrekt gespleißt, die dann ein mit SMN identisches Protein
kodieren. Selten zeigen Menschen mit einer SMN1-Deletion keine SMA Symptome, was
einen Schutzmechanismus durch andere modifizierenden Gene vermuten lässt. Die
Identifizierung solcher Modifiergene würde ein besseres Verständnis der zellulären
Prozesse ermöglichen, die durch den SMN-Mangel beeinträchtigt sind, sowie die
Entwicklung neuer Therapieansätze fördern.
Wir berichten hier von einem neuen SMA-Modifiergen, Neurocalcin delta (NCALD), das
eine reduzierte Expression in SMN1-deletierten asymptomatischen Probanden im
Vergleich zu den SMA-kranken Familienmitgliedern sowie nicht verwandten SMA
Patienten zeigte. Weitere vorläufige Studien in zellulären Systemen und einfacheren
Tiermodellen (C. elegans, Zebrafisch) haben gezeigt, dass die Reduktion von NCALD die
Symptome von SMA mildert. Daher haben wir weitere Studien zum protektiven Effekt der
NCALD-Reduktion in SMA Mausmodellen unternommen. Als Erstes verfolgten wir eine
Strategie zur Generierung einer induzierbaren Ncald-Knockdown-Mauslinie. Dafür haben
wir effiziente shRNA-Sequenzen gegen Ncald identiziert und in einen Zielvektor kloniert,
der in embryonale Mausstammzellen mittels Elektroporation integriert wurde. Da jedoch
eine Ncaldko/ko Mauslinie bei dem Jackson Laboratory verfügbar wurde, haben wir diese
Strategie eingestellt. Als Nächstes haben wir dann das Ncaldko-Allel heterozygot mit dem
etablierten schwer betroffenen SMA Mausmodell gekreuzt und eine umfangreiche
Phänotypanalyse durchgeführt. Die Herunterregulierung von NCALD hat mehrere
Merkmale des SMN-Mangels verbessert, z. B. die Axonlänge von kultivierten
Motoneuronen, die Größe der Acetylcholinrezeptoren (AChR) Cluster an der
neuromuskulären Endplatte sowie die spinalen Motoneuronennetzwerke, evaluiert durch
die Zahl der glutamatergischen Inputs auf die Zellkörper der Motoneurone. Die geringe
SMN-Menge führte jedoch zu Defekten in verschiedenen inneren Organe der SMA-
Mäuse, wodurch unabhängig von der NCALD-Expression das frühe Sterben der Mäuse
verursacht wurde. Wir vermuteten daher, dass die Erhöhung der allgemeinen SMN-Menge
nötig wäre, um die vollständige Wirkung des Modifiers zu erlauben. Tatsächlich wurden
alle oben aufgeführten Eigenschaften beständig verbessert, wenn die SMA-Ncaldko/wt
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Mäuse mit einer suboptimalen Dosis vom SMN-ASO (Antisense Oligonukleotid) injiziert
wurden; zusätzlich ist auch die Größe der Muskelfaser gewachsen. Überraschend hat die
Verminderung von NCALD auch in dem intermediären SMA-Mausmodell keine
Verlängerung der Lebenserwartung der SMA-Ncaldko/wt+ASO Mäuse erzielt. Wir
vermuten, dass die durch den SMN-Mangel bedingten Defekte in anderen inneren
Organen durch das überwiegend in Neuronen exprimierte NCALD Protein korrigiert
werden. Es werden zur Zeit Studien von NCALD-Reduktion in einem noch milderen SMA-
Modell durchgeführt, das ausschließlich motorische Defekte, aber keine Beeinträchtigung
der Lebenserwartung zeigt. Möglicherweise spiegelt dieses Modell besser den Phänotyp
der asymptomatischen Probanden wieder, die alle das SMN2-Gen in vier Kopien tragen.
Hypothetisch würde solch ein genetisches Profil im Menschen zu einem milden SMA Typ
ohne Einschränkung der Lebenserwartung führen. Die ersten Ergebnisse zeigen, dass die
NCALD-Reduktion das motorische Verhalten der mild betroffenen SMA-Tiere verbessert.
Letztlich vermuteten wir, dass die Herunterregulierung von NCALD für eine
kombinatorische Therapie geeignet wäre, in der eine Kombination von ASOs einerseits
die Menge von SMN erhöhen und andererseits die von NCALD vermindern würde. In einer
Kollaboration mit Ionis Pharmaceuticals (USA) wurde ein Screen von dem Ncald-Gen
durchgeführt, um die effizientesten Ncald-ASO Sequenzen zu identifizieren. In unserem
Labor wurde dann zwei Ncald-ASOs mittels einer intrazerebroventrikulären Injektion in
neogeborene Mäuse getestet. Während das Ausmaß der Herunterregulierung von NCALD
zufriedenstellend war, erwies sich die Verträglichkeit der ASOs als problematisch. Daher
werden weitere Tests benötigt, um das Therapiepotenzial der Herunterregulierung von
NCALD unter dem Aspekt der Sicherheit und Effizienz zu untersuchen.
1Introduction
1 Introduction
1.1 SMA: clinical pathology, subtypes and genetics
The proximal spinal muscular atrophy (SMA) is after cystic fibrosis the second most
frequent autosomal recessive disease with the carrier frequency of about 1 in 35-40 and
estimated incidence of 1 in 6,000-10,000 (Wirth et al. 2013). First cases of SMA were
described in 1890s by an Austrian physician, Guido Werdnig, and a German physician,
Johann Hoffmann (Werdnig 1891, Hoffmann 1893). The disease pathology is
characterized by progressive neurodegeneration, where the large alpha motor neurons
are lost from the ventral horns of the spinal cord. The remaining motor neurons can show
swollen appearance as effect of chromatolysis and contain phosphorylated neurofilament,
ribosomes or vesicles (Harding et al. 2015).
Neurogenic atrophy of skeletal muscle is another hallmark of the disease that affects
proximal muscles more than the distal ones, the lower limbs more than the upper ones
and intercostal and axial muscle groups more than the diaphragm (Dubowitz 2009).
Muscles of severely affected SMA patients have small, atrophic fibers interspersed with
large, hypertrophic ones; some atrophic fibers are immature with central nuclei. Muscles
fiber of more mildly affected SMA patients show evidence of repeated de- and re-
innervation (Monani and De Vivo 2014).
Muscle wasting was long assumed to be the consequence of motor neuron death,
however, many findings originated from autopsies from severe SMA patients and reflected
more the endpoint stage of the disease, making it difficult to differentiate between the
primary cause and secondary defects. Much insight in the early pathophysiology of SMA
was granted by the studies of SMA animal models, particularly in mice (see 1.3). The
observation that muscle wasting precedes the loss of motor neuron bodies in the spinal
cord led to the discovery of distal defects at the neuromuscular junctions (NMJ) as one of
the earliest effects of low SMN (Kariya et al. 2008). These encompass both morphological
abnormalities: frequently reported accumulation of phosphorylated neurofilament
(Cifuentes-Diaz et al. 2002, Murray et al. 2008), delayed maturation (Kariya et al. 2014),
signs of denervation (Ling et al. 2012), as well as functional changes: impaired
neurotransmitter release (Kong et al. 2009) and altered calcium homeostasis (Ruiz et al.
2010). This distal phenotype was later confirmed in human samples and established SMA
as an axonopathy, where defects begin at the synapse and presumably by a dying-back
mechanism eventually lead to cell death in the spinal cord (Harding et al. 2015). Mouse
2studies unraveled also defects of the glutamatergic synapses that harbour on the motor
neurons in the spinal cord, hinting to an impairment of the entire motor neuron circuitry
(Ling et al. 2010, Mentis et al. 2011). These defects are depicted in Fig. 1.
Fig. 1: The schematic overview of SMA pathology.
In the spinal cord, the SMA hallmarks are loss of spinal motor neurons in the anterior ventral horns, occasional
motor neuron mispositioning (heterotropy) into ventral white matter and reduced number of inputs from
proprioceptive neurons. The abnormalities at the neuromuscular junction involve neurofilament aggregation,
impaired neurotransmitter release and maturation delay. The skeletal muscle of SMA individuals is affected
by muscle fiber atrophy (adapted from (Fallini et al. 2012, Monani and De Vivo 2014).
The clinical presentation of SMA can be highly variable: historically patients were classified
into four classes (types) according to the age of onset and motoric milestones achieved
(Lunn and Wang 2008). These types will be briefly described herein; however, SMA is
nowadays increasingly acknowledged as a clinical continuum, ranging from a very severe
form with onset in utero (Dubowitz 1999) to the very mild form with middle and late onset.
The most severe form affecting ~60% of SMA patients is type 1 (MIM #253300), known
also as Werdnig-Hoffman disease after the doctors who first described it. It is also the most
common genetic cause of infant death (Melki et al. 1994). The patients can be described
as non-sitters, as the majority does not acquire the ability to sit unaided. The first
symptoms usually observed in the first 6 months of life are poor head control, low muscle
tone (hypotonia) resulting in a clinical picture of a “floppy infant”, “frog-leg” position and
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bell-shaped chest due to the weak intercoastal muscles and areflexia. The muscle
weakness is generalized and affects the limb muscles, as well as muscles important for
swallowing and respiration. Unfortunately, the progressive nature of the disease results in
most SMA type 1 patients in a complete loss of movement (paralysis). Previously, the
expected survival did not exceed 2 years, with most patients succumbing to respiratory
dysfunction. However, nowadays the standards of care of SMA type 1 patients have
prolonged the expected survival due to ventilation and nutritional assistance (Oskoui et al.
2007). Still, the clinical trials set the time of a complete dependency on assisted ventilation
as an endpoint equal with the actual death of a patient (Finkel et al. 2014).
In the intermediate type 2 (MIM #253550), affecting ~27% of SMA patients, first symptoms
manifest between 6 and 18 months of age. These patients learn to sit unaided but not to
stand or walk (sitters), and frequently suffer from scoliosis as a result of weak trunk
muscles. They usually reach adulthood but the life expectancy is still reduced (Dubowitz
1964).
Type 3 (MIM #253300), present in ~12% of SMA patients, is a milder form diagnosed >18
months of age. Patients learn to walk independently, though this ability is lost as the
disease progresses and they become wheelchair-bound; however, the life expectancy is
unaffected (Kugelberg and Welander 1956).
Very rarely (in ~1% of patients), SMA shows adult onset in the fourth to sixth decade,
following a normal active early life (Zerres et al. 1995). These individuals are classified as
type 4 (MIM #271150); as all types described above, they suffer from progressive muscle
weakness and can be in need of a wheelchair, but with normal life expectancy.
The high variability of SMA is a direct result of the genetic background of this disorder. The
disease causing gene was mapped to the longer arm of chromosome 5 (Brzustowicz et al.
1990, Gilliam et al. 1990, Melki et al. 1990), and in 1995 the SMN (survival of motor
neuron) gene was identified as absent or mutated in >98% SMA patients from the study
cohort (Lefebvre et al. 1995). Further studies of this genomic region unraveled the
presence of a copy number variant (CNV), which is constituted of two ~500kb repeat units
arranged in an inverted manner; the number of the repeat units may vary from 0-4 on each
chromosome and the entire region is prone to rearrangement and gene conversion. The
telomeric repeat unit contains the evolutionary older SMN1 gene and the centromeric one
– its duplication, SMN2 gene. These genes both encode the same protein, SMN (survival
of motor neuron), and are almost identical except for five silent nucleotides located in the
3’ end of the genes: one in exon 7 (c.840C>T), one in exon 8 (nt 27869 G>A), one in intron
6 (nt 27092 G>A) and two in intron 7 (nt 27289 A>G and 27404 A>G) (Burglen et al. 1996).
4Out of those, the critical change is the c.840C>T transition at position 6 in exon 7 which
disrupts an exonic splicing enhancer (ESE) and abolishes the binding of SF2/ASF (Lorson
et al. 1999); instead, it creates a novel binding site for hnRNPA1 and thus an exonic
splicing silencer (ESS) (Kashima and Manley 2003). As a result, most of the SMN2
transcripts are alternatively spliced so that they lack exon 7 (Lorson et al. 1999). This ∆7
SMN2 mRNA is translated to a truncated SMN protein which does not oligomerize properly
and is rapidly degraded (Lorson and Androphy 2000). Only a small proportion of SMN2
mRNA escapes this defective splicing and gives rise to a functional full-length SMN
protein. The scheme of SMN1 and SMN2 splicing and translation is depicted in Fig. 2.
Fig. 2: The genetic landscape of SMA.
In SMA patients, SMN1 gene is absent or mutated, however, all of them retain one or more copies of the SMN2
gene. SMN2 differs from SMN1 by a C>T transition (in exon 7) that leads to a frequent exon 7 skipping during
splicing of SMN2 pre-mRNA. As a result, most transcripts lack exon 7 and encode a truncated, unstable protein
that is rapidly degraded. Only small proportion of SMN2 transcript carries exon 7 and encode the full-length
SMN protein. Both genes are subject of complex regulation by many cis and trans factors: Two exonic splicing
enhancers within exon 7 are shaded in light grey. Factors promoting exon 7 inclusion are dark grey boxes,
while factors favouring exon 7 skipping are red boxes. The intronic splicing silencer ISS-N1, which is bound
by hnRNP-A1, is shaded red in intron 7, and the antisense oligo preventing hnRNP-A1 binding is highlighted
in yellow. (adapted from (Wirth et al. 2013).
For healthy individuals, who carry at least one SMN1 copy, the majority of their SMN
protein comes from SMN1 and the amount produced from SMN2 is negligible; indeed, 10-
15% of the general population carry no SMN2 gene at all. Classic SMA patients, however,
who lack functional SMN1, are solely dependent on the SMN protein produced from SMN2
gene. Predictably, the SMN2 copy number is inversely correlated with SMA severity as
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are the levels of SMN protein (Feldkotter et al. 2002). Still, this correlation is not sufficient
to predict the clinical severity exclusively from the number of SMN2 copies, especially for
the intermediate types, e.g. three SMN2 copies have been reported for all three types
(Feldkotter et al. 2002). The cause for this variability is first, presence of SMN2 gene
variants that produce more full-length SMN protein (Prior et al. 2009, Vezain et al. 2010),
and second, action of SMN-independent modifiers, as haploidentical siblings of SMA
patients (with the same SMN2 copy number) can show a phenotype of a different severity,
reaching even full rescue (Cobben et al. 1995, Hahnen et al. 1995, Oprea et al. 2008).
1.2 SMN protein
SMN1 and SMN2 genes both encode an identical survival of motor neuron (SMN) protein
which has the length of 294 aminoacids and the molecular weight of 38 kDa. SMN is
ubiquitously expressed and localizes both to the nucleus, where it is frequently found in
structures called Gems, and to the cytoplasm, commonly as part of a large multiprotein
complex together with Gemin2-8 und Unrip2 (Pellizzoni 2007). The housekeeping function
of the SMN complex is the assembly of Sm proteins onto small nuclear ribonucleoproteins
(snRNPs), crucial factors in pre-mRNA splicing (Pellizzoni et al. 1998). Impairment of
snRNP assembly has been shown in SMA mice in correlation to the severity of the
phenotype; furthermore, it was suggested that transcripts necessary for motor neurons
activity are preferentially affected by deficient snRNP assembly (Gabanella et al. 2007).
Numerous attempts have been undertaken to identify these transcripts in order to explain
why motor neurons seem particularly susceptible to low SMN level and thus to prove the
so called “snRNP theory” of SMA, which deems motor neurons as more sensitive to a
global splicing defect: yet, although many splicing changes were detected, it could not be
excluded that these are secondary effects from cellular stress (Zhang et al. 2008).
Alternatively, low SMN could affect the splicing of one or a subset of important motor
neuron-specific genes and thus specifically compromise this cell type: recently, Stasimon
was identified as one such potential neuronal transcript which shows specific splicing
defect when SMN is low and in vivo experiments in Drosophila and zebrafish underlined
the critical role of Stasimon for motor circuit function (Lotti et al. 2012). Recent
technological advances in cell-specific transcriptome analyses combining laser
microdissection with deep RNA sequencing (RNA-seq) revealed dysregulation of many
neuronal genes, such as complete exon skipping in agrin, which is critical for NMJ
maintenance, upregulation of C1, a complement factor promoting synapse pruning, and
downregulation of Etv1/ER81, a transcription factor required for establishing sensory-
motor, in motor neurons from PND1 SMA mice. These early defects of motor neuron
6specific synaptogenesis genes connect the SMN depletion to the hallmark SMA pathology
(Zhang et al. 2013). Another comprehensive RNA-seq study covering multiple tissues in
an SMA mouse model could identify splicing changes in several Ca2+ channel genes,
which might explain disrupted Ca2+ homeostasis observed in SMA (Doktor et al. 2016).
Also many genes associated with mitochondrial bioenergetics were reported to by
dysregulated in SMN deficient motor neurons, which corresponded to increased oxidative
stress, impaired mitochondrial mobility and enhanced fragmentation of mitochondrial
network in these neurons under SMA disease conditions; intriguingly, these deficiencies
occur presymptomatically and may therefore have a role in SMA initiation (Miller et al.
2016).
Other studies found that cytoplasmic SMN localises to axons and growth cones of motor
neurons with some components of the nuclear SMN complex, but in the absence of Sm
proteins, therefore a non-canonical, motor neuron-specific function of SMN was
hypothesized, the “axonal theory”. Evidence for a role of SMN in axons has come from
studies in cultured spinal motor neurons from SMA mice and in zebrafish which both
showed axonal truncation; moreover, reduced amount of ß-actin mRNA and altered
distribution of calcium channels were observed in the growth cones of SMA motor neurons
(McWhorter et al. 2003, Rossoll et al. 2003, Jablonka et al. 2007). Further studies found
reduced axonal localization of other neuronal transcripts in SMA motor neurons (cpg15,
GAP43) and some suggested a general defect of protein synthesis within neuronal growth
cones (Akten et al. 2011, Fallini et al. 2016). In the proposed model SMN is necessary for
the assembly of ribonucleoproteins (mRNP) responsible for the transport and local
translation of axonal mRNAs which are important for axon outgrowth and growth cone
dynamics. SMN deficiency would thus contribute to axon generation and in a dying-back
mode also to muscle denervation and motor neuron cell death (Fallini et al. 2012).
1.3 Animal models of SMA
Studies of animal models contributed greatly to the knowledge of SMA pathomechanism,
although obviously not all characteristics are common between species, even mammals.
When first attempts were undertaken to model SMA as constitutive deficiency of the SMN
protein, soon the human specificity of the disease was revealed: most other species
(except for primates) carry only one Smn gene indispensable for survival as homozygous
whole body knock-out turned out to be embryonic lethal in fly, nematode, zebrafish or
mouse (Schrank et al. 1997, Schmid and DiDonato 2007). These models were made
available for SMA research by careful reduction of SMN protein, e.g. using RNA
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interference or conditional genetic ablation; however, most relevant SMA models for
human studies, particularly for testing of potential therapeutics, are transgenic mouse
lines. A large number of SMA mouse models have been generated in order to
accommodate the variability observed in patients; the most widely used ones will be briefly
described herein. Still, interpretation of animal disease models needs to be performed with
great care and caution, as the severe SMA phenotype in mice is increasingly
acknowledged as a multi-systemic disorder, with involvement of multiple organs, e.g.
brain, heart, liver, pancreas (Hamilton and Gillingwater 2013). At the same time, these
defects have been only sporadically observed in the most severe SMA patients; it is
possible, however, that the full scope of the disease, particularly in the severe type 1
patients, is only beginning to be understood (Shababi et al. 2014).
The mouse genome harbours only a single Smn gene and its complete deletion results in
early embryonic lethality (E8.5), underlining the housekeeping function of SMN protein
(Schrank 2003). Heterozygous Smnko/wt animals do not show gross abnormalities
(unchanged life expectancy), however some studies used these mice as a mild SMA
model of SMA as some neuromuscular changes occur in older animals (Jablonka et al.
2000). To mimic the SMN deficiency in mice, in most models variable numbers of human
SMN2 gene were integrated: two SMN2 copies rescued the embryonic lethality of Smnko/ko
and generated a mouse model phenotypically resembling human severe SMA type 1
(Smnko/ko; hSMN2tg/tg) with a reduced survival of 5 days, while eight SMN2 copies fully
rescued the phenotype (Monani et al. 2000). When an additional transgene, SMN∆7,
which lacks exon 7 and therefore encodes exclusively the misspliced transcript, was
included, the survival was prolonged to 13-15 days, enabling more detailed phenotypic
analysis as well as screening of therapeutics (Le et al. 2005).
Another severe mouse model of SMA (Hsieh-Li et al. 2000) is the so called “Taiwanese”
or Hung mice, as it was generated by the research group of professor Hung Li in Taiwan.
This model combines the knock-out of the endogenous murine Smn gene with a 115 kb
transgene that carries the entire coding region and the flanking sequence of the two
tandem copies of the human SMN2 gene. Importantly, the SMN2 containing transgene is
present in tandem as two copies on one allele. Depending on how many copies of the
transgene are present in Smnko/ko animals, mouse lines of different severity could be
obtained, somehow mimicking the SMA spectrum in humans: the most severe line does
not develop hairy fur and dies before PND10, the intermediate shows variable phenotype
and survives between 2 to 4 weeks and the mildest line reaches adulthood and is fertile,
however it has shortened and later in life also necrotic tail. Of note, this SMA mouse model
8was initially studied on a mixed genetic background and therefore the offspring showed a
large variability in survival.
Our group has established a breeding scheme crossing the mildest line of the Hung mice
Smnko/ko; hSMN2tg/tg (importantly, each hSMN2tg allele carries two tandem copies of the
gene, therefore these mice have four SMN2 copies in total), with heterozygous Smnko/wt
animals (Riessland et al. 2010). All offspring carry one allele with two SMN2 copies, and
can be either homozygous (SMA) or heterozygous (HET) for the Smnko allele. The SMA
animals recapitulate many hallmarks observed in humans, such as diminished NMJs, loss
of spinal motor neurons and muscle atrophy. Additionally, numerous non-neuronal organs
show anatomical abnormalities: heart, lungs and intestine (Schreml et al. 2013). The mean
survival is strongly dependent of the genetic background: while SMA mice on FVB
background survive on average 9.9 days, on C57BL/6 background it is prolonged to 15.5
days (Riessland et al. 2010, Ackermann et al. 2013). It has been shown that genetic
heterogeneity mitigates the severity of the disease phenotype, as crossing mice from two
distinct strains (FVB x C57BL/6N) leads to SMA mice with mixed background which survive
for 19.2 days, which is longer that the mean survival observed at any pure background
(Ackermann et al. 2013).
Being a house-keeping protein involved in a key cellular process, SMN plays an important
role in many cell types, not only in the motor neurons, therefore the question remains,
which tissues need to be targeted therapeutically. As numerous Cre lines have become
available allowing a tissue-specific expression of transgenes, it is now possible to test the
need of SMN independently in various tissues have become possible (Nagy et al. 2009).
It has been shown in mouse models that selective depletion of SMN either in spinal cord
motor neurons or in the skeletal muscle gives rise to SMA symptoms (Cifuentes-Diaz et
al. 2002, Park et al. 2010). Interestingly, a motor neuron-specific ablation of SMN induces
a milder phenotype than a constitutive one, indicating that also other organs contribute to
the overall SMA phenotype. Indeed, also a liver specific SMN deficiency lead to severe
developmental defects that resulted in late embryonic lethality (Vitte et al. 2004).
As SMA presents a significant clinical variability in humans, it would be very helpful to
represent this with a range of SMA mouse models with variable severity of symptoms.
Therefore, numerous attempts to generate genetic intermediate SMA mouse models have
been undertaken: when one allele with the human SMN2 carrying a A2G missense
mutation in exon 1 (identified in SMA patients) was crossed onto the severe Monani model
(Smnko/ko; hSMN2tg/tg; hSMN2A2G/0), the survival was prolonged to ~8 months (Monani et
al. 2003). Another model helped to determine the critical threshold of SMN levels to
prevent the disease symptoms: when an Smn2B allele with a 3 bp substitution in the exon
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7 exonic splicing enhancer (ESE) and 15% of wildtype SMN expression was combined
with the Smnko allele, resulting mice survived for ~4 weeks, while the homozygous Smn2B/2B
were phenotypically normal (Bowerman et al. 2011). Recently another mouse model was
generated that after a survival of ~ 60 days succumbed to sudden cardiac failure, proving
the susceptibility of other organs to SMN deficiency (Bogdanik et al. 2015).
Another approach to obtain an intermediate SMA model would be by administration of
suboptimal doses of compounds that increase SMN levels but do not achieve a complete
rescue: one example of this strategy could prove that the genetic modifier PLS3 is capable
of extending lifespan of SMA mice, provided that sufficient SMN levels are present to
ameliorate severe defects of peripheral organs, such as heart, lung and intestine
(Hosseinibarkooie et al. 2016).
1.4 SMA therapy
There is still no approved therapy for SMA, however, since SMN1 and SMN2 were
identified as the disease causing and modifying genes for SMA, the researchers have not
only learned much about SMA biology but also made great advancements towards finding
a cure. As in SMA the SMN protein is missing, to elevate SMN levels would be the
straightforward therapeutic approach. This requires, however, the establishment of safe
and efficient ways of SMN delivery. This has been achieved by development of new viral
vectors with clinical potential.
As all SMA patients carry the SMN2 gene, which produces low levels of SMN protein,
another promising approach would be to identify pharmacological compounds which
enhance full-length SMN expression from SMN2, either by upregulating transcription or
correcting splicing towards greater proportion of full-length transcript. Many screens of
chemical agents were performed aiming at identification of compounds capable of
increasing SMN. Also neuroprotective agents and muscle function enhancers were
speculated as potential drugs for SMA. In the following, these four classes will be briefly
described; for more detailed review, see (Kaczmarek et al. 2015) .
1.4.1 SMN replacement therapy
In gene therapy, a DNA sequence encoding the full-length SMN protein is delivered to the
SMA patients packaged into modified viral vectors (so called self-complementary adeno-
associated vectors, scAAV) that can reach the target tissues when administered
systemically, e.g. intravenously. A caveat of this method is the necessity of the vectors to
cross the blood-brain barrier (BBB), therefore, great advantage came from a serotype
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scAAV9 that penetrated BBB and transduced effectively spinal motor neurons (Duque et
al. 2009). The first proof-of-concept study showed that exogenous administration of
scAAV9-SMN results in an almost complete rescue of a severe SMA mouse model;
furthermore, the therapeutic window of this intervention was characterized: while the gene
delivery on PND1 rescued neuromuscular pathologies and the survival, delaying the
intervention till PND5 resulted in a partial phenotype correction, and little improvement was
observed when SMN-scAAV9 was administered on PND10 (Foust et al. 2010). This
therapeutic approach proceeded fast to clinical trials (ClinicalTrials Identifier:
NCT02122952).
1.4.2 Compounds increasing SMN by enhancing protein stability or SMN2 transcription
First class of drugs extensively studied for SMA therapy were histone deacetylase
inhibitors (HDACIs). The acetylation status of histones, core chromatin proteins, is crucial
for epigenetic regulation of gene expression: inhibition of histone deacetylation can
increase in a non-specific manner the transcription of many genes, also SMN2. Numerous
HDACIs have been reported to increase full-length SMN2 transcripts in fibroblasts from
SMA patients and SMA mouse models: short-chain fatty acids VPA, sodium butyrate and
phenylbutyrate, as well as hydroxamic acids LBH589, SAHA, TSA, JNJ-26481585 and the
benzamide M344 (Sumner et al. 2003, Riessland et al. 2006, Avila et al. 2007, Garbes et
al. 2009, Riessland et al. 2010, Schreml et al. 2013). Some HDACIs showed motor function
and survival improvement in SMA mouse model, however, the transition to human trials
was not very successful, as frequently no or at best moderate improvement could be
observed (Mercuri et al. 2007, Swoboda et al. 2009, Swoboda et al. 2010). A potential
cause for these apparently disappointing results could be variable responsiveness of the
treated patients to the HDACIs as those who were classified as responders indeed showed
positive impact of the treatment (Garbes et al. 2009).
SMN levels could also be enhanced by increasing the protein stability: as SMN is degraded
by ubiquitin proteasome system, its inhibition could potentially increase SMN in SMA
patients. Indeed, bortezomib, an FDA-approved proteasome inhibitor, ameliorated motor
phenotype in SMA mice (Burnett et al. 2009). Also aminoglycosides, antibiotics that
promote the read-through of the stop codon in exon 8 of SMN2, were reported to stabilize
SMN protein in patients’ fibroblasts and moderately improved the phenotype of SMA mice
(Mattis et al. 2009). Other non-HDACI compounds that were shown to increase SMN levels
were: hydroxyurea, beta-adrenergic agonists albuterol and salbutamol tested in patients
cell lines, and quinazoline, prolactin, activators of p38 (celecoxib, BAY 55-9837) and
NMDA receptor activators tested in SMA mouse models (Grzeschik et al. 2005, Angelozzi
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et al. 2008, Biondi et al. 2010, Farooq et al. 2011, Farooq et al. 2013, Hadwen et al. 2014).
Particularly noteworthy are small-molecule splicing modifiers SMN-C1, -C2 and -C3,
developed by PTC Therapeutics, that led to an impressive survival rescue in severe SMA
mice from 14 days to >6 months (Naryshkin et al. 2014); however, the clinical trials of
these substances were suspended as some long-term safety concerns came up in animal
studies.
1.4.3 Correcting SMN2 splicing using antisense oligonucleotides (ASOs)
A strategy that is currently likely the most advanced towards an SMA-specific, FDA
approved therapy is splicing correction of SMN2 by antisense oligonucleotides. These
active compounds benefited greatly from the elucidation of the complex cis and trans
regulation of exon 7 inclusion or skipping in SMN1/2 genes as depicted in Fig. 2. This
allowed the identification of a tandem motifs hnRNP A1/A2 in intron 7, which constitute a
potent intronic splicing silencer (ISS). Blocking this ISS by sequence-complementary
ASOs resulted in enhanced production of full-length SMN in patients’ cell lines and in mice
carrying the SMN2 transgene (Hua et al. 2008, Singh et al. 2009). The mechanism of
action of these SMN-ASO in order to promote exon 7 inclusion is depicted in Fig. 3.
Once the suitable locus for SMN-ASO treatment was identified, many following studies in
vivo attempted to optimize the ASO chemistry and delivery route (Porensky et al. 2012,
Zhou et al. 2013). Unexpectedly, the greatest survival rescue of a severe SMA mouse
model was achieved by systemic administration of SMN-ASO while the positive impact of
a CNS-specific intracerebroventricular ASO injection was significantly smaller, suggesting
the importance of peripheral SMN restoration for a long-term survival rescue (Hua et al.
2011, Passini et al. 2011). The company Ionis Pharmaceuticals who cooperated with the
researchers in the former study launched Phase I (NCT01494701, completed) and
numerous Phase II clinical trials of the ASO currently under the name nusinersen
(previously ISIS-SMNRx) which brought very promising results, so that Phase III trials soon
followed. Very recently, Ionis Pharmaceuticals and their partner Biogen announced that a
Phase III trial (NCT02193074) has shown an acceptable safety profile and significant
improvement of treatment in type 1 SMA infants and is ready for filing FDA approval, which
would make nusinersen the first drug ever approved and developed specifically for SMA
(Biogen and Ionis Pharmaceuticals 2016). Understandably, this announcement raised
hope and excitement in the community of both researchers and patients.
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Fig. 3. The mechanism of action of SMN-ASO.
Single-stranded ASOs interact with proteins at the cell membrane and are taken up by endocytosis. In the
cytoplasm they escape the endosome and enter the nucleus, where they bind to the SMN2 pre-mRNA and
disable the binding of hnRNP, which normally suppresses exon 7 splicing. In the presence of ASO, exon 7
inclusion in the SMN2 transcript is promoted and subsequently the production of full-length SMN protein is
enhanced (courtesy of Frank Bennett, Ionis Pharmaceuticals, Carlsbad, California).
1.4.4 SMN-independent therapeutics: neuroprotective agents
Increasing SMN levels has not been the only therapeutic strategy to counteract SMA:
numerous compounds with a neuroprotective mode of action have been tested, building
on the research of other neurodegenerative disease, e.g. amyotrophic lateral sclerosis.
Olesoxime (TRO01922) has been identified in a screen of rat motor neurons as a
compound that most potently promoted the motor neuron survival; the neuroprotective
function is presumably mediated by inhibition of mitochondrial permeability transition pore
complex (mPTP) at the mitochondrial membrane (Bordet et al. 2007). The positive effect
of olesoxime could be recapitulated in vivo in a model of motor neuron degeneration and
also a Phase II clinical trials in SMA patients (NCT01302600) has shown positive results.
Another neuroprotectant riluzole restored the outgrowth defects in SMN deficient cells,
likely through activation of small conductance Ca+ activated K+ channels; furthermore, it
improved the phenotype in SMN-deficient C.elegans and mouse models (Haddad et al.
2003, Dimitriadi et al. 2013).
Actin cytoskeleton dynamics has emerged as a pathway impaired by SMN deficiency
(Oprea et al. 2008, Bowerman et al. 2009, Nolle et al. 2012). One of its hallmark is an
aberrant expression profile of the actin stabilizer profilin IIa and an overactivation of the
small GTPase protein RhoA, observed in SMN deficient cell lines and in the intermediate
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Smn2B/KO mice (Bowerman et al. 2007). Therefore, compounds that would inhibit RhoA
kinase (ROCK) and thus prevent the RhoA overactivation were speculated as SMA drugs:
Y-27632 and Fasudil increased the lifespan, improved NMJ maturation and muscle fiber
size in the Smn2B/KO mice (Bowerman et al. 2010, Bowerman et al. 2012). Notably, both
compounds also act systemically and could improve not only motor neuron phenotype, but
also heart physiology and glucose metabolism (Coque et al. 2014).
All therapeutic strategies for SMA discussed above are depicted in Fig. 4.
Fig. 4: SMA therapy strategies with their specific target site in an exemplary motor neuron.
BAY 55-9837, an agonist of the VPAC2 receptor in the plasma membrane, activates the p38 pathway.
Olesoxime inhibits mPTP opening in mitochondria and acts neuroprotectively. Quinazolines prevent SMN2
mRNA decapping by inhibiting the scavenger enzyme DcpS. Aminoglycosides increase the probability to
read through a stop codon in exon 8 of SMN2. ROCK inhibitors Fasudil and Y-27632 have a neuroprotective
effect. Riluzole acts neuroprotectively by activating SK (small conductance Ca+-activated K+) channels in the
cell membrane. HDAC inhibitors increase FL-SMN2 levels. Viral gene therapies (particularly scAAV9) are
able to deliver SMN1 DNA in the cell nucleus. ASOs, salbutamol and PTC SMA C1-C3 act as splicing
modulators promoting FL-SMN expression. Quercetin prevents accumulation of β-catenin. Bortezomib
increases SMN levels by inhibiting proteasomal degradation (adapted from (Kaczmarek et al. 2015).
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1.5 Modifier genes in SMA
It is meanwhile widely accepted that seemingly simple Mendelian traits which result in
genetic disorders can have phenotypes varying in features such as age of onset, severity,
etc. One cause of these variable phenotypes, apart from obvious environmental factors,
can be modifier genes (Nadeau 2001). SMA itself is a prominent example of such
modification by the SMN2 gene.
Genetic modification occurs when expression of one gene (the modifier) alters the
phenotypic manifestation of the target gene. The modification can occur at the level of
gene expression (when the modifier induces the up- or downregulation of the target gene)
or at any other level: molecular or cellular (when protein interactions or entire signaling
pathways are changed), to the end phenotype at the organ, system or whole organism
level. Studies of genetic modifiers can be therefore a powerful tool to find both direct and
indirect interactions.
As some mechanisms that affect SMN expression were already discussed, this part will
focus on SMN-independent genetic modifiers of SMA.
1.5.1 Identification of SMA modifiers in model organisms and biochemical screens
For the identification of genetic modifiers, the invertebrate SMA models: nematode C.
elegans and fruitfly D. melanogaster proved particularly useful as many established
genetic tools enabled high-throughput screenings which would not be possible in higher
organisms. In Drosophila a screen with a collection of annotated transposons (Exelis)
uncovered >25 novel modifiers, among them players in conserved signaling pathways:
FHF (fibroblast growth factor), NHR (nuclear hormone receptor) and BMP (bone
morphogenetic protein) (Chang et al. 2008). A follow-up large-scale screen complemented
with protein interaction studies and bioinformatics analysis uncovered an interactome of
>300 genes altering the Smn-dependent phenotype in vivo (Sen et al. 2013). Another
screen in C. elegans aimed at the identification of cross-species SMA modifiers by re-
testing those found in Drosophila, and vice versa (Dimitriadi et al. 2010).
SMA is undoubtedly a disease of SMN deficiency, however, it is still unclear what function
(s) of SMN protein are responsible for the major neuromuscular pathology. To better
understand the cellular consequences of low SMN levels, biochemical screens have been
performed using libraries of annotated compounds and samples from SMA mice were
subjected to a proteomic analysis (Makhortova et al. 2011, Wishart et al. 2014).
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In summary, the modifiers identified with the aforementioned screens unraveled the
following pathways to be dysregulated in SMA: cytoskeleton actin dynamics, synaptic
vesicle trafficking and neurotransmission, axonal transport and local translation, and
control of gene expression (reviewed in (Wirth et al. 2016).
1.5.2 Identification of SMA modifiers in asymptomatic SMN1-deleted relatives of SMA
patients
A rare, but very powerful approach to identify SMA modifying genes are studies of
asymptomatic human subjects, when genetic testing of SMA families uncovers relatives
who carry homozygous SMN1 deletion, yet without any disease symptoms. Our
hypothesis is that the protective phenotype of these unaffected individuals is mediated by
modifier genes, which by different expression levels (up- or downregulation) are able to
counteract the SMN deficiency and prevent the disease phenotype. Using this strategy,
our group has previously identified Plastin 3 (PLS3) as the first fully protective SMA
modifier in six unrelated SMA families with haploidentical patients and their unaffected
siblings: an mRNA microarray analysis detected a 40fold PLS3 upregulation in
lymphoblastoid cell lines from the latter. Plastin 3 is an F-actin bundling protein with two
EF-hands for Ca+ binding. Functional studies revealed that PLS3 overexpression rescued
the axonal outgrowth defect both in vitro in cultured motor neurons derived from SMA mice
and in vivo in Smn-deficient zebrafish (Oprea et al. 2008). Final proof of the protective
effect mediated by high PLS3 levels came from mouse studies: when PLS3 was
overexpressed in the severe SMA mouse models (Taiwanese and SMN∆7), no survival
improvement could be observed, presumably due to dysfunction of multiple organs related
to very low SMN levels (Ackermann et al. 2013, McGovern et al. 2015). However, already
in a slightly milder SMA mouse model (with a mixed genetic background) PLS3
overexpression showed a moderate effect on survival, induced a stronger motor
performance and improved neuronal connectivity, which was visible both in the
morphological and electrophysiological qualities of the NMJs (Ackermann et al. 2013).
Notably, when PLS3 transgene was overexpressed homozygously in an intermediate
ASO-mediated SMA model, which showed a mean survival of 28 days, the lifespan was
prominently rescued and reached >250 days in 60% of animals (Hosseinibarkooie et al.
2016). This study underlined the importance of intermediate SMA mouse models, which
faithfully recapitulate the variable disease severity observed in humans: as all unaffected
individuals carried three or four SMN2 copies, most probably they would not present with
the severe SMA type, but rather the intermediate range (type 2 or 3). Mechanistically,
PLS3 and its interaction partner CORO1C ameliorate the SMA phenotype by enhancing
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endocytosis which has recently emerged as an important cellular process impaired in SMA
(Hosseinibarkooie et al. 2016).
1.5.3 Neurocalcin delta – a novel potential modifier for SMA in humans
The foundation of the work presented in this thesis was the identification of Neurocalcin
delta (NCALD) as a novel putative modifier gene for SMA (see chapter 2.1). In humans
Neurocalcin delta (NCALD) gene is located on the antisense strand of chromosome
8q22.3 and spans the length of ~437 kb. The NCALD mRNA is transcribed from the
antisense strand and >30 isoforms of variable length have been reported. The main
isoform is 2289 bp long and includes 7 exons, however only 3 exons are protein-coding,
as the starting codon is located in exon 5. While the 3’UTR of the transcript is remarkably
long (>1500 bp), the coding sequence has the length of only 579 bp and gives yield to a
small protein of 193 aminoacids and molecular weight of ~20-22 kDa.
Neurocalcin delta (NCALD) belongs to a conserved protein family of neuronal calcium
sensors (NCS). Biochemically, the NCS proteins do not possess an intrinsic enzymatic
activity but transduce Ca2+ signals to their downstream effectors.  These are likely specific
for each NCS protein, which would partially explain the non-overlapping functions of NCS
proteins despite a high sequence and structure homology (Burgoyne and Haynes 2015).
Other factors which regulate the specificity of NCS proteins are their tissue-specific and
subcellular localization, Ca2+ affinity and kinetics. These characteristics enable the NCS
proteins to integrate Ca2+ signaling spatially, temporally and over a wide range of
concentrations (Haynes et al. 2012). Common for all NCS protein is the presence of four
calcium-binding EF-hands domains. However, the EF-hand domain 1 is inactive in all NCS
proteins and the EF-domain 4 is active only in some of them (Braunewell and Klein-Szanto
2009). Structurally, NCALD posseses an N-terminal myristoylation moiety that determines
the protein localization. At low intracellular calcium concentration, the myristoyl group is
contained within the protein structure and NCALD is mainly cytosolic; however, when
calcium levels are elevated, the myristoyl group is exposed to the outside and NCALD can
associate to the membranes, also of the trans-Golgi compartment (Burgoyne 2007).
Interestingly, when cytosolic Ca2+ was elevated by ionomycine treatment, NCALD
colocalized with clathrin, a key component of the cellular endocytotic machinery,
particularly strongly in the trans-Golgi network; as their interaction could be confirmed with
biochemical methods, this suggested a possible role of NCALD in the regulation of the
transport of clathrin-coated vesicles (Ivings et al. 2002).
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Functionally, little is known about NCALD: SNPs in NCALD were identified in a number of
GWAS studies as potentially involved in susceptibility to bipolar disorder and dietary fat
intake (Xu et al. 2014, Rudkowska et al. 2015). It has also been linked to few forms of
cancer in lung, ovaries and prostate (Isaksson et al. 2014, Roudier et al. 2016, Shi et al.
2016). In humans, a deletion of the NCALD region was associated with epilepsy and
intellectual disability (Kuroda et al. 2014). Recent studies have also found differential
NCALD expression in mice lacking paraoxonase (Pon1), a gene linked to the Alzheimer’s
disease (Suszynska-Zajczyk et al. 2014), as well as in a rat model of schizophrenia
(Vercauteren et al. 2007).
Hippocalcin (HCPA) is a more studied member of NCS family that has shown some
functional similarity with NCALD: both were implicated as involved in the activation of the
slow calcium-activated afterhyperpolarizing current (Villalobos and Andrade 2010). An
Hpca knock-out mouse line has shown impairment in spatial and associative memory
(Kobayashi et al. 2005). Interestingly, recently genetic mutations in HPCA in humans were
reported to cause autosomal-recessive primary isolated dystonia, a disorder characterized
by movement impairment and frequently accompanied by tremor. Functional studies could
show that HPCA reduction in cortical neurons and astrocytes severely altered their
response to physiological stimuli: the neurons showed no Ca2+ rise in response to
membrane depolarization by KCl and a lower amplitude in response to glutamate, while
astrocytes showed a diminished amplitude under ATP stimulus (Charlesworth et al. 2015).
The possible interpretations of these results would be that HPCA deficiency alters the
maintenance of membrane potential and in consequence the cellular response to
membrane depolarization, or that it inhibits voltage-dependent Ca2+ channels. However,
also opposing functions of hippocalcin and neurocalcin have been reported: while the
reduction of the former had a detrimental effect on neuronal outgrowth (Oh et al. 2008), a
similar effect was achieved by NCALD overexpression (Yamatani et al. 2010).
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2 Preliminary results
2.1 NCALD is downregulated in asymptomatic SMN1-deleted individuals
The indication that Neurocalcin delta may be a novel SMA modifier originated from the
diagnostics of a four-generation SMA family from Utah (USA), with two SMA type I patients
carrying two SMN2 copies (pedigree depicted in Fig. 5). Surprisingly, in two generations
five relatives were identified who carried homozygous deletion of SMN1 and four copies
of SMN2, which would normally predestine a milder SMA type, however, these individuals
remain fully asymptomatic. Under the assumption that the protective phenotype stems
from a common genetic modifier (as it was inherited across generations), the family was
tested using a dual approach combining data from an mRNA expression microarray and
an Affymetrix SNP array (Applied Technologies). The SNP analysis showed that regions
on chromosomes 1-3, 5, 8, 13 and 18 co-segregated in all five unaffected individuals but
not in the SMA patients. Cross-reference to the mRNA expression results showed that
Neurocalcin delta (NCALD) was the single gene identified by both approaches. NCALD
showed a 4-5fold downregulation in the five unaffected individuals when compared to their
two SMA type 1 relatives and to the control group of unrelated SMA patients with the same
SMN2 copy number (Riessland et al. under review).
Fig. 5: Pedigree of the family with NCALD reduction in asymptomatic individuals.
SMA type I patients are marked with black filled symbols, asymptomatic SMN1-deleted individuals with grey
filled symbols and carriers heterozygous for SMN1 deletion with dotted symbols. The numbers below the
symbols represent the number of SMN2 copies in the given individual.
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As the unaffected members of the Utah family showed a common phenotype of lower
NCALD levels, which co-segregated with the asymptomatic phenotype, we hypothesized
that NCALD reduction rescues the SMA symptoms. To test the hypothesis, NCALD
depletion was first analyzed in various cellular and non-vertebrate animal models.
2.2 NCALD reduction rescues SMA phenotype in vitro and in vivo across species
The first functional analyses performed by Markus Rießland, a postdoctoral fellow in Wirth
lab, showed that NCALD reduction ameliorates SMA symptoms in cellular SMA models
and in smn-deficient zebrafish. In vitro studies were performed in primary motor neurons
from SMA mice, which showed shorter axons in comparison to HET controls; concurrent
NCALD depletion by siRNA rescued the impaired axonal outgrowth (Fig. 6a). In zebrafish,
smn deficiency resulted in truncated axons, which were restored by concomitant ncald
depletion; additionally, enhanced axonal branching was observed (Fig. 6b). In
collaboration with Anne C. Hart (Brown University), the effect of Ncald depletion in the
Smn-deficient nematode C.elegans was tested: while Smn deficiency lead to impaired
pharyngeal pumping, concomitant Ncald depletion improved this phenotype (Fig. 6c).
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Fig. 6: NCALD reduction ameliorated neuronal outgrowth defects mediated by SMN deficiency.
a) Primary motor neurons (MNs) from SMA mice show significantly shorter axons than MNs from HET controls.
Reduction of NCALD by siRNA mediates a rescue of the axonal outgrowth defects in vitro. b) In zebrafish
morpholino-mediated (MO) smn depletion leads to truncation of spinal axons (white arrows). Concomitant
ncald depletion by smn+ncald MO rescues axon truncation and increases branching (white arrowheads). c)
ncald reduction rescued pharyngeal pumping defect in C. elegans (Riessland et al. under review).
Siginficance was determined with the two-tailed student’s t-test. n.s. not significant, **P<0.01, ***P<0.001.
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3 Aim of the study
SMA is a Mendelian genetic disease, inherited in an autosomal recessive manner. SMA is
caused by homozygous deletions or rarely other mutations of SMN1. In rare cases SMN1-
deleted individuals remain asymptomatic, despite carrying only three or four SMN2 copy
genes, which in general are insufficient to compensate for the lack of SMN1 (Hahnen et
al. 1995, Cobben et al. 1996). These naturally occurring events suggest a protection
through other genetic modifiers. Plastin 3 (PLS3) has been identified as a first fully
protective SMA modifiers in humans (Oprea et al. 2008). The protection was validated in
various SMA animal models: in nematode, fruitfly, zebrafish and mouse (Oprea et al. 2008,
Dimitriadi et al. 2010, Ackermann et al. 2013, Hosseinibarkooie et al. 2016).
Preliminary work in our laboratory identified Neurocalcin delta (NCALD) as a novel
protective SMA modifier. NCALD showed reduced expression and linkage to chromosome
8 in five SMN1-deleted asymptomatic members of an SMA family.  As NCALD knock-down
showed a positive effect on the SMA-like phenotype in cell lines and in non-mammalian
animal models, we aimed to verify the impact of NCALD reduction in SMA mouse models.
Notably, the SMA mouse models recapitulate many characteristics of the human
phenotype, which can be analyzed upon a therapeutic intervention or a genetic
modification, as described here. The aims of this thesis were the following:
1. Generation of a new inducible Ncald knock-down mouse line using the shRNA
strategy proposed in (Kleinhammer et al. 2011) and crossing with the SMA mouse
model, followed by a detailed analysis.
2. Since a constitutive Ncaldko/ko mouse line became available in 2014 at the Jackson
Laboratory, we changed our strategy and used the heterozygous Ncaldko/wt as a
model for NCALD reduction. As SMA is a clinically variable disorder depending on
the genetic constitution of the patient (mainly on the SMN2 copy number),
subsequently we will study the effect of reduced NCALD in two SMA models of
different severity: one severe (Hsieh-Li et al. 2000) and one intermediate (Hua et
al. 2011, Hosseinibarkooie et al. 2016). For the latter, SMN-ASO will be injected at
a suboptimal dose to moderately prolong survival.  Both models will be subjected
to a detailed in vivo and ex vivo analysis to delineate the effect of reduced NCALD
on the organs primarily affected in SMA. In vivo studies will include survival, weight
monitoring and motoric tests. Ex vivo analysis will include expression analysis,
microscopic evaluation of MNs and NMJs as structures impaired in SMA, as well
as histochemical studies of skeletal muscles and intestine as peripheral organs
with reported defects in SMA mice (Ackermann et al. 2013, Schreml et al. 2013).
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Also primary motor neurons from embryonic spinal cord will be cultured and
analyzed.
3. Since NCALD reduction is anticipated to have a direct therapeutic potential, in
collaboration with Ionis Pharmaceuticals we will generate Ncald-ASOs and test
them in vivo in SMA mice.
The findings of these studies will provide first insights into the effect of NCALD suppression
in mammalian models of SMA, showing both its advantages and possible caveats. The
studies of modifier genes can be of great importance for understanding the molecular
mechanism of disorders and especially for designing therapeutic strategies.
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4 Materials and methods
4.1 Materials
4.1.1 Laboratory equipment
Analytical balance AX2202M Ohaus
Analytical balance (fine scale) ARJ 120-4M Kern
Bacterial incubators Innova 44 New Brunswick Scientific
Innova 4230 New Brunswick Scientific
Bioruptor Diagenode
Cell incubator Heracell™ 150 Heraeus
Cell culture hood Herasafe™ KS 12 Heraeus
Centrifuges AllegraX22-R Beckmann Coulter
Avanti J-20XPI Beckmann Coulter
5415R Eppendorf
5415D Eppendorf
5804 Eppendorf
Concentrator 5301 Eppendorf
Galaxy Mini VWR
Cryostat CM3050 S Leica
Electrophoresis chambers
Agarose gels MGV-620T C.B.S & Scientific
SGE-020-02 C.B.S & Scientific
E-H6 Febicon
SDS-PAA gels Mini-Protean 3 cell Bio-Rad
Electroporation cuvettes GP cuvettes, 0.4 cm Bio-Rad
Electroporation system Gene pulser Xcell Bio-Rad
Embedding module EG1150 H Leica
Fibre optic light source KL 1500 LCD Leica
Gel documentation ChemiDoc XRS Bio-Rad
Heating block HTMR132 HLC Bio Tech
Heating magnetic stirrer MR 3001 Heidolph
Horizontal shaker 3015 GFL
Homogenizer Precellys 24 Peqlab
Microplate reader Safire2 Tecan
Microscopes
Bright field Axioskop 2 Zeiss
Fluorescent AxioImager.M2 Zeiss
Apotome Zeiss
Inverted DMIL Leica
Stereo S8 AP0 Leica
VisiScope SBL 350 VWR
Microscope cameras AxioCam MRm Zeiss
AxioCam ICc 1 Zeiss
AxioCam ERc 5s Zeiss
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Microtome RM2255 Leica
Microwave R-898 (AL)-A Sharp
Neubauer chamber 1100000 LO Laboroptik Ltd
pH meter inoLab pH level WTW
Photometer BioPhotometer Eppendorf
Photometer NanoDrop 1000 Peqlab
Pipettes
Research 2.5/10/20/200/1000 µl Eppendorf
Automatic Research Pro (10/100 µl) Eppendorf
Repetitive Multipette Plus Eppendorf
Pipettor Easypet Eppendorf
Power supplies PowerPac™ Basic/HC/1000 Bio-Rad
Real-time thermocycler 7500 RealTimePCR System Applied Biosystems
Rotating wheel
Roller mixer SRT9 Stuart
RM5 Hartenstein
Thermocyclers DNAengine Dyad/Tetrad MJ Research
C1000 Touch Bio-Rad
S1000 Bio-Rad
Tissue processor ASP300 Leica
Vacuum pump PM126040-026.3 Biometra
Vortex 444-1372 VWR
Water bath 1083 GFL
Water bath FBC 620 Fischer Brand
4.1.2 Mouse work equipment
Ear tag applicator 1005-s1 National Band & Tag Co.
Ear tags 1005-1 National Band & Tag Co.
Forceps BD047R Aeskulap
FM002R Aeskulap
Dumont #55 Fine Science Tools
Heating pad 76084 Trixie
Microliter syringe (5 µl) 75 N SYR Hamilton
Operating scissors BC 321R Aeskulap
BC 341R Aeskulap
Student Vannas Spring Scissors FD012R Fine Science Tool
4.1.3 Chemicals
If available, chemicals used in this work had the purity grade “pro analysis”.
β-Mercaptoethanol (99%, p.a) AppliChem
2-Propanol (≥ 99.5%) AppliChem
Acetone AppliChem
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Agarose Sigma
Ammonium persulfate AppliChem
Ampicillin AppliChem
Bacto Agar AppliChem
Bovine serum albumin (BSA) Sigma
Bromophenol blue AppliChem
Coomassie Brilliant Blue R-250 AppliChem
Dimethyl sulfoxide Sigma
Doxycycline hyclate Sigma
Eosin Y (acidic) Sigma
Ethanol (≥ 99.5%, p.a.) AppliChem
Ethidium bromide (1% in H2O) AppliChem
Ethylenediaminetetracetic acid (EDTA) AppliChem
Glycerol (86%, p.a.) AppliChem
Glycine AppliChem
Hematoxylin Sigma
Hydrochloric acid (37%) AppliChem
Hydroxymethylaminoethane (Tris) AppliChem
Kanamycin AppliChem
Methanol (≥ 99.9%, p.a.) AppliChem
Milk powder (low fat) AppliChem
Mowiol Sigma
Paraformaldehyde Fluka
Sodium chloride (p.a.) AppliChem
Sodium dodecyl sulfate (SDS) AppliChem
Sucrose AppliChem
TBE buffer (10x) AppliChem
Tetratmethylenediamine (TEMED) AppliChem
Triton X-100 AppliChem
Trizma base Sigma
Tryptone (microbiology base) AppliChem
Tween-20 AppliChem
Water (HPLC grade) Sigma
Yeast extract (microbiology grade) AppliChem
4.1.4 Reagents
4.1.4.1 Reagents for molecular biology
10x PCR master mix New England Biolabs
AquaPlus Mix 40% (29:1) Acrylamide AppliChem
Bradford reagent AppliChem
Complete Mini Protease Inhibitors Roche
DNA ladder (100bp/1kb) Life Technologies
dNTPs Peqlab
Horse serum Life Technologies
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Page Ruler Prestained Protein Ladder Thermo Fisher Scientific
PBS (10x) Roche
Ponceau S Sigma
Restore Western Blot Stripping Buffer Sigma
RIPA buffer Sigma
Super Signal West Pico ECL Substrate Thermo Fisher Scientific
4.1.4.2 Cell culture reagents and media
1x PBS Dulbecco, w/o Ca2+, Mg2+ Life Technologies
B-27 Supplement (50x) (#17540) Life Technologies
β-mercaptoethanol 1000x (ME) (#31350-010) Life Technologies
Amphotericin B Promocell
Brain derived neurotrophic factor (BDNF) Peprotech
Cilliary neurotrophic factor (CNTF) Peprotech
DMEM (+ 4.5 g/L D-Glucose, +L-Glutamine) Life Technologies
+Pyruvate) (#11995-065)
DNAse I (2000 U/ml) New England Biolabs
Fetal Calf Serum (FCS) Biochrom AG
Gelatin (2%) Sigma
Geneticin (G418-Sulfate) Life Technologies
Glial cell-line derive neurotrophic factor (GDNF) Peprotech
HEPES Life Technologies
Leukemia inhibitory factor 1000x (LIF) Millipore
Lipofectamine® 2000 Life Technologies
Mitomycin C (MMC) Sigma
Neurobasal® Medium (1x) (#21103) Life Technologies
Non-essential amino acids 100x (NEAA) Life Technologies
OptiMEM® (1x) (#31985) Life Technologies
Penicillin/Streptomycin Life Technologies
Poly-D-Lysine Applichem
Pansera ES PAN-Biotech
Trypsin/EDTA Life Technologies
Trypsin Worthington
4.1.5 Kits
Power SYBR Green Master Mix Thermo Fisher Scientific
NucleoSpin Gel and PCR Clean-up Macherey Nagel
PureYield Plasmid Miniprep System Promega
PureYield Plasmid Midiprep System Promega
QuantiTect Reverse Transcription Kit QIAGEN
RNeasy Mini Kit QIAGEN
RNase-free DNase I Set QIAGEN
pcDNA3.1/CT-GFP-TOPO TA Expression Kit Thermo Fisher Scientific
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4.1.6 Enzymes
AscI New England Biolabs
BscBI New England Biolabs
Platinum Taq DNA Polymerase High Fidelity Life Technologies
RNase A Life Technologies
RNase-free DNase I QIAGEN
T4 DNA ligase Promega
4.1.7 Antibodies
4.1.7.1 Primary antibodies and staining reagents
α-Actin beta, HRP-conjugated, mouse Proteintech
Rhodamine-labeled Bungarotoxin Thermo Fisher Scientific
α- Choline Acetyltransferase (ChAT), goat Millipore
α-GFP, mouse Biochemistry, University of
Cologne
α-HB9/HLXB9, rabbit Abcam
α-Neurocalcin delta, rabbit Proteintech
α-Neurofilament M, rabbit Millipore
α-Neurofilament, mouse (2H3-c) Hybridoma Bank
α-Survival Motor Neuron, mouse BD Transduction Lab.
α-Synaptic Vesicle 2, mouse (SV2-c) Hybridoma Bank
α-Tau, mouse Santa Cruz
4.1.8 Secondary antibodies
HRP-conjugated goat α-mouse IgG Dianova
HRP-conjugated goat α-rabbit Cell Signaling
Goat α-mouse Alexa 488 IgG (NMJ staining) Thermo Fisher Scientific
Donkey α-rabbit Alexa 488 (Vglut1, HB9) Thermo Fisher Scientific
Donkey α-goat Alexa 568 IgG (ChAT) Thermo Fisher Scientific
Goat α-mouse Alexa 568 IgG (tau) Thermo Fisher Scientific
4.1.9 Solutions and media
4.1.9.1 Cell culture media
All cell culture media was stored at 4°C. MMC-solution and Doxycycline solution were
aliquoted and stored at -20°C.
Common media (for MEF, HEK293T and NSC34 cells)
DMEM 500 ml
FCS 50 ml
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Pen/Strep (10 U/ml) 7 ml
Amphotericin B (250 µg/ml) 1.25 ml
Doxycycline solution (10 mg/ml)
Doxycycline 1 g
1x PBS 100 ml
 aliquot and store at -20°C
Embryonic stem (ES) cell media
DMEM 500ml
Pansera ES 75 ml
HEPES 12 ml
Non-essential aminoacids 100x (NEAA) 6 ml
ß-mercaptoethanol 1.2 ml
LIF 90 µl
Pen/Strep 7 ml
Freezing media (10 ml)
FCS sterile filtered 9 ml
DMSO 1 ml
Gelatin (0.1%, for 50 ml)
Gelatin (2%) 2.5 ml
PBS 47.5 ml
Mitomycin C (MMC) medium (100 µg/ml)
Common media w/a antimicrobials 200 ml
MMC 2 mg
 sterile filtered aliquots stored at -20°C
Motor neuron culture media
Neurobasal®Medium 500 ml
B-27 supplement (50x) 10 ml
L-Glutamine 5 ml
Pen/Strep 7 ml
Amphotericin B 1.25 ml
BDNF 50 ng/ml
CNTF 50 ng/ml
GDNF 50 ng/ml
Motor neuron plating media (for 50 ml)
DMEM 45 ml
FKS 2.5 ml
Glucose (20%) 1.5 ml
Pen/Strep 0.7 ml
Amphotericin B 0.15 ml
 sterile filtered before use
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4.1.9.2 Solutions for work with bacteria
LB-media (pH 7.5, for 1 L)
Bacto Trypton 10 g
Yeast extract 5 g
NaCl 5 g
Deionized H2O to 1 L
 adjust pH to 7.5, autoclave and store at 4°C
LB-Agar (for 500 ml)
LB-media 500 ml
Agar 7.5 g
 autoclave and store at 4°C
4.1.9.3 Solutions for work with DNA
10x annealing buffer (for 10 ml)
Tris/HCl (1 M, pH 7.5) 1 ml
NaCl (5 M) 2 ml
EDTA (0.5 M) 0.2 ml
ddH2O to the final volume of 10 ml
dNTP mix (for 1 ml)
dNTP (100 mM) 12.5 µl of each dNTP
ddH2O to the final volume of 1 ml
Tail lysis buffer (ph 7.4, for 500 ml)
EDTA (0.5 M) 5 ml
NaCl (5 M) 20 ml
SDS (20%) 5 ml
Tris/HCl (1 M, pH 8.5) 50 ml
Deionized H2O to the final volume of 500 ml
 Proteinase K (200 µg/ml) added freshly before use
TE-4 buffer (for 100 ml):
Tris (1 M, pH 8.0) 1 ml
EDTA (0.5 M, pH 8.0) 20 µl
Deionized H2O to the final volume of 100 ml
 RNase A (50 µg/ml) added freshly before use
4.1.9.4 Solutions for work with proteins
Ammonium Persulfate (APS) solution (10%, for 10 ml):
APS 1 g
Deionized H2O to the final volume of 10 ml
 aliquoted and stored at -20°C
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Blocking solution (6%, for 100 ml)
Milk powder (low fat) 6 g
TBS Tween buffer to the final volume of 100 ml
Electrophoresis buffer (10x, for 1 L)
Trizma® base 30.29 g
Glycine 144.13 g
SDS 10 g
Deionized H2O to the final volume of 1 L
Laemmli buffer for SDS page (3x, for 10 ml)
Tris/HCl (1M, pH 6.8) 2.4 ml
Glycerol 3 ml
SDS (20%) 3 ml
Bromophenol blue 6 mg
ß-mercaptoethanol 1.6 ml
Separating gel for SDS PAGE (12%, for 10ml)
Deionized H2O 4.85 ml
AquaPlus Mix (39:1) Acrylamide 2.55 ml
Tris (1.5 M, pH 8.8) 2.6 ml
SDS (10%) 0.1 ml
APS (10%) 0.1 ml
TEMED 40 µl
Stacking gel for SDS PAGE (for 4 ml)
Deionized H2O 2.96 ml
AquaPlus Mix (39:1) Acrylamide 0.52 ml
Tris (1 M, pH 6.8) 0.52 ml
SDS (10%) 40 µl
APS (10%) 40 µl
TEMED 4 µl
TBS Tween buffer (for 5 L)
Tris (20 mM) 12.1 g
NaCl (137 mM) 40 g
Tween-20 (0.5%) 25 ml
Deionized H2O to the final volume of 5 L
 adjust pH to 7.56
Transfer buffer (for 5 L)
Trizma® Base 12.1 g
Glycine 56.3 g
Methanol 1 L
Deionized H2O to the final volume of 5 L
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Tris-HCl (1 M, pH 6.8, for 100 ml)
Tris-HCl 15 g
Deionized H2O to the final volume of 100 ml
 adjust pH to 6.8 with 37% HCl
Tris-HCl (1.5 M, pH 8.8, for 200 ml)
Tris-HCl 45.25 g
Deionized H2O to the final volume of 200 ml
 adjust pH to 8.8 with 37% HCl
4.1.9.5 Solutions for histo- and immunohistochemical stainings
Blocking solution (motor neuron and NMJ staining, for 10 ml)
BSA (4%) 0.4 g
1% Tween/1x PBS 2 ml
1x PBS to the final volume of 10 ml
Blocking solution (spinal cord cryosections, for 10 ml)
BSA (4%) 0.4 g
Horse serum (5%) 0.5 ml
1% Tween/1x PBS 2 ml
1x PBS to the final volume of 10 ml
4% paraformaldehyde (PFA) in PBS (pH 7.3, for 1 L)
PFA 40 g
Deionized H2O to the volume of 900 ml
 adjust pH to 7.3
Deionized H2O to the volume of 1 L
 aliquot and store at -20°C
4.1.10 Primers and oligonucleotides
Sequences for primers and oligonucleotides for shRNA cloning were designed with
SeqBuilder software and purchased as lyophilized from Integrated DNA Technologies.
Stock solutions at a concentration of 100 pmol/µl were prepared from lyophilized products
and subsequently diluted to 10 pmol/µl. The oligonucleotides for shRNA annealing were
diluted at a concentration of 50 µM.
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Table 1: Primers for cloning Ncald / qRT-PCR / genotyping
Application Name Sequence Amplicon
length (bp)
Annealing
temp (°C)
Cloning Ncald cDNA fwd ATGGGGAAACAGAACAGC 513 58
rev TGAACTGGCCGGCACTGCTG
qRT-PCR Ncald fwd GCTGGAGATTGTACAGGCGATC 130
61rev GAGCTTTCCATCTCTATTGGTATC
Gapdh fwd GGCTGCCCAGAACATCATCC 169
rev GTCATCATACTTGGCAGGTTTCTC
Genotyping Pgk fwd CACGCTTCAAAAGCGCACGTCTG 622
65Neo rev GTTGTGCCCAGTCATAGCCGAATAG
Hygro fwd GAAGAATCTCGTGCTTTCAGCTTCGATG 550
rev AATGACCGCTGTTATGCGGCCATTG
Ncald mut fwd CGGTCGCTACCATTACCAGT 824 60
rev GCATGTGTGACAACAGACCC
Ncald wt fwd AGCATTTCTGCCTTGCTGAT 201 58
rev TTTCCCTTACGGGGATGCT
Smn KO rev AGCCTGAAGAACGAGATCAGC 950
59
fwd-1 ATAACACCACCACTCTTACTC
fwd-2 GTAGCCGTGATGCCATTGTCA 1050
Table 2: Oligonucleotides for cloning shRNA into the pEx-H1-tetO-CAG-teR vector
Name Target
gene
Sense sequence Original
vector
bp
shRNA#1 Ncald GCCAGGTGATTCACCCATTAT pLKO.1 21
shRNA#2 Ncald CCTGAAGTCATGCAGGACTTA pLKO.1 21
shRNA#3 Ncald GCAAACGGTGATGGGACAATA pLKO.1 21
shRNA#4 Ncald CGCCAGATGGATACCAATAGA pLKO.1 21
shRNA#5 Ncald GCTTCCAAATTTGCAGAGCAT pLKO.1 21
shScramble1 none CCTAAGGTTAAGTCGCCCTCGCTC pLKO.1 24
shRNA#6 Ncald GGATGCTTCCAAATTTGCAGAGCATGTCT pGFP-V-RS 29
shScramble2 none GGATTTCAGTCAATGTACACGTTCGTCAC pGFP-V-RS 29
Antisense oligonucleotides (ASOs) were obtained within a collaboration from Ionis
Pharmaceuticals, either already diluted at a given concentration (mg/ml) or lyophilized. In
the latter case, the specific ASO was dissolved in sterile PBS and the stock concentration
was determined by absorbance measurement at 260 nm (AD260) and calculated with the
following equation: ASO concentration [mg/ml] = (AD260 x dilution factor x molecular
weight) / (extinction coefficient x path length x 1000). For the injections, a working solution
of 10 mg/ml was prepared and controlled photometrically.
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Table 3: Antisense oligonucleotides for in vivo injection
Name Ionis
number
Target
gene
Sequence Chemistry Delivery
route
bp
SMN-ASO 387954 SMN2 ATTCACTTTCATAATGCTGG Uniform MOE,
PS
s.c. 20
ASO1 673636 Ncald TGGCATTTGAATATGTGTTT MOE-gapmer,
mixed backbone
i.c.v. 20
ASO2 673672 Ncald AACACTTAATTTGGTCTGCA MOE-gapmer,
mixed backbone
i.c.v. 20
ASOctrl 676626 scramble GTTTTCAAATACACCTTCAT MOE-gapmer,
mixed backbone
i.c.v. 20
4.1.11 Plasmids
The following plasmids have been used in the work presented here. The correct cloning
of inserts was verified by sequencing.
Table 4: List of used and produced plasmids
Name Vector
backbone
Insert Resistance
to antibiotics
Source of original
plasmid
CT-GFP-
Ncald-TOPO
pcDNA3.1/CT
-GFP-TOPO
Ncald cDNA Ampicillin Life Technologies
TRC
shRNA#1
pLKO.1 shRNA#1 against
Ncald
Ampicillin RNAi Consortium,
TRCN0000104695
TRC
shRNA#2
pLKO.1 shRNA#2 against
Ncald
Ampicillin RNAi Consortium,
TRCN0000104696
TRC
shRNA#3
pLKO.1 shRNA#3 against
Ncald
Ampicillin RNAi Consortium,
TRCN0000104697
TRC
shRNA#4
pLKO.1 shRNA#4 against
Ncald
Ampicillin RNAi Consortium,
TRCN0000104698
TRC
shRNA#5
pLKO.1 shRNA#5 against
Ncald
Ampicillin RNAi Consortium,
TRCN0000104699
TRC control pLKO.1 scramble shRNA Ampicillin Addgene #1864
GFP
shRNA#6
pGFP-V-RS shRNA#6 against
Ncald
Kanamycin Origene
GFP
shScramble
pGFP-V-RS scramble shRNA Kanamycin Origene
Dox
shRNA#4
pEx-H1-tetO-
CAG-tetR
shRNA#4 against
Ncald
Ampicilin
Geneticin
Dr. Ralf Kühn (MTA)
Dox
shRNA#6
pEx-H1-tetO-
CAG-tetR
shRNA#6 against
Ncald
Ampicilin
Geneticin
Dr. Ralf Kühn (MTA)
Dox
shScramble
pEx-H1-tetO-
CAG-tetR
scramble shRNA Ampicilin
Geneticin
Dr. Ralf Kühn (MTA)
ϕC31
integrase
pCAG-Int
(NLS)
ϕC31 integrase
ORF
Ampicillin Dr. Ralf Kühn (MTA)
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4.1.12 Software packages and internet databases
 1D Scan EX Scanalytics Inc.
(densitometric analysis)
 EndNoteX7 Thomson Research
(reference organization)
 Fiji (ImageJ) Open Source
(image analysis)
 GraphPad Prism GraphPad Software
(graph design, statistical analysis)
 Inkscape Inkscape Community
(figure design)
 Lasergene Package DNAstar Inc.
(DNA sequence analysis)
 Office 2013 Microsoft
(text processing, data analysis)
 Quantity One 4.5.1 Bio-Rad
(image acquisition and analysis)
 ZEN Zeiss
(image acquisition and analysis)
 Ensembl http://www.ensembl.org/
 GeneCards http://www.genecards.org/
 Medline https://www.ncbi.nlm.nih.gov/pubmed
 NCBI http://www.ncbi.nlm.nih.gov/
 OMIM http://www.ncbi.nlm.nih.gov/omim
 UCSC http://genome.ucsc.edu/
 UniProt http://www.uniprot.org/
4.2 Methods
Unless stated otherwise, all molecular biology methods were adapted from the standard
reference work “Molecular Cloning: A Laboratory Manual (volume 1-3)” by Joseph
Sambrook and David W. Russell. The culture, transfection and selection of ES cells was
performed according to the guidelines from the work “Laboratory protocols for conditional
gene targeting” by Raul M. Torres and Ralf Kühn.
4.2.1 Working with nucleic acids
4.2.1.1 Isolation of DNA
In order to isolate DNA from mouse tissue for genotyping purposes, a small piece of tissue
(mostly a tail tip) was put in 493 µl Tail lysis buffer, freshly supplemented with 7 µl
proteinase K (200 µg/ml) and incubated at 55°C under shaking until it was completely
dissolved, usually o.n. Fully dissolved tissue suspension was centrifuged for 5 min at
35Materials and methods
maximum speed (16200 x g) to pellet potential debris. The supernatant was transferred to
a new 1.5 ml tube with 500 µl isopropanol and DNA was precipitated with gentle shaking
and centrifuged for 10 min at maximum speed. After discarding the supernatant, the pellet
was washed with 200 µl 70% ethanol to remove residual salt and centrifuged again for 5
min at maximum speed. The ethanol was removed and the pellet was dried for 10 min in
a concentrator centrifuge and subsequently resuspended in 100 µl TE-4 with RNase for
min 1 h at 37°C. 1 µl of the DNA suspension was used for genotyping PCR.
Isolation of DNA from ES cells for genotyping was performed on the 96-well plate, where
cells were grown until fully confluent. Each well was washed with 100 µl PBS and 50 µl
Tail lysis buffer with 1 mg/ml freshly added proteinase K was added. The plate was
wrapped with parafilm and wet towels and placed in a box to prevent evaporation and put
in a 55°C incubator o.n. On the following day the plate was cooled down at room
temperature for 1 h and 100 µl of cold 96% ethanol was added to each well to precipitate
DNA for 2 h. The presence of the precipitate was monitored under the binocular. Then the
plate was carefully inverted to dispose of the ethanol so that most DNA remained attached
to the bottom and subsequently each well was washed 3x with 100 µl of 70% ethanol. After
the last wash, DNA was air dried for 15 min and resuspended in 100µl TE-4 with RNase
and 1 µl of the DNA suspension was used for genotyping PCR.
4.2.1.2 Polymerase chain reaction (PCR)
If a specific genomic fragment was needed for cloning or genotyping purposes, it was
amplified using the polymerase chain reaction, which is one of the most important
molecular techniques, developed in 1980s by Kary Mullis (Mullis et al. 1986). It is an
enzymatic technique that amplifies certain DNA fragments using complementary
oligonucleotides (primers) that flank the fragment of interest in order to start the reaction.
DNA is amplified by a thermostable DNA polymerase from Thermophilus aquaticus,
termed Taq polymerase, which synthesizes new DNA starting from the 3’ end of a single-
strand DNA template. The components of a PCR are: a ribonucleic acid as template
(mainly genomic DNA, but also cDNA), primers, Taq polymerase, MgCl2 as a necessary
co-factor, all dNTPs as building blocks, buffer and water. Currently, many manufacturers
offer all PCR components (except template DNA and primers) as convenient and
inexpensive ready-to-use Master mixes which are optimized for a wide range of annealing
temperatures. For genotyping, such a 2x Master mix (New England Biolabs) was routinely
used. An exemplary PCR composition with individual components or with a Master mix is
given in Table 5.
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Table 5: A standard 20 µl PCR composition
Left side – with individual components, right side – with 2x Master Mix
Components Volume [µl] Components Volume [µl]
10x PCR buffer 2
2x Master mix 10100 mM of dNTP 3
MgCl2 0.75
Taq polymerase 0.15
ddH2O 11.1 ddH2O 7
Primer fwd (10 pmol) 1
Primer fwd (10 pmol) 1
Template DNA 1
Each PCR consists of a series of three steps: denaturation, primer annealing and
elongation; these three steps together constitute one PCR cycle. Each step requires
different temperature conditions: the denaturation is performed at 95°C to separate two
strands of the template DNA, the primer annealing depends on the sequence of an
individual primer (specifically on its length and CG/AT proportion) and the elongation
depends on the amplicon length, as the amplification speed of the Taq polymerase is ~ 1
kb/min. An exemplary PCR program is given in Table 6.
Table 6: A standard thermocycler PCR program
Step Duration Temperature [°C]
1. Initial denaturation 5 min 95
2. Denaturation 30 sec 95
3. Primer annealing 30 sec Primer dependent,
usually 58-62°C
4. Elongation 1 min per 1 kb 72
Repeat steps 2-4 for 35x
5. Final elongation 10 min 72
Cooling - 4
4.2.1.3 Agarose gel electrophoresis
The agarose gel electrophoresis aims to separate DNA fragments depending on their size
using an electric field. As DNA has a negative charge, it migrates towards the positively
charged pole in the electric field (the anode).
Routinely 1% gels were prepared by solving agarose powder in 1x TBE buffer (e.g. 0.5 g
in 50 ml for one gel) by warming up in a microwave. Upon complete dissolving the solution
was cooled under stirring and ethidium bromide was added (final concentration 1 µg/ml).
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This solution was poured into a gel chamber with well combs and left to solidify. Then the
gel was covered with 1x TBE, the combs were removed and PCR samples (with loading
dye already included in the master mix or added separately) were carefully pipetted into
the wells. The gel was run for 20-30 min at 110-120 V and the separated bands were
documented with the ChemiDoc XRS Imaging System (Bio-Rad).
4.2.1.4 Cloning
Cloning involved generation of plasmids (circular DNA fragments) which were further used
as molecular tools to express a desired protein or an shRNA sequence in the cells of
interest. The plasmids were obtained either commercially or by material-transfer
agreement and contained a number of functional sequences, such as promoters
(constitutive or inducible), resistance genes for selection in bacteria and tags to mark
exogenously expressed proteins. The crucial element of a plasmid is a multiple cloning
site, which contains many loci recognized by restriction enzymes, which are site-specific
endonucleases of bacterial origin. During incubation with a specific restriction enzyme, a
circular plasmid was cut in a locally controlled manner and subsequently a new DNA
fragment of choice (e.g. an open reading frame or an shRNA sequence) was built in
(ligated) into the plasmid and amplified in bacteria culture. Eventually, the desired plasmid
DNA was isolated from bacteria using commercial kits and further transfected into cells.
4.2.1.5 Annealing of shRNA oligonucleotides
For cloning into the Dox-inducible pEx-H1-tetO-CAG-tetR vector, the identified potent
shRNAs were ordered as two self-complementary oligonucleotides with the following
sequence: 1) oligonuncleotide A: 5’-AGATGCC-sense target sequence-GAAGCTTG-
antisense target-sequence-CTTTTTT-3’, 2) oligonucleotide B 5’-CGCGAAAAAAG-sense
target sequence-CAAGCTTC-antisense target sequence-GGCATCT-3’. Both
oligonucleotides are depicted in Fig. 7. The oligonucleotides were dissolved in ddH2O at
the concentration of 50 µM and annealed using the annealing mix and temperature
conditions given in Table 7. The ready double-strand oligonucleotide was then directly
used for ligation into pre-digested pEx-H1tetO-CAG-tetR vector as described in 4.2.1.7.
Fig. 7: Annealing of shRNA oligonucleotides
Two self-complementary oligonucleotides A and B including the shRNA sequence are designed and annealed
resulting in a cloneable DNA fragment (Kleinhammer et al. 2011).
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Table 7: The composition and conditions of an oligonucleotide annealing reaction
Components Volume [µl]
oligonucleotide A 2.5
oligonucleotide B 2.5
10x annealing buffer 5
ddH2O 45
Incubate at 95°C for 5 min.
Cool down to 4°C in a thermocycler at a rate 0.5° C/min
4.2.1.6 Digestion with restriction enzymes
The restriction enzymes are sequence-specific endonucleases of bacterial origin that cut
DNA by hydrolyzing phosphodiesther bonds between two nucleotides. Digestion with
restriction enzymes was used for opening the circular plasmids in order to clone annealed
shRNAs. Routinely, 3 µg of plasmid DNA was mixed with 10x buffer, 100x BSA and the
appropriate enzyme (3 U per 1 µg of plasmid DNA) and incubated for 4 h at 37°C. An
exemplary composition of a digestion with restriction enzymes is given in Table 8. The
digested plasmids were then subjected to gel electrophoresis and the single band of the
correct size was cut out and purified using NucleoSpin Gel and PCR Clean-up kit
(Macherey Nagel).
Table 8: The composition of a standard digestion using restriction enzyme
Component Amount
Plasmid DNA 5 µg
AscI (10 U/µl) 2 µl
BsaBI (10 U/µl) 2 µl
100x BSA 0.5 µl
10x CutSmart Buffer 5 µl
ddH2O 35.5 µl
4.2.1.7 Ligation of DNA fragments
To ligate DNA fragments (usually linearized plasmids and inserts, e.g. annealed shRNAs),
the T4 DNA ligase was used (Promega). This enzyme catalyzes the joining of two DNA
strands by creating a new chemical bond between the 5’-phosphate group of one DNA
strand and the 3’-hydroxyl group of the second DNA strand. The ligation reaction is
facilitated by the presence of complementary “sticky” ends which can be generated by
digestion with the same restriction enzyme. A standard ligation requires an excess of
insert, therefore the vector and insert were used in a 1:3 molar ratio. The composition and
temperature conditions of a standard ligation reaction are given in Table 9. Typically, 2-4
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µf of the product of ligation reaction were subsequently used for transformation into
chemocompetent bacteria as described in 4.2.2.1.
Table 9: The composition of a typical ligation reaction (10 µl)
Component Amount
10x Ligation buffer 1 µl
T4 DNA ligase 1 µl
Linearized vector 1 µl
Insert 3x amount of vector
ddH2O to the final volume of 10 µl
4.2.1.8 TOPO cloning
TOPO TA cloning method was used to generate the GFP-Ncald overexpressing plasmid.
This technique uses the enzyme topoisomerase I derived from the Vaccinia virus instead
of a standard ligase; it further utilizes the terminal transferase activity of the Taq
polymerase which adds a single deoxyadenosine (A) to the 3’ end of the PCR products. A
TOPO vector is linearized with a specific 5’-(C/T)CCTT-3’ sequence and a covalently
attached topoisomerase at the free 3’ ends of both strands. When the TOPO vector is
mixed with PCR products, their free 5’ ends with the deoxyadenosine overhangs are
ligated by the topoisomerase to the complementary 3’ deoxythime at the ends of the
vector. This reaction proceeds efficiently at room temperature in the presence of
necessary salts.
To clone Ncald coding sequence in the pcDNA3.1/CT-GFP-TOPO vector, the coding
sequence was amplified from cDNA using specific primers and Taq polymerase. The PCR
product was purified using NucleoSpin Gel and PCR Clean-up kit (Macherey Nagel) and
4 µl of it was mixed with 1 µl salt solution and 1 µl pcDNA3.1/CT-GFP-TOPO vector. This
reaction was incubated at room temperature for 30 min and subsequently 2 µl of the
reaction was transformed into TOP10 chemocompetent E.coli as described in 4.2.2.1.
4.2.1.9 Isolation of RNA
Total RNA was isolated from cells using the RNeasy Kit (QIAGEN) according to the
maunfacturer’s protocol. In short, the cells were washed with 1x PBS and lysed in RLT
buffer supplemented with ß-mercaptoethanol to inhibit RNases. Then an equal volume of
70% ethanol was added to the cell lysate and the entire volume was loaded on a silica
column. Subsequently, the silica membrane was washed and the digestion with DNase I
was performed to eliminate contamination of DNA. Finally, the total RNA was eluted from
the column with RNase free water.
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The concentration of RNA was determined using the Quant-iT RiboGreen RNA Assay Kit
performed in triplicated for each sample and analyzed with the TECAN Safire2 microplate
reader.
4.2.1.10 Reverse transcription of RNA into cDNA
As RNA is not suitable as template for quantitative real-time PCR, it requires a reverse
transcription to a more stable cDNA. For this purpose, QuantiTect Reverse Transcription
Kit (QIAGEN) was used according to the manufacturer’s protocol. The DNA wipe-out
served as an additional measure to avoid contamination with genomic DNA. For qRT-PCR
routinely 300 ng RNA and for samples of the standard series 600 ng RNA was reverse
transcribed to cDNA in a 10 µl reaction in a thermocycler. The exemplary composition and
temperature conditions of the reaction are given in Table 10.
Table 10: The composition of a typical reverse transcription reaction (10µl)
Component Amount
RNA 300 ng
DNA wipe-out 1 µl
RNase-free H2O to the final volume of 6µl
Incubate at 42°C for 2 min
5x RT buffer 2 µl
Primer mix 0.5 µl
Reverse transcriptase 0.5 µl
Incubate at 42°C for 20 min
4.2.1.11 Quantitative real-time PCR (qRT-PCR)
In order to quantitatively analyze the transcript of interest, quantitative real-time PCR was
utilized. qRT-PCR follows the same kinetics as any PCR, only that product amplification
can be monitored in real-time by measuring a DNA binding fluorescent dye, SYBRgreen.
SYBRgreen dye emits green light when excited and its fluorescent signal is the strongest
when bound to double stranded DNA. Therefore, SYBRgreen fluorescence was measured
during each elongation stage at 72°C. At this temperature, most double stranded DNA
comes from the PCR product; however, as SYBRgreen binds unspecifically to any double
stranded DNA irrespective of its sequence, it is crucial for qRT-PCR primers to amplify a
single product. In this study, this was verified by melting curve analysis where single peak
was visible, as well as by agarose gel electrophoresis.
As the template for qRT-PCR, the reverse transcribed cDNA (4.2.1.10) was diluted in
TE-4 at a 1:4 ratio for the samples and at a 2:3 ratio for the standards. For the qRT-PCR,
2x Power SYBR Green Master mix (ThermoFisher Scientific) was used. The composition
of a typical qRT-PCR is shown in Table 11.
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Table 11: The composition of a typical qRT-PCR (10µl)
Component Amount
2 x Power SYBR Green Master Mix 5 µl
Primer fwd (10 pmol) 0.5 µl
Primer rev (10 pmol) 0.5 µl
diluted cDNA template 3 µl
RNase-free H2O to the final volume of 10µl
4.2.2 Working with bacteria
Most work in bacteria (propagating the GFP-Ncald and shRNA plasmids) was performed
in TOP10 chemocompetent Escherichia coli (Life Technologies). The propagation of pEx-
H1tetO-CAG-tetR plasmid required a bacterial strain free of methylases for the subsequent
digestion with methylase-sensitive endonucleases, therefore for this purpose the SCS110
bacteria strain (Agilent) was used.
4.2.2.1 Transformation
Competent bacteria were thawed on ice and 5 µl of the ligation mix (see 4.2.1.7) was
added and gently mixed by inverting the tube. The bacteria-DNA mixture was incubated
on ice for 1 h. After the incubation step, the heat shock was performed for 45 sec at 42°C.
The tube was again put on ice and 250 µl of LB media was added. Next, the tube was
placed on a horizontal shaker for 1 h at 37°C. Subsequently, the bacteria-DNA mixture
was distributed with a glass spatula on plates containing LB agar supplemented with the
correct antibiotics (Ampicilin or Canamycin at the concentration of 50 µg/ml) and the plates
were incubated o.n. in an incubator at 37°C.
4.2.2.2 Picking clones and colony PCR for clone identification
Single clones were picked from o.n. incubated LB agar plates with sterile tips and lysed by
osmotic shock in 20 µl ddH2O: 5 µl of the clone suspension were used for colony PCR and
with the rest 15 µl an o.n. culture for plasmid DNA preparation was inoculated. The colony
PCR was designed in a way that one primer was located in the plasmid and the other one
in the insert to ascertain a successful ligation. This way, only clones carrying a correctly
ligated plasmid would yield a PCR product.
4.2.2.3 Preparation of plasmid DNA
Only clones which tested positive in the colony PCR were used for o.n. culture and used
for isolation of plasmid DNA with the PureYield Plasmid Miniprep System (Promega)
according to manufacturer’s instructions. The sequence of the plasmid with the intended
insert was validated by Sanger sequencing (GATC Biotech, Konstanz).
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To isolate a larger amount of high-purity plasmid DNA for transfection, a large o.n. culture
was prepared of plasmids with validated sequence. Routinely, 200 ml o.n. culture was
processed with PureYield Plasmid Midiprep System (Promega), which includes an
endotoxin removal step, and ~ 500 µl of plasmid DNA at the concentration > 500 ng/ml
was obtained. A small volume (0.5 ml) of the o.n. culture was mixed with the same volume
of sterile 50% glycerol, snap-frozen and stored as stock at -80°C.
4.2.3 Working with proteins
As proteins are highly sensitive biomolecules which are easily degraded at higher
temperatures, all work with proteins was carried out on ice. Additionally, a cocktail of
protease inhibitors (Roche) was routinely added to lysis buffer.
4.2.3.1 Isolation of proteins from cells
Cultured cells were washed with 1x PBS and a sufficient amount of RIPA buffer was added
so that whole surface of cells was covered. Then the cells were scraped using a cell
scraper and cell suspension was collected in 1.5 ml Eppendorf tubes and incubated on ice
for 10 minutes. After that step the cell suspension was centrifuged for 20 min at 4°C at the
speed of 16200 x g. The supernatant containing proteins was transferred to a fresh tube
and the pellets were discarded. Subsequently, protein concentration was determined by
Bradford assay. The protein lysates were stored at -80°C.
4.2.3.2 Isolation of proteins from tissues
The tissues for protein isolation were collected during mice dissection and immediately
snap-frozen. For protein isolation the tissue samples were homogenized using Precellys24
device (Peqlab): the tissue sample was placed into a 2 ml tube with ceramic beads and a
sufficient amount of cold RIPA buffer. The program for homogenization was 25 sec at 5500
rpm. Subsequently, the samples were sonicated for 5 minutes using Bioruptor® Plus
device (Diagenova) to fragment DNA and therefore prevent smear during SDS-PAGE.
Finally, the tissue suspension was centrifuged for 30 min at 4°C at the speed of 16200 x
g. The supernatant was processed exactly as in 4.2.3.1.
4.2.3.3 Bradford assay
The Bradford assay was used to determine the protein concentration (Bradford 1976).
Bradford reagent is characterized by a shift in its absorption maximum from 470 to 595 nm
upon protein binding, which can be measured photometrically. A photometer was first
calibrated for the Bradford assay using a standard curve of BSA dilutions. 1 µl of the lysate
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of unknown protein concentration was mixed with 499 µl of Bradford solution and
incubated for 15 min at room temperature; in parallel, a blank containing 1 µl of the lysis
buffer (routinely RIPA buffer) with 499 µl of the Bradford solution was prepared. First the
absorption of the blank, and then of all samples was measured at a wavelength of 595 nm
and the protein concentration was calculated from the measured values by comparison to
the BSA standard curve.
4.2.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
The protein lysates were analyzed by SDS-PAGE followed by Western blotting. First, a
specific amount of protein lysate (15-20 µg) was mixed with 3x Laemmli buffer and
denatured for 5 min at 95°C. The addition of the SDS both in the Laemmli buffer and the
polyacrylamide (PAA) gel gives the proteins a strong negative charge exceeding their
native charge. This allows the separation of all proteins in the lysates according only to
their molecular weight, irrespective of their intrinsic charge.
For SDS PAGE, a 12% PAA separating and a stacking gel were prepared between two
0.5 mm glass plates (detailed composition given in 4.1.9.4). These two gel types differ by
the PAA concentration and pH. The stacking gel contains less PAA and forms larger pores,
so that the proteins can migrate easily and concentrate at the border between both gels.
The separating gel contains more PAA and forms smaller pores, so that bigger proteins
migrate more slowly and can be identified in the upper part of the gel, while smaller
proteins move easily to the bottom part of the gel.
The separating gel was poured first and covered with isopropanol to secure a smooth egde
of the gel. After gel polymerization, the isopropanol was washed out and the stacking gel
was carefully pipetted on top of the separating gel and well combs were inserted.
The protein lysates with 3x Laemmli loading buffer were loaded into the wells of the
stacking gel and separately, a protein ladder PAGE Ruler Plus (Thermo Fisher Scientific)
was loaded in order to estimate the size of analyzed proteins. PAA gel electrophoresis
was performed in the Mini-Protean 3 cell system (Bio-Rad) at 50-100 V in 1x
electrophoresis buffer.
4.2.3.5 Western blot
After the size separation by SDS-PAGE the samples were transferred from the separating
gel to a nitrocellulose membrane (Hartenstein) by wet blotting in the transfer system (Bio-
Rad). The gel transfer was arranged from the following components (all of them previously
equilibrated in the transfer buffer): a sponge pad, a Whatman paper layer, the gel, the
nitrocellulose mebrane, again a Whatman paper layer and finally a sponge pad. All
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components were fixed in a transfer device and transferred to a transfer chamber filled
with transfer buffer. The protein transfer was performed for 2 h at 110 V in a cold room.
During the transfer negatively charged proteins migrate in the electric field to the positively
charged anode and by hydrophobic interaction adhere to the membrane.
4.2.3.6 Immunochemical detection of proteins
After the transfer the membrane was washed with TBS-T to remove residual methanol and
stained with the Ponceau solution to assess the quality of the transfer. After washing away
the Ponceau dye with TBS-T the membrane was blocked for at least 1 h in 6% milk solution
and subsequently incubated overnight at 4°C with the primary antibody diluted in 3% milk
solution. After the given incubation time, the membrane was washed 3x 10 min with TBS-
T and subsequently incubated with the secondary antibody solution. The primary and
secondary antibodies with the respective dilutions and incubation times are listed in Table
12. Finally, the membrane was again washed 3x 10 min with TBS-T and incubated for 5
min in the SuperSignal® Wets Pico Chemiluminiscent Substrate (Thermo Fisher Scientific)
in order to visualize the proteins stained with the specific antibodies. The visualization was
performed using ChemiDoc XRS Imaging System (Bio-Rad).
Table 12: Primary and secondary antibodies used for protein detection
Antibody Dilution Incubation time
HRP anti-ß-actin 1:10000 2 h
anti-GFP 1:2500 o.n.
anti-NCALD 1:1000 o.n
anti-SMN 1:200 o.n.
Secondary antibody
anti-mouse-HRP 1:5000 1 h
anti-rabbit-HRP 1:5000 1 h
4.2.4 Working with cells
All work with cell lines was performed in sterile conditions in a laminar flow culture hood.
Additionally, cell culture media was supplemented with antibiotics and anti-fungal agents
to prevent contamination. All cells were kept in sterile cell incubators at 37°C with 5% CO2.
4.2.4.1 Culturing cell lines
The adherent cell lines HEK293T and NSC34 as well as human and murine fibroblasts
were grown as monolayers in the standard DMEM medium with 10% fetal calf serum (FCS)
and split upon reaching 70-80% confluence. The splitting of a cell line occurred in the
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following steps: first, the old medium was removed and the cells were washed briefly with
1x PBS. Then, dependent of the culture dish or flask used, a sufficient volume of Trypsin-
EDTA was added to cover the entire monolayer and incubated for 5 min at 37°C, when
the trypsinization was stopped by equal volume of fresh culture medium and cell were split
into new flasks at a variable ratio depending on the growth pace of the respective cell line.
4.2.4.2 Freezing cells
The solution of trypsinized cells was centrifuged at 1200 x g for 10 min. The cell pellet was
briefly washed with 1x PBS and then resuspended in the freezing medium (sterile filtered
solution of 90% FCS and 10% DMSO) and frozen at a -1°C/min rate using a cryo container.
The frozen cells were first stored in -80°C freezer and transferred for long-time storage to
the liquid nitrogen tank.
4.2.4.3 Transfection of cells
The knock-down potential of the shRNAs against Ncald was tested by transfecting the
shRNA vectors into NSC34 cells. For transfection, 90% confluent NSC34 cells on a 6-well
plate were used, with 2.5 x 105 cell per well. For each well 2 µg of the shRNA plasmid was
transfected using the Lipofectamine® 2000 reagent. The transfection mix was prepared in
two 1.5 ml tubes: the first tube contained 10 µl Lipofectamine® 2000 and 500 µl OptiMEM,
the second tube contained 2 µg of shRNA plasmid DNA and 500 µl OptiMEM. After 5 min
incubation at room temperature, the content of both tubes was mixed and again incubated
for 20 min at room temperature. Meanwhile each well with the NSC34 was supplemented
with 2 ml of fresh standard medium without antibiotics and after the incubation time the
transfection mix was added in droplets to the cells. After 4 h the medium containing the
transfection mix was replaced with standard medium with antibiotics. The transfected cells
were lysed 48 h after transfection for protein or RNA analysis.
The HEK293T cells were transfected in the same manner, with the only difference that
250 ng DNA of the GFP-Ncald overexpressing vector was co-transfected with 2 µg of the
shRNA plasmid DNA per well. When Doxycycline-inducible shRNA plasmid was
transfected, the standard media was supplemented with 4 µg/ml Doxycycline.
4.2.5 Working with mice and mouse tissues
4.2.5.1 Generating a new Ncald knock-down mouse line
In order to study the effect of NCALD reduction in vivo in a mammalian model, we planned
to generate a new Ncald knock-down mouse line along the strategy proposed in
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(Kleinhammer et al. 2011). The necessary steps are outlined in the Fig. 8 and the
methodology is described in more detail in the following paragraphs and in the chapter
5.1. Within this project, steps 1 to 5 were completed; however, as we decided to apply the
recently available Ncaldko/wt mouse line (see 4.2.5.7.2) as a model of NCALD reduction,
the steps 6 to 9, which would require the assistance of the Centre for Mouse Genetics of
the University of Cologne in order to produce living transgene animals, were discontinued.
Fig. 8: The necessary steps of a mouse generation strategy using an inducible shRNA targeting vector.
Steps 1 to 5 were performed according  to the guidelines proposed in (Torres and Kühn 1997, Kleinhammer
et al. 2011).
4.2.5.2 Culturing embryonic stem (ES) cells
Mouse embryonic stem (ES) cells are pluripotent cell lines derived from blastocysts of an
early stage embryo (around 3 days post fertilization). ES cells retain the capacity to
develop into all lineages and are able to contribute to a newly developing embryo. Targeted
manipulations of the genome of ES cells have made it possible for researchers to generate
transgene animals, particularly mice, either by removing a specific DNA fragment or – in
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most cases – by an integration of desired DNA fragments either randomly or into defined
loci in the genome of the ES cells (Thomas and Capecchi 1987). The cultivation of ES
requires certain conditions in order to prevent differentiation and sustain their pluripotent
state: the cells are routinely cultured on mitotically inactivated murine embryonic
fibroblasts (MEFs), so called feeders, which secrete differentiation preventing leukemia
inhibitory factor (LIF), and allow the ES cells to keep their rounded morphology (Evans
and Kaufman 1981). Additionally, recombinant LIF is added to the ES medium.
The ES cell line used here was the IDG26.10-3 cell line with a modified Rosa26 locus (see
5.1). As mentioned above, the ES cells were routinely cultured on feeders, except when
they were harvested for DNA or mRNA analysis, when they were cultured on gelatinized
plates instead. The ES cells were fed daily with fresh ES medium and grown only until 60-
70% confluence; accordingly, they were split at least every second day as described in
4.2.4.1.
4.2.5.3 Preparation of feeder cells
The feeder cells are mitotically inactivated murine embryonic fibroblasts (MEFs), derived
from Neomycin-resistant mice. MEFs are generated from E13.5 embryos; in order to
assess the embryonic age, it is necessary to determine the start of the pregnancy, which
is achieved by a plug check. A female mouse is housed with a male and daily monitored
for the presence of the vaginal plug which indicates the mating. The day when a plug has
been observed is considered E0.5 and weight progression of the presumably pregnant
female is monitored. If the female has gained weight, it was sacrificed on E13.5 and the
embryos were carefully released out of the uterus. The head and liver of the embryo were
removed and a small fragment of the head was used for genotyping. The remaining tissue
was transferred to a Petri dish and rinsed twice in 1x PBS, whereupon the tissue was
incubated in 25 ml Trypsin-EDTA at 37°C for 30 min. The trypsinization was stopped using
25 ml of the standard medium and cells were centrifuged at 200 x g for 5 min. The cell
pellet was resuspended in standard medium prior to cell counting and 2.5 x 106 cells were
plated on a 15 cm Petri dish. MEFs were grown till confluent and split three times at a 1:3
ratio, yielding in the end 27 plates of MEFs at passage 3. These MEFs were then subjected
to mitotic inactivation by Mitomycin C (MMC) treatment. MMC was dissolved in standard
medium without antibiotics at a final concentration of 10 µg/ml and sterile filtered. A 15 cm
Petri dish with confluent MEFs was rinsed once with 1x PBS and 15 ml of MMC medium
was added for 2-4 at 37°C in a sterile incubator. After the incubation, the MMC medium
was removed and cells were washed twice with 1x PBS, trypsinized and counted and
aliquots of 1 x 106 cells were frozen. One aliquot was sufficient for one 10 cm pre-
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gelatinized dish (30 min incubation with 0.1% gelatin in 1x PBS at 37°C). The feeders were
routinely thawed one day before splitting the ES cells.
4.2.5.4 Electroporation of the vector DNA into ES cells
In order to manipulate the genome of ES cells, vector DNA carrying the desired transgene
needs to be stably integrated. This is best achieved by electroporation as the electric
current leads to a temporary permeabilization of the cell and the nuclear membrane and
the exogenous DNA can insert the nucleus. Traditionally, the integration of the transgene
depended on a rare event of homologous recombination where the homology arms of the
targeting vectors would align to complementary regions in the genome of the acceptor cell
and become integrated during mitosis. However, the frequency of such a genomic
integration is very low, so that many clones required screening in order to identify the
successfully recombined ones. Our strategy utilized an enzyme, ϕC31 integrase, which
would be electroporated together with the targeting vector and upon expression by the ES
cell would mediate the recombination (the mechanism is described in detail in 5.1).
The ES cells were fed with fresh ES medium 3-4 h prior to the electroporation. 15 µg of
the targeting vector and 15 µg of the ϕC31 integrase plasmid were diluted in 1x PBS at a
final concentration of 0.5 µg/µl. Each 10 cm plate of ES cells was washed with 1x PBS and
trypsinized with 2 ml Trypsin-EDTA for 3-5 min at 37°C, whereupon 2 ml of standard
medium were added to stop the trypsinization. The ES cell suspension was thoroughly
pipetted to singularize the cells and subsequently centrifuged for 5 min at 1000 x g. The
cells were resuspended in 1x PBS and counted using the cell-counting chamber;
subsequently, the cells were again centrifuged and dissolved at a concentration of 1.25 x
106 cells/ml. 0.8 ml of the ES cell suspension was mixed with the 15 µg + 15 µg DNA of
both plasmids and electroporated with a single pulse of 230 µV at 500 F. The
electroporation mix was supplemented with 30 ml of fresh ES medium and distributed onto
three 10 cm feeder plates. 24 h after electroporation, the medium was exchanged to the
selection medium with 140 µg/ml G418 (Geneticin).
4.2.5.5 Selection and isolation of ES clones
After single resistant ES clones have become visible after 7-8 days under G418 selection,
they were grown for 2-3 more days until reaching the suitable size for isolation. Again, the
ES clones were fed with fresh ES medium 3-4 h before the procedure. A U-shaped 96-
well plate with 50 µl Trypsin in each well was prepared for clone collection and kept on ice
to block the enzyme activity. The plates with ES clones are washed once and then covered
with 1x PBS and single ES clones are gently pipetted off the feeder plate with <20 µm of
1x PBS and transferred to the Trypsin-EDTA plate. After the complete 96-well plate has
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been filled with ES clones, it is incubated for 5 min at 37°C, whereupon the trypsinization
is stopped with 100 µl of ES medium per well. Each ES clone is singularized by energetic
pipetting and the entire volume of ES clone suspension is transferred into a bottom-shaped
96-well plate with feeders. The single ES clones on 96-well plates are cultured in G418
selection media until reaching 50-60% confluence, upon which each plate was split onto
three fresh 96-well plates with feeders. When these have reached 50-60% confluence, two
of them were frozen (see 4.2.5.6) and one was split onto three gelatinized 96-well plates,
which were cultured for 3 more days and used for DNA analysis.
4.2.5.6 Freezing of 96-well plates with ES clones
The 96-well feeder plates with ES clones were frozen, so that after DNA analysis the ES
clones with the correctly integrated transgene could be reclaimed by thawing and
expansion. A 50-60% confluent 96-well plate with ES clones was washed with 1x PBS and
trypsinized by adding 50 µl Trypsin/EDTA to each well and incubating for 5 min at 37°C,
whereupon the trypsinization was stopped with 50 µl of the freezing medium (80% Pan-
Sera ES, 20% DMSO). Each ES clone was singularized by pipetting, whereupon 100 µl
mineral oil were added to each well. The plate was sealed with parafilm and stored at -
80°C.
4.2.5.7 Mouse strains
As the genetic background of a mouse strain has been shown to affect the gene
expression and therefore the phenotypic outcome, most animal studies utilize inbred
mouse strains that are highly homozygous (Linder 2006). The experiments in this work
were performed on the genetically pure background, either C57BL/6N (for the studies of
the Ncaldko/wt allele in SMA mice, both severe and ASO-injected intermediate ones) or FVB
(for the preclinical testing of the Ncald-ASOs). All mice were housed in the mouse facility
of the Institute of Genetics, Cologne. The experiments have been described in an animal
experimental protocol that was permitted by the local animal protection committee under
the reference number 84-02.04.2014.A126. All mice were humanly euthanized according
to protocols approved by the Landesamt für Natur, Umwelt and Verbraucherschutz of
Northrhine Westfalia (LANUV NRW).
In the following paragraphs details are given for the two strains used in this study: SMA
mice and Ncaldko/ko mice.
4.2.5.7.1 SMA mice
The FVB.Cg-Tg(hSMN2)2Hung Smn1tm1Hung/J mice were obtained from The Jackson
Laboratory (Stock number #005058) (Hsieh-Li et al. 2000). These mice carry a targeted
insertion of a hypoxanthine phosphoribosyl transferase (HPRT) cassette instead of exon
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7 of Smn. If this transgene is bred homozygously, it results in early embryonic lethality.
Therefore, in order to obtain viable mice with an SMA phenotype, another transgene
carrying tandem hSMN2 copies was crossed onto the Smnko/ko background. If both
transgenes are present homozygously, Smnko/ko; hSMN2tg/tg mice have no survival or
fertility impairment (Hsieh-Li et al. 2000). In our breeding scheme adapted from (Riessland
et al. 2010), Smnko/ko; hSMN2tg/tg mice are crossed with heterozygous Smnko/wt; Ncaldko/wt
animals and the resulting offspring can have one of four genotypes (see Fig. 9): half of the
animals are homozygously lacking the Smn gene and show the disease phenotype
(termed here SMA and SMA-Ncaldko/wt), while another half with only heterozygous Smnko/wt
show a normal phenotype (termed here HET and HET-Ncaldko/wt). Originally, the
purchased SMA mice were on a pure FVB background; however, the line used in this
worked has been previously backcrossed for >7 generations with C57BL/6N wildtype to
obtain a pure C57BL/6N background (Ackermann et al. 2013).
4.2.5.7.2 Ncaldko/ko mice
The B6N.Cg-Ncaldtm1.1(KOMP)Vlcg/J mice were also obtained from the Jackson
Laboratory (Stock number #018575). These mice were generated by the Knockout Mouse
Phenotyping Program (KOMP2) using the VelociGene strategy developed by the
Regeneron company to target most difficult genes. The insertion of VelociGene cassette
ZEN-Ub1 created a 28620 bp deletion between positions 37298567-37327186 of
chromosome 15 (Genome Build37); the neomycin cassette used for selection was
subsequently excised by Cre expression. The Ncaldko/ko mice were viable and fertile, but
in our observation the fertility of homozygous knock-out mice was diminished compared
to wildtype. The phenotypic analysis revealed a number of abnormalities, particularly
concerning body weight and size, skeleton and adipose tissue, cardiovascular and vison
systems, as well as some neurological and behavioral changes (Jackson Laboratory
2016). We crossed the Ncaldko allele with Smnko/wt animals and used the resulting
Ncaldko/wt; Smnko/wt animals (preferably male due to a compromised maternal behavior of
the females) for breeding with the Smnko/ko; hSMN2tg/tg mice to obtain SMA-Ncaldko/wt and
HET-Ncaldko/wt offspring for analysis (Fig. 9).
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Fig. 9: The breeding scheme to obtain SMA and HET animals with reduced NCALD levels
Preferably, male animals carrying the allele were used for breeding as the breeding performance and paternal
care of mothers was inferior to wildtype.
4.2.5.8 Generation of primary motor neurons
Primary motor neurons were prepared from spinal cords of E13.5 of embryos; similar to
the MEF isolation, the start of the pregnancy needed to be determined by plug check. On
E13.5, the pregnant female was sacrificed and embryos were carefully released from the
uterus. Subsequently, the embryo was placed on a Sylgard-filled Petri dish and covered
in 1x PBS. In order to open the embryo dorsally, it was fixed ventrally with fine minutien
pins using forceps and the skin of the embryo above the spinal cord was carefully removed.
The spine was released by scraping out along the vertebrae with sharp pins and the
surrounding meninges membrane and glial cells were removed as thoroughly as possible.
The clean spinal cord tissue was place in 500 µl 1x PBS in a 1.5 ml tube and centrifuged
for 10 min at 4°C and 1000 x g. Then the 1x PBS was pipetted off and the spinal cord was
resuspended in 500 µl of 1% Trypsin in 1x PBS and centrifuged again for 7 min at 4°C and
1000 x g. The Trypsin solution was removed and 500 µl of motor neuron plating medium
with DNase I (100 U/ml) was added and the tissue was completely dissolved by pipetting.
After 2 min incubation for the undissolved debris to sediment, the cell suspension was
transferred to a fresh 1.5 ml tube and the cells were counted using the Neubauer chamber.
For immunofluorescent staining to determine axonal length, 75.000 cells/well were plated
on poly-D-lysine (PDL) coated coverslips in a 12-well plate containing 2 ml of plating
medium. For protein analysis, 2 x 105 cells/well were plated on PDL-coated 6-well plates
with 2 ml of plating medium. On the following day, the plating medium was replaced with
Neurobasal® medium with growth factors. For the staining, the motor neurons were
cultured for 6 days and for the protein analysis for 7 days.
52
4.2.5.9 Immunofluorescent staining of motor neurons
In immunofluorescent stainings (of cells or tissues, see 4.2.5.14), the proteins of interest
are specifically detected using a primary antibody, which is subsequently visualized by the
binding of a fluorophore-conjugated secondary antibody.
For immunofluorescent staining, cells were seeded out and cultured on coverslips. After
they have grown in the cell culture incubator for a given time, cells were washed with 1x
PBS and fixed with 4% PFA supplemented with 4% sucrose for 15 min. After the fixation
cells were washed again and permeabilized for 5 minutes with 1% Triton detergent in 1x
PBS. Subsequently, cells were blocked with 4% BSA in PBS with 0.2% Triton for 1 h at
room temperature. Primary antibodies (rabbit anti-HB9 1:250, mouse anti-Tau 1:500) were
diluted in the blocking solution and applied to the cells after blocking for o.n. incubation at
4°C. On the following day, the cells were washed 3x for 5 min with 1x PBS and then
incubated in a dark chamber with secondary antibodies (Alexa 488 anti-mouse and Alexa
568 anti-rabbit, both 1:250) diluted in 1x PBS for 1 h at room temperature. Then the cells
were again washed 3x with 1x PBS and 1x with ddH2O to remove residual salts. Finally,
the coverslips were mounted on glass slides with Mowiol and stored at 4°C for microscope
analysis.
4.2.5.10 Motoric tests
To assess the motoric fitness of mice, an array of tests suitable for neonatal mice (till
PND14) was developed and we applied two of the suggested tests: the tube test and the
righting reflex test were recruited (El-Khodor et al. 2008).
4.2.5.10.1The tube test
In the tube test the animal is placed with its head downwards in a softly bedded 50 ml
Falcon tube and holds on to the tube edge by its hind limbs. Based on the positioning of
the hind limbs towards each other, the so called hind limb score (HLS) was evaluated: 4
for fully spread hind limbs and upright tail, 3 for hind limbs parallel to each other, 2 for hind
limbs occasionally clasping together and lowering the tail to support the hold, 1 for hind
limbs permanently clasped together and 0 for no hold and falling into the tube. The
positions reflecting the respective scores are presented in Fig. 10.
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Fig. 10: The tube test positions corresponding to the respective values of the hind limb score
Following feature were highlighted: A) normal separation of hind limbs; B) hind limbs are closer together
reflecting the weakness; C) hind limbs are touching each other; D) hind limbs are clasped together; E) the tail
remains raised; F) the tail is lowered (adapted from (El-Khodor et al. 2008).
4.2.5.10.2The righting reflex test
For the righting reflex, the animals were placed on their back on a flat surface and the time
to reposition themselves was measured over a 10 sec period. The time to right was
replaced with a score value in the following manner: >1 sec = 0, 1-2 sec = 1, 3-4 sec = 2,
5-6 sec = 3, 7-8 sec = 4, 9-10 sec = 5, <10 sec = 6.
4.2.5.10.3Weight measurement
To monitor the weight progression, the analyzed animals were weighted daily for the first
14 days and then weekly (the longer living HET and HET-Ncaldko/wt animals) on a bench
scale. The average was calculated separately for male and female animals to account for
sex-related weight differences and a mean of these two values was considered.
4.2.5.11 The injection of antisense oligonucleotides
The SMN-ASO (Hua et al. 2008) was dissolved in sterile 1x PBS at a concentration of 10
µg/µl and stored at -20°C; repeated thaw-and-freeze cycles were avoided. The
subcutaneous injection (in the skin fold of the neck) at a dose of 30 µg (3 µl) was performed
twice, on PND1 and 2.
The Ncald-ASOs (ASO1, ASO2 and ASOctrl, manufactured by Ionis Pharmaceuticals)
were dissolved in sterile 1x PBS at concentrations of 30 and 60 µg/µl and stored at -20°C.
The detailed injections regimens and doses are described separately for each experiment
in the results section in chapter 5.4.
4.2.5.12 Preparation of mouse tissues and organs
In order to prepare mouse tissues and organs, a mouse was sacrificed by decapitation (till
PND13) or carbon dioxide euthanasia. The mouse body was placed dorsally on a
preparation tray and the forelimbs and hind limbs were fixed with needles. The animal was
opened with a central cut of the abdominal skin which was gently detached from the
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muscle and removed above ribs to expose the whole abdomen. Routinely, first the TVA
muscle was prepared (see 4.2.5.15). Next, the inner organs such as heart, lungs, liver and
intestine were carefully isolated using ligature scissors and dissecting forceps and either
snap frozen in liquid nitrogen (for subsequent protein analysis) or placed in embedding
chambers for further procedures.
4.2.5.13 Isolation of mouse spinal cord
The mouse spinal cord was routinely isolated from sacrificed mice as the last tissue and
thus cut out of the body cavity, otherwise the fur and skin on the dorsal side of the animals
was removed, the head and the tail were cut off and the vertebral column was carefully
detached excised from the surrounding ventral connective tissue. Then the backbone was
fixed with minutien pins to a Sylgard-plate and using forceps and microscissors, all
vertebrae were individually removed to visualize the spinal cord beneath. The spinal cord
was released and the upper half was snap frozen in a 1.5 ml tube for protein analysis,
while the lower lumbar part was fixed in 4% PFA for subsequent sectioning.
4.2.5.14 Immunohistochemical staining of spinal cord sections
For immunofluorescent staining, lumbar parts of mouse spinal cords were fixed with 4%
PFA o.n. at 4°C. On the following day, the spinal cords were briefly washed with 1x PBS
and then incubated at 4°C for two subsequent nights with sucrose (20% and 30%,
respectively) for cryoprotection. The cryoprotected tissue samples were embedded in
OptiTec medium and then sectioned using the cryotome device (Leica). The sections were
collected in 1.5ml Eppendorf tubes containing 1x PBS for further processing. Then
sections were briefly centrifuged at 4200 x g, washed with 1x PBS and permeabilized with
2% Triton in 1x PBS at room temperature for 30 min on a rotating wheel. Subsequently
the sections were blocked for 1 h at room temperature in 4% BSA and 5% Horse serum in
1% Triton in 1x PBS. After that the sections were incubated with primary antibodies
dissolved in the blocking solution at 4°C overnight. The motor neurons were visualized by
anti-ChAT antibody and the glutamatergic synapses on the motor neuron soma by anti-
VGlut1 antibody. On the following day, the spinal cord sections were washed 5x 10 min
with 1x PBS and then incubated in the dark chamber with secondary antibodies diluted in
1x PBS for 2 h at room temperature. Then the sections were again washed 5x 10 min with
1x PBS and 1x with ddH2O. Finally, the sections were mounted on glass slides with Mowiol
and stored at 4°C for microscope analysis.
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4.2.5.15 Preparation of mouse muscle tissue: Transversus abdominis (TVA) and Extensor
digitorum longus (EDL)
The isolation of the proximal Transversus abdominis (TVA) muscle was performed as
described in (Murray et al. 2014). The decapitated body of the sacrificed mouse was
prepared as described in 4.2.5.12 and then the complete fur and skin covering the upper
trunk were removed over the head. The exposed abdominal wall was carefully cut above
the bladder and on both sides laterally toward the spinal cord. Then a cut was made on
the dorsal side of the animal along the spine towards the neck through the dorsal part of
the ribcage using micro scissors. With the final section on both sides through the
diaphragm, the whole ribcage and the abdominal muscles were released and placed on a
Sylgard-filled Petri dish with 1x PBS. The abdominal wall was stretched with forceps and
pinned with fine minutien pins. The muscle was fixed for 20 min with 4% PFA and upon
kept in 1x PBS. Under the stereomicroscope two upper muscle layers (external oblique
muscle and internal oblique muscle) were gently removed with forceps to expose the TVA
muscle. A triangular piece of the TVA muscle was cut out and stored in 1x PBS for
subsequent immunohistochemical staining.
To isolate the Extensor digitorum longus (EDL), the hind limb was cut off the euthanized
animal and the fur and skin were removed. The hind limb was pinned to the Sylgard plate
at the feet and the knee and the dissection was performed under the stereomicroscope.
First the fleshy Tibialis anterior muscle located directly under the skin had to be sectioned
off at the tendons, then the visually available EDL muscle was gently separated from the
tibia bone with the forceps and sectioned off at the tendons using microscissors. As the
EDL muscle was exclusively used for muscle fiber size determination, it was fixed in 4%
PFA o.n. at 4°C, dehydrated and embedded in paraffin in an automated tissue processor
(Leica) and subsequently sectioned using a microtome (Leica).
4.2.5.16 Immunohistochemical staining of the TVA muscle
The TVA muscle samples were immunohistochemically stained in order to visualize the
neuromuscular junctions. After processed as described in 4.2.5.15, the muscle fragments
were washed 3x 10 min in 1x PBS and subsequently permeabilized in 2% Triton X in 1x
PBS for 30 min and blocked in the blocking solution (see 4.1.9.5) for 1 h; both
permeabilization and blocking were conducted at room temperature on a rocking platform.
The primary antibodies (mouse anti-SV2, 1:100, rabbit anti-NF, 1:250 or only mouse anti-
NF, 1:250) were diluted in the blocking solution and 200 µl of the antibody solution was
added per TVA fragment for an o.n. incubation at 4°C. On the following day, the TVA
fragments were washed 6x 10 min with 1x PBS to prevent a high background from the
primary antibodies. Subsequently, TVA fragments were stained for 10 min with rhodamine-
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conjugated Bungarotoxin diluted in 1x PBS (0.5 µg/ml) in order to visualize the AChR
clusters at the endplates. Next, the samples were incubated with secondary antibody
(Alexa 488 anti-mouse, 1:250) in 1x PBS for 1 h in the dark. After this incubation, final
washing steps were carried out: 2x 5 min with 1% Triton/1x PBS, 2x 10 min with 1x PBS
and 1x 10 min in ddH2O. TVA fragments were mounted in Mowiol on glass slides and
stored at 4°C for microscopic analysis.
4.2.5.17 Hematoxylin and eosin staining of paraffin sections
In this study H&E stainings were performed to stain muscle tissue for subsequent fiber
size measurements as well as to perform a gross histological analysis of the intestine as
a non-neuronal organ affected in SMA. Upon o.n. fixation in 4% PFA the tissue specimens
were prepared for sectioning by dehydration and paraffin-embedding using an automated
tissue processor (Leica) and subsequently sectioned using a microtome (Leica).
In order to stain with H&E, the 7 µm sections were deparaffinized by incubation in Xylol for
30 min and rehydrated in a series of decreasing EtOH concentrations (100%, 96%, 70%,
50 %, 3 min each). Sections were quickly washed in 1x PBS and then in H2O for 1 min.
Next, sections were incubated in Hematoxylin for 6 min, shortly rinsed with H2O and
afterwards washed in H2O for 15 min. Afterwards the sections were rinsed quickly in fresh
H2O to remove excess dye and placed into Eosin solution for 1 min. Finally, the sections
were rinsed in H2O 6-7 times and then dehydrated in increasing EtOH concentrations
(50%, 70%, 96% and 100%, 1 min each). Finally, sections were air dried and embedded
in Eukitt mounting medium.
4.2.6 Microscopic image acquisition and analysis
All fluorescent images were acquired with a fully motorized fluorescence microscope
AxioImager.M2 equipped with an AxioCam MRm camera and an ApoTome device for
optical sectioning (Zeiss). For the NMJ and spinal cord images, Z stacks of 30-50 images
at a 0.5 µm interval were acquired. The images included in this thesis represent the
maximum intensity projections of the Z stacks. The image analysis was performed with the
ZEN (Zeiss) or Fiji software (Open Source).
For the analysis of VGlut1+ inputs on motor neuron soma, a custom macro developed by
Peter Zentis (CECAD imaging facility) with Fiji 3D Viewer extension was applied. The
macro segmented each image into two channels: one for ChAT+ motor neuron soma and
another for VGlut1+ inputs and ensured that voxels were isometric. Subsequently, both
single-channel images were smoothed: in the motor neuron soma image each pixel was
replaced with the median of its 6x6x4 neighborhood and an optional automatic background
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removal was performed by Li’s Minimum Cross Entropy thresholding method (Li and Tam
1998). In the VGlut1+ image each pixel was replaced with the median of its 16x16x16
neighborhood. In the smoothed VGlut1+ image the inputs were automatically segmented
using the 3D simple segmentation function of the 3D ImageJ Suite (Ollion et al. 2013)
under the following criteria: the intensity threshold was obtained from Otsu's threshold
clustering algorithm applied to the stack histogram (Otsu 1979) and 20 voxel was used as
a minimum size criterion. In smoothed ChAT+ image the experimenter draws the smallest
possible cuboids around non-overlapping motor neuron soma. Within the cuboid further
segmentation was performed automatically using the Otsu method to obtain input values
for a 3D hysteresis thresholding (3D ImageJ suite). The resulting mask was dilated by 4
voxels and finally holes in the mask were filled. Once all suitable motor neurons soma
within an image were selected, the macro processed each 3D selection, again using
functions of the 3D ImageJ suite, so that it first quantified all VGlut1 inputs within the
selection and then calculated only those relevant for a given motor neuron soma within 2
µm distance. Additionally, the volume of each motor neuron soma was determined.
All bright field images were acquired with a Axioskop2 microscope with an AxioCam ICc 1
camera (Zeiss) and processed with the ZEN (Zeiss) or Fiji software (Open Source).
4.2.7 Statistical analysis
Statistical analysis was performed with the GraphPad Prism 6 software. To test the
significance of RNA expression or protein levels, two-tailed unpaired student’s tests were
applied. Significance of in the phenotypic analyses in vivo was determined with two-way
ANOVA with Tukey’s correction for multiple comparisons. The survival was analyzed with
the Kaplan-Meier log rank method. Significance of histological analyses assessing the
NMJ and muscle fiber area, motor axon length and glutamatergic inputs on motor neurons
was determined with two-tailed unpaired student’s tests.
Values of P<0.05 were considered significant and three levels of statistical significance
were distinguished: *P<0.05, **P<0.01 and ***P<0.001.
58
5 Results
5.1 SMA mouse model with NCALD reduction – a transgene shRNA approach
As other in vitro and in vivo studies performed in our group as well as in collaboration with
the group of Anne C. Hart (Brown University) pointed strongly towards a rescuing potential
of NCALD downregulation on the SMA phenotype, ultimately we wanted to test this
hypothesis in a mammalian model of SMA, and the best studied model for that purpose is
the mouse. However, at that time no Ncald knock-out or inducible Ncald knock-down
mouse was available, so to analyze the effect of NCALD ablation on the SMA in vivo, we
needed to generate a new mouse line. To optimally model the phenotype present in the
Utah family members, who do not show complete loss-of-function but rather a reduction
of NCALD, we decided to apply a strategy of inducible gene knock-down in the mouse
using RNAi (Kleinhammer et al. 2011), which is making use of two molecular tools
described herein.
First, a modified line of mouse embryonic stem cells, IDG26.10-3, enables a more efficient
integrase-assisted recombination. In this line, a hygromycin resistance gene, driven from
a pgk promoter, has been inserted in the Rosa26 locus (Hitz et al. 2007) and is flanked by
a pair of attP sites, which are recognized by the ϕC31 integrase, a site-specific
bacteriophage which catalyzes unidirectionational recombination between attachment
motifs found in phage and bacterial genomes, termed attP and attB (Thyagarajan et al.
2001). The targeting vector is carrying the knock-in cassette flanked by attB; when it is
delivered to the cells together with the ϕC31 integrase expressing plasmid, the cassette
will be inserted in the genome specifically as a single copy into the attP-modified Rosa26
locus, with simultaneous excision of hygromycin gene. Therefore, both the genomic
localization and the number of transgenes integrated can be tightly monitored. The Rosa26
locus is commonly used for transgene recombination as an integration of a single vector
copy in this locus is sufficient to induce body-wide expression transgene (Nyabi et al.
2009).
Second, the downregulation of the gene of interest can be achieved by a knock-in of a
gene-specific shRNA sequence, which can be expressed constitutively or in a cell type
specific manner (using Cre recombinase system). Its expression can also be induced by
Doxycycline administration. We utilized the latter approach, where shRNA is expressed
from a Tet off/on H1 promoter, as best suited for our purpose as we could not exclude the
possibility that NCALD depletion impairs the development of the mice. The system
proposed by the group of Ralf Kühn had the advantage that all components necessary for
Dox-inducible shRNA expression were incorporated into a single vector: the shRNA
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sequence under the Doxycyclin-inducible H1 promoter, tet repressor (tetR) expressed
from a strong CAG promoter and neomycin resistance gene for later selection. When both
ϕC31 integrase and shRNA plasmids are delivered together to the ES cells by
electroporation, the ϕC31 integrase recognizes attP and attB sites, excises both cassettes
flanked by them: the hygromycin gene in the ES cells genome and the transgene cassette
(containing shRNA sequence and all regulatory components) and integrates the latter into
the host genome. The structure of the targeting vector and the modified Rosa26 locus are
schematically showed in Fig. 11.
Fig. 11: The shRNA mouse generation strategy
An shRNA against the gene of interest is cloned in the Dox-inducible targeting vector (pEx-H1-tetO-shRNA-
CAG-tetR) and by a recombinase-mediated cassette exchange (RMCE) mediated by the ϕC31 integrase it is
integrated in the modified Rosa26.10 locus of murine ES cells. The transgene integration can be verified by
PCR (adapted from (Kleinhammer et al. 2011).
The ES clones that underwent successful RMCE can be selected in cell culture via their
Neomycin resistance: upon excision of the hygromycin, the Neomycin gene is expressed
from the pgk promoter. Further details to the verification of transgene integration in the ES
are included in 5.1.2.
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The schematic mode of action of the H1-tetO-shRNA-TetR cassette within the targeting
vector is depicted in Fig. 12.
Fig. 12: Induction of shRNA expression upon Doxycycline induction.
In the absence of the inducer (Doxycycline), the constitutively expressed tetR binds to the tet-responsive
element within the H1 promoter and by steric hindrance prevents shRNA expression. When Doxycycline
(depicted as small circles) is applied, it would bind tightly to tetR and block its binding to the H1 promoter,
enabling shRNA expression (Wiederschain et al. 2009) (adapted from (Kleinhammer et al. 2011).
5.1.1 Selection of the efficient shRNA sequences against Ncald
The crucial step and a prerequisite for generation of a functional knock-down mouse model
is the selection of the most efficient shRNA sequence. Despite the progress in the
algorithm development for in silico prediction of effective si- and shRNAs, it is still
necessary to validate the sequences experimentally. Therefore, we obtained a
commercially available collection of lentiviral pLKO.1 vectors carrying five different shRNA
sequences directed against mouse Ncald (ThermoFisher Scientific). Fig. 13 shows the
localization of the shRNAs in the mouse Ncald gene and their sequences are listed in
Table 2.
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Fig. 13: The longest transcript (3733 bp) of mouse Ncald (NM_134094)
All 7 exons are depicted as green arrows and the coding sequence with the start codon in exon 5 and the stop
codon in exon 7 is highlighted as a yellow box. The sites targeted by the tested shRNAs are marked by red
triangles. Additionally, two ASO sequences described in chapter 5.3 are marked by blue triangles in the 3’UTR
of Ncald (5’ and 3’ UTR are depicted as black arrows upstream and downstream of the Ncald exons).
We transfected the Ncald-shRNA plasmids into mouse NSC34 cells and evaluated the
knock-down of endogenous NCALD by Western blot and by qRT-PCR (Fig. 14). However,
with this approach we were not able to determine the most potent shRNA sequence as all
vectors yielded low levels of silencing, possibly because of poor transfection efficiency of
lentiviral plasmids, which are originally designed for packaging and transduction of
lentiviral particles (Moffat et al. 2006). Also the results of replicate experiments remained
inconsistent, for example shRNA#2 was the least efficient in experiment 1 and the most
efficient in experiment 3 (Fig. 14a).
Fig. 14: Analysis of Ncald knock-down on protein and mRNA in NSC34 cells transfected with shRNAs
a) Western blots of cell lysates and b) quantification of NCALD knock-down efficiency from three independent
shRNA transfection experiments in NSC34 cells. Beta-actin (ACTB) was used as loading control. c)
Quantification of qRT-PCR of Ncald levels. Gapdh was used as housekeeping gene.
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Therefore, we decided to optimize the shRNA testing by applying an improved design of
longer shRNAs (29bp) in an EGFP-vector to better monitor the transfection efficiency
(Origene). Additionally, as the NSC34 cells were apparently not an optimal system for
shRNA screening, we developed an alternative, albeit more artificial, experimental set-up
using HEK293T cells. This cell line guarantees excellent transfection efficiency but due to
its kidney origin it does not express endogenous NCALD. Therefore, we co-expressed in
this cellular system a plasmid encoding Ncald-GFP (recognized by an anti-GFP antibody)
and shRNA vectors and by that we were able to identify two potent shRNA sequences:
one 21bp-sequence (shNcald#4) located in the exon 6 of Ncald led to ~90% knock-down,
and second 29bp-sequence (shNcald#6), which targeted exon 5 of Ncald, was the most
efficient one and achieved >95% knock-down (when compared to scramble shRNA). The
blots and knock-down quantification are depicted in Fig. 15. The limitation of this method
was that we could only validate shRNA sequences which targeted the coding sequence of
Ncald as the Ncald-GFP overexpressing vector contained only the minimal cDNA ranging
from the start to the stop codon, without any intronic regions or 5’ and 3’UTR, therefore
shRNA#1 had to be excluded from these tests.
Fig. 15: Identification of efficient shRNA sequences in an Ncald-GFP overexpression set-up
a) Blots of HEK293T cells co-transfected with Ncald-GFP plasmid and shRNA plasmids against Ncald coding
sequence. Transfection was performed in triplicates. b) Quantification of GFP-NCALD levels upon co-
transfection with respective shRNA plasmids: shNcald#4 and shNcald#6 were most potent in reducing GFP-
NCALD.
Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant, *P<0.05, **P<0.01,
***P<0.001.
The two shRNA sequences: shNcald#4 and shNcald#6 were subcloned to the targeting
vector which carried all necessary elements for Tet off/on regulation and their knock-down
efficiency was again confirmed under Doxycycline administration (Fig. 16).
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Fig. 16: Efficient knock-down of GFP-NCALD upon Dox-mediated shRNA expression
a) Western blot and b) quantification of GFP-NCALD knock-down in HEK293T cells co-transfected with Ncald-
GFP and Dox-inducible shRNA#4 and shRNA#6. Addition of Doxycycline reduced GFP-NCALD to 33%
(shRNA#4) and 18% (shRNA#6) of control levels. GFP-NCALD was not changed upon Doxycycline
administration in HEK293T cells transfected with scramble shRNA.
The experiment was performed in triplicates. Statistical analysis was performed using two-tailed student’s t-
test. n.s. not significant, *P<0.05.
5.1.2 Stable integration of the shRNA cassette in ES cells
Finally, we electroporated the targeting Ncald-shRNA vectors in combination with a vector
expressing the ϕC31 integrase, a protein needed for directional recombination into the
Rosa26 locus of IDG26.10-3 murine embryonic stem (ES) cells. Following electroporation,
the ES cells were cultured in selection conditions for ~10 days in the presence of G418
antibiotic to specifically select clones with integrated neomycin resistance cassette which
would be a hallmark of successful recombination. Then individual clones were picked and
expanded on two types of 96-well plates until confluence when they were treated as
following: the feeder-coated plates were frozen and stored in -80°C for future expansion,
whereas gelatin-coated plates were processed for DNA analysis.
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The DNA analysis consisted of two PCR reactions:
- PCR Nr.1, where the forward primer was located in the pgk-promoter and the reverse in
the neomycin gene, therefore the PCR product spanned the boundary between the
Rosa26 locus and the integrated transgene and was obtained only when successful RMCE
occurred (positive control of recombination);
- PCR Nr.2, where both primers aligned to the hygromycin gene, therefore the PCR
product was obtained in ES clones with unchanged Rosa26 locus, suggesting an
incomplete recombination, as the hygromycin gene was intended to be excised in the
course of the RMCE (negative control of recombination) (see Fig. 11).
For clones that scored positive for PCR Nr.1 and negative for PCR Nr.2 a successful and
complete recombination was anticipated. An exemplary agarose gel showing products of
both PCRs for the screened ES clones is shown in Fig. 17.
Fig. 17: Validation of the successful recombination in individual ES clones.
PCR results of 12 first clones (A1-B4) from one 96-well plate are depicted: P stands for PCR Nr.1 (pgk-
promoter), H stands for PCR Nr.2 (hygromycin) and M is the 100bp DNA ladder. All clones have undergone
recombination (positive for PCR Nr.1) but in clones A2, A7, A8 and B2 (positive for PCR Nr. 2) the
recombination was not complete as the hygromycin gene is still present.
Four ES clones with verified integration of the shRNA transgene were thawed and cultured
in the presence of 4 µg/ml of Doxycycline. The degree of Ncald knock-down was validated
by qRT-PCR. All clones showed efficient Ncald depletion following Dox induction, while no
such effect was observed in the unrecombined IDG26.10-3 cell line without the shRNA
transgene. The results of the qRT-PCR are depicted in Fig. 18.
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Fig. 18: Quantification of Ncald in ES clones upon Doxycycline induction
Clones 1-4 tested positive for the presence of the shRNA transgene and the unrecombined ES cell line
IDG26.10-3 were cultured in the presence or absence of Doxycycline [4 µg/ml] for 120 h and subsequently the
levels of Ncald were determined by qRT-PCR. For each clone the levels of the untreated sample were set to
100%. Gapdh was used as the housekeeping gene.
The experiment was performed in triplicates. Mean ± SEM. Statistical analysis was performed using the two-
tailed student’s t-test. n.s. not significant, *P<0.05, **P<0.01, ***P<0.001.
In the next steps the correctly integrated ES clones were supposed to be thawed,
expanded and injected into blastocysts, which would then be implanted into
pseudopregnant female mice to generate animals chimeric for the shRNA transgene.
However, at this stage of our mouse generation project we learned that a Ncald knock-out
mouse line is available at Jackson Laboratory (from April 2014, stock number #018575).
As this mouse model was both viable and fertile in the homozygous state, we decided to
stop the generation of the inducible Ncald knock-down mouse line and instead continue
with a stronger genetic model to unequivocally determine the potential of NCALD reduction
to improve the SMA phenotype.
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5.2 Severe SMA mouse model with NCALD reduction – a transgene knock-out
approach
The female and male Ncaldko/wt mice purchased from the Jackson Laboratory were on a
pure C57BL6/N background (backcrossed for min. 7 generations) and therefore could be
directly crossed with the SMA model used in our group.
The knock-out of mouse Ncald was achieved using the VelociGene strategy developed by
the Regeneron company (for further details see also 4.2.5.7.2). This first targeting pipeline
for mouse ES cells utilized bacterial artificial chromosome (BAC)-based targeting vectors
to replace the coding sequence of the target gene with a lacZ reporter and promoter-driven
neo selection cassette (Valenzuela et al. 2003). For the construction of targeting vectors,
cDNA sequences surrounding the translation initiation and termination signals of each
target gene were used, and in a single recombination, modified BAC ES clones were
generated with gene deletion of up to 70 kb size. This strategy was therefore particularly
suitable for targeting the large Ncald gene (> 426 kb).
As reported by the Jackson Laboratory, Ncaldko/ko mice were viable and fertile, but in our
observation the fertility of homozygous knock-out mice was severely diminished compared
to wildtype. Especially female Ncaldko/ko animals were not suited for breeding purposes:
although they gave birth to living pups, in most cases they did not feed their offspring
sufficiently and only very rarely litters of Ncaldko/ko dams survived to weaning. This
phenotype was less exacerbated in Ncaldko/wt females, although also here the interval
between pregnancies was noticeably longer than for wildtype. Surprisingly, Smnko/wt;
Ncaldko/wt females also showed a compromised maternal behavior, therefore, in order to
obtain consistent conditions for the in vivo analysis of SMA pups, only Smnko/wt; Ncaldko/wt
males were used for breedings (see also Fig. 9). Another striking characteristic of Ncaldko/wt
and Ncaldko/ko mice was a prominent weight reduction in comparison to wildtype.
5.2.1 Analysis of NCALD expression in wildtype, Ncaldko/wt and Ncaldko/ko mice
The protein analysis of diverse regions of CNS (hippocampus, cortex, cerebellum, spinal
cord) as well as peripheral organs (various muscles: TVA, EDL, Gastrocnemius, Tibialis,
as well as lung, kidney, liver and heart) confirmed the reported predominantly neuronal
expression profile of NCALD, with strongest expression in the hippocampus and cortex.
To a lesser degree NCALD could also be detected in peripheral organs: lung, liver and
kidney. At comparable exposure time and equal amount of protein, very weak NCALD
signal could be observed in muscle tissue or in the heart (Fig. 19a). Compared to SMN,
NCALD showed overall much lower expression levels (Fig. 19b).
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Fig. 19: Analysis of NCALD expression in wildtype mouse tissue on PND10
a) NCALD expression in different organs: CNS, skeletal muscles and peripheral organs. Stain-free gel was
used to determine total protein level. Membrane was also probed with an anti-SMN antibody as a ubiquitous
protein. b) Quantification of NCALD and SMN in various organs.
We analyzed the spinal cord and hippocampus samples of the Ncaldko mouse line by
Western blotting. As expected, we could see that NCALD signal had reduced intensity in
Ncaldko/wt mice and the band was completely absent in samples from Ncaldko/ko animals,
confirming the specificity of the antibody and the complete knock-out of Ncald (Fig. 20).
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Fig. 20: Analysis of NCALD expression in mutant mouse tissue on PND10
a) Western blot of spinal cord and b) hippocampus lysates obtained from PND10 Ncaldwt/wt, Ncaldko/wt and
Ncaldko/ko mice. Already one Ncaldko allele decreased the NCALD levels to ~40% in spinal cord and ~20% in
hippocampus. The NCALD specific band was absent in Ncaldko/ko animals.
The experiment was performed in triplicates. Mean ± SD. Statistical analysis was performed using the two-
tailed student’s t-test. *P<0.05.
5.2.2 Crossing the Ncaldko allele in the severe SMA mouse model
In our group, the Taiwanese SMA mouse model has been used for in vivo studies (Hsieh-
Li et al. 2000). In this model, to obtain offspring with SMA symptoms, the following two
parental lines are crossed (Riessland et al. 2010):
1) Smnko/wt – the mouse line is maintained in a heterozygous state as a complete Smn
knock-out is embryonic lethal.
2) Smnko/ko, hSMN2tg/tg – here the homozygous knock-out of mouse Smn is compensated
by two transgene alleles, of which each carries two tandem copies of human SMN2. The
animals survive till adulthood and are fertile; their only remaining phenotype common with
severely affected SMA animals is the tail and ear necrosis.
Crossing these two parental lines gives rise to two possible genotypes as offspring:
1) Smnko/ko, hSMN2tg/0 – In short referred to as SMA mice, these mice are severely affected
with motor neuronal and muscular defects as well as a multi-organ impairment. They show
poor weight gain (after the disease symptoms start, they show gradually a substantial
weight loss) and frequently develop diarrhea; depending on the genetic background, the
mean survival ranges from 9.9 days (FVB) to 15.5 days (C57BL6/N) and 19.2 days (mixed
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background 50% FVB:50% C57BL6/N) (Riessland et al. 2010, Ackermann et al. 2013,
Schreml et al. 2013).
2) Smnko/wt, hSMN2tg/0 – In short referred to as HET mice and used as controls. These
mice present generally an asymptomatic phenotype: their survival is not decreased and
they reach adulthood. Their motor performance and their weight progression are normal
(Ackermann et al. 2013).
As the generation of SMA animals carrying complete Ncald knock-out required a mouse
line with three transgenes, we first pursued the analysis of heterozygous Ncald knock-out
in SMA animals, particularly as this would better model the human phenotype of NCALD
depletion and not a complete absence. For that, the following breeding scheme was used
(see also Fig. 9):
Ncaldwt/wt, Smnko/ko, hSMN2tg/tg x Ncaldko/wt, Smnko/wt, hSMN20/0
The resulting offspring carried one of the four genotypes:
1) Ncaldwt/wt, Smnko/ko, hSMN2tg/0 – identical with the SMA mice described above.
2) Ncaldwt/wt, Smnko/wt, hSMN2tg/0 – identical with the HET mice described above.
3) Ncaldko/wt, Smnko/ko, hSMN2tg/0 – SMA mice with reduced NCALD levels due to the
presence of one Ncaldko allele, in short referred to as SMA-Ncaldko/wt mice.
4) Ncaldko/wt, Smnko/wt, hSMN2tg/0 – HET mice with reduced NCALD levels, in short referred
to as HET-Ncaldko/wt mice.
Animals of all four genotypes listed above were subjected to in vivo analyses concerning
their survival, weight progression and motoric performance. In parallel, the effect of
NCALD reduction on SMA phenotype was studied in motor neurons derived from E13
embryos, as well as in the spinal cord, muscle tissue and intestine obtained from PND10
mice of the four genotypes under study.
5.2.3 Phenotypic in vivo analysis of SMA-Ncaldko/wt mice: survival and weight
First, we monitored the survival and weight progression for all four genotypes (Fig. 21).
Although NCALD reduction could rescue the effects of SMN reduction in other models
(particularly those related to neuronal outgrowth and differentiation, e.g. neurite length in
cells and axon length in zebrafish), in a severe SMA mouse model we did not observe any
difference in mean survival between SMA and SMA-Ncaldko/wt mice (Fig. 21a). In parallel
also the weight progression was monitored and the onset of SMA symptoms in this mouse
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model started on PND5, as from this time point the weight between SMA and HET animals
differed significantly and the difference increased, confirming the progressive nature of the
disease (Fig. 21b). At all time points the weight of SMA and SMA-Ncaldko/wt animals was
not statistically different. For both genotypes the death corresponded to a prior period of
noticeable weight loss or stagnation (as opposed to a significant weight gain in HET
littermates) and frequent diarrhea which underlines the involvement of gastrointestinal
tract in the disease phenotype of the severe SMA mice (Sintusek et al. 2016).
While weight monitoring was only possible for up to 2 weeks on average for SMA animals,
we were able to perform long time studies of HET and HET-Ncaldko/wt animals (Fig. 21c).
Interestingly, the weight of HET and HET-Ncaldko/wt mice differed significantly onwards
from 8 weeks of age. Most strikingly, upon reaching the adulthood at ~ 8 weeks of age the
HET-Ncaldko/wt animals have reached almost their final weight while their HET counterparts
continued to gain weight. The difference in mean body weight was irrespective of the sex
but more pronounced in male mice (significant difference between HET and HET-Ncaldko/wt
male started already from week 8th). Upon dissection the decreased body weight
manifested itself at the level of adipose tissue, which was abundant in HET animals
subcutaneously, peritoneally and epigonadally, but present at a strikingly lower amount in
HET-Ncaldko/wt animals. Already the absence of one Ncald gene copy was sufficient to
trigger the lower body weight, which was not exasperated by the complete loss of NCALD
as the weight of HET-Ncaldko/wt and HET-Ncaldko/ko animals was not significantly different
at any time point observed, despite the latter showing a trend to lower values (Fig. 21c).
This observation suggested that NCALD plays a crucial role in regulating body weight,
particularly concerning the body composition and the amount of adipose tissue. In SMA-
Ncaldko/wt animals this effect of NCALD reduction on body weight was not pronounced,
presumably because it did not yet manifest during their shortened lifespan. In conclusion,
elucidating the mechanism how NCALD affects body weight should be the subject of future
studies.
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Fig. 21. Survival and weight studies of SMA-Ncaldko/wt mice
a) Mean survival was not changed between SMA (12.9 ± 3.2 days, n=28) and SMA-Ncaldko/wt mice (13.1 ± 5.3
days, n=22). Survival of both genotypes was not different from each other but highly significantly different from
HET controls. Significance of the survival curves was assessed with the Mantel-Kox log-rank test. b) During
the time period represented on the graph mean body weight did not differ significantly between of SMA and
SMA-Ncaldko/wt mice; at the same time, body weight of both SMA groups was significantly smaller from both
HET groups, starting from PND5. SMA n=18, SMA-Ncaldko/wt n=25, HET: n=30, HET-Ncaldko/wt: n=34. c) Mean
body weight of HET-Ncaldko/wt mice was significantly reduced when HET-Ncaldko/wt to HET littermates from the
11th week of life onward. HET: n=14, HET-Ncaldko/wt: n=28, HET-Ncaldko/ko: n=11. The significance calculated
against HET controls is indicated above the line for HET-Ncaldko/wt mice and below the line for HET-Ncaldko/ko
mice. Mean ± SD.
For statistical analysis of the weight studies two-way ANOVA with Tukey correction for multiple comparison
was applied. *P<0.05, **P<0.01, ***P<0.001.
5.2.4 Phenotypic in vivo analysis of SMA-Ncaldko/wt mice: motoric skills
Previous studies by our and other groups reported affected motoric skills in SMA animals
as compared to HET littermates. As the SMA mice die usually in the first two weeks of
age, the motoric tests have to be suitable for neonatal mice, while still reflecting the muscle
strength and performance. The SMA research community has been applying various tests
to address this issue: tail-suspension test (self-clasping), negative geotaxis, righting reflex
(scored proportionally to the time needed to right) and hind-limb suspension test (also
known as the tube test). The last assay was specially developed to assess the muscle
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strength of proximal hind limbs in neonatal rodents (between PND2 and 12) and following
parameters can be evaluated: the latency to fall (in seconds), the number of pulls and the
hind-limb position (El-Khodor et al. 2008). In our group the last two assays have previously
been used for studies of modifier genes as well as therapeutic treatments (Garbes et al.
2009, Riessland et al. 2010, Ackermann et al. 2013, Schreml et al. 2013). Therefore, we
used both the righting reflex test and the tube test to analyze the motoric skills of the four
genotypes under study.
The results of the righting reflex test showed that except for very early time point, SMA-
Ncaldko/wt animals needed on average more time to right themselves than SMA littermates,
and this difference was significant on PND6 and PND9 (Fig. 22a). SMA-Ncaldko/wt mice
performed also significantly worse than HET animals through the symptomatic period
(from PND6 till PND11).
The tube test was less sensitive than the righting reflex test, although to guarantee
consistency it was in > 90% performed by the same operator (Fig. 22b). We saw that SMA
animals performed on average better that SMA-Ncaldko/wt mice and this difference was
significant on PND12.
Fig. 22. Evaluation of motoric skills of SMA-Ncaldko/wt mice
NCALD reduction did not improve motoric performance of SMA-Ncaldko/wt mice in comparison to SMA
littermates as assessed by a) righting reflex test or b) tube test. The mean number of animals evaluated for
motoric performance per day: SMA: n=20, SMA-Ncaldko/wt: n=17, HET: n=27, HET-Ncaldko/wt: n=30.
For both motoric tests two-way ANOVA with Tukey correction for multiple comparisons was applied. *P<0.05,
**P<0.01, ***P<0.001. The significance is indicated for SMA-Ncaldko/wt mice in comparison to SMA (black stars)
or HET (green stars) littermates.
In conclusion, the tests evaluating motoric skills need to be improved in order to detect
apparently subtle differences in the motoric skills of SMA-Ncaldko/wt mice: in the righting
reflex test, the time of observation could be extended to 30 seconds (instead of 10) and in
the tube test, latency to fall could be added as a second parameter.
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Parallel to our in vivo phenotypic studies, we set out to analyze the effect of NCALD
reduction on the neuromuscular system, which is known to be primarily affected in SMA.
First, we cultured spinal motor neurons in vitro and evaluated the axonal length under
reduce NCALD. Then we performed multiple morphological analyses in tissues obtained
from PND10 mice: we quantified the glutamatergic inputs on motor neurons, the cell size
of spinal motor neurons in vivo, the neuromuscular junction area in the Transversus
abdominis (TVA) muscle and the muscle fiber size in (EDL) muscle. Eventually, we
evaluated histologically the intestine as a representative non-neuronal organ, where
defects have been also reported in severe SMA mouse models (Sintusek et al. 2016). In
these analyses all four genotypes were included (SMA, SMA-Ncaldko/wt, HET, HET-
Ncaldko/wt), with minimum three animals of each genotype. All analyses were performed in
a blinded manner, i.e. the genotypes of the animals were encrypted before the actual
analysis and decoded only after the final data have been collected.
5.2.5 NCALD reduction in motor neurons from SMA mice restored axonal outgrowth in
vitro
To analyze the effect of NCALD reduction on the primary tissue affected in SMA, we
cultured spinal motor neurons from E13 embryos of the four genotypes listed above. We
confirmed that NCALD levels were reduced in SMA-Ncaldko/wt and HET-Ncaldko/wt motor
neurons by Western blotting (Fig. 23a).
The motor neurons were fixed at DIV6 and the total axonal length, length of the longest
axon and the number of branches were evaluated. The quantification results as well as
representative images of all four genotypes are depicted in Fig. 23b-e.
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Fig. 23: Motor neurons from SMA-Ncaldko/wt mice show longer axons and increased branching than
SMA mice
a) Western blot and quantification of NCALD and SMN expression in lysates from motor neurons of indicated
genotypes. N = 2 samples per genotype. Mean ±SD. b) Representative images of motor neurons of all
genotypes analyzed stained with antibodies against HB9 (green, motor neuron soma) and Tau (red, axons)
and DAPI (blue, nucleus). Scale bar, 25 µm. c) The mean length of the longest axon was determined for all
genotypes. Motor neurons from SMA-Ncaldko/wt embryos developed in vitro longer axons than from SMA
littermates, although the rescue did not reach HET levels. d) The mean number of branches per MN was
determined. NCALD reduction resulted in an increased branching both in SMA-Ncaldko/wt and HET-Ncaldko/wt
MNs. e) The cumulative length of the longest axon and its branches was determined for all genotypes. This
total axon length was highly significantly improved in SMA-Ncaldko/wt MNs when compared to SMA ones and
did not differ between SMA-Ncaldko/wt, HET and HET-Ncaldko/wt MNs.
For all genotypes at least 120 MNs in total were evaluated, from three embryos from three different litters. The
analysis was performed double-blinded (the genotypes were disguised during the image acquisition and the
data analysis). Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant, *P<0.05,
**P<0.01, ***P<0.001.
As predicted from previous experiments, where NCALD reduction by RNAi rescued the
axon length of SMA motor neurons (Riessland et al. under review), also genetic ablation
of NCALD resulted in longer axons in motor neurons derived from SMA-Ncaldko/wt embryos.
This effect could be already observed when only the longest axons were measured (Fig.
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23b). Moreover, we noticed an enhanced branching both in SMA-Ncaldko/wt and HET-
Ncaldko/wt motor neurons, which was in line with the phenotype observed in smn+ncald MO
zebrafish.
5.2.6 Neuromuscular junctions of SMA-Ncaldko/wt mice show larger AChR clusters
As SMA is primarily a disease of neuromuscular system, we focused our attention on the
synapse which is crucial for this system, namely at the neuromuscular junction (NMJ). It is
known that NMJs in SMA mice show the following abnormalities: smaller area covered by
acetylcholine receptors (AChR), which can be visualized with fluorescently labeled
Bungarotoxin, delayed maturation both on a morphological level (as determined by the
structural complexity of the endplate) (Gogliotti et al. 2012) and molecular level (retention
of fetal Z-agrin) (Kong et al. 2009), as well as prolonged polyinnervation (Torres-Benito et
al. 2011).
As not all muscles are equally affected by the SMA-related atrophy, with the more proximal
muscles showing a more severe impairment, we selected for analysis Transversus
abdominis (TVA), a muscle of the anterior and lateral abdominal wall which has been
widely studied in the context of SMA (Murray et al. 2008). TVA is crucial for compressing
ribs and viscera as well as involved in expiration. The muscle samples were prepared as
in 4.2.5.15 and subsequently the size of the Bungarotoxin-positive endplates was
assessed (Fig. 24).
The area occupied by AChR as visualized by rhodamine-labelled bungarotoxin (BTX) was
significantly smaller in SMA animals than in HET controls. At the same time, the AChR
area was significantly increased in SMA-Ncaldko/wt animals when compared to SMA
littermates, yet it did not reach the levels of HET animals (SMA: 140.5 ± 22.8 µm2, SMA-
Ncaldko/wt: 174.1 ± 9.2 µm2, HET: 246.5 ± 18.9 µm2. Mean ± SEM). This finding was the
first indication that NCALD suppression in a mammalian SMA model might actually
improve structures known to be affected in SMA. This is of particular importance, as NMJ
is increasingly acknowledged as the structure where the SMA pathogenesis is initiated
(Boido and Vercelli 2016), underlining the axonopathic character of this disease. Recent
findings highlight the contribution of skeletal muscle to the SMA phenotype (Fayzullina and
Martin 2014) and neuromuscular junction is the synapse which requires the proper cross-
talk of axon and muscle fiber to be formed and maintained.
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Fig. 24: Analysis of NMJ size in the TVA muscle of PND10 mice
a) Representative images and b) quantification of mean Bungarotoxin-positive NMJ area in the TVA of PND10
animals of all four genotypes under study, stained with antibodies against SV2 and NF (green) and
Bungarotoxin (BTX, magenta) to visualize the AChR clusters. The mean NMJ area of SMA-Ncaldko/wt mice is
significantly larger than in SMA littermates but does not reach the levels of HET animals. Scale bar, 10 µm.
Bars depict the values within the 25-75% range, whiskers cover the 5-95% range.
For all genotypes at least three animals were analyzed, 100-120 NMJs were measured per animal. The
analysis was performed double-blinded. Statistical analysis was performed using two-tailed student’s t-test.
***P<0.001.
We extended our initial analysis with two further time points to include a presymptomatic
stage at PND5 and a late symptomatic stage at PND13. At PND5 the difference in the
NMJ area was already significant between SMA and HET animals, which is in line with the
NMJ defect being one of the earliest SMA defects (Ling et al. 2012, Yoshida et al. 2015).
The NMJ area in the TVA of SMA-Ncaldko/wt animals was not significantly different from
SMA littermates (SMA: 126.5 ± 14.6 µm2, SMA-Ncaldko/wt: 125.2 ± 28.4 µm2. Mean ± SEM);
however, for all genotypes except for SMA mice, the NMJ area increased between PND5
and PND13 (Fig. 25a). These results indicate that NCALD reduction counteracts the
developmental impairment of the NMJ synapse in SMA mice.
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Fig. 25: Analysis of NMJ size in the TVA muscle of PND5 and PND13 mice
a) Quantification of mean Bungarotoxin-positive NMJ area in the TVA of PND5 and PND13 animals of all four
genotypes under study. Mean SD. b) Representative images of NMJs in the TVA muscle on PND13 stained
with an antibody against NF (green) and Bungarotoxin (BTX, magenta) to visualize the AChR clusters. No
denervation was observed in PND13 SMA mice, confirming that in this mouse model denervation is not a
prominent phenotype, even at the late stage of the disease. Scale bar, 25 µm.
For all genotypes and time points at least three animals were analyzed, 100-120 NMJs were measured per
animal. Mean ± SD. Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant,
***P<0.001.
We observed that practically all endplates in the TVA muscles received axonal inputs,
even at the late disease stage on PND13 (Fig. 25b), which is in line with a recent study
reporting only very limited denervation in the Taiwanese SMA model (Lin et al. 2016).
5.2.7 Number of glutamatergic inputs on spinal cord motor neurons is increased in SMA-
Ncaldko/wt mice
The motor neurons are the cell type most severely affected in SMA both in their number
and size (Monani et al. 2000), with specifically alpha motor neurons degenerating and
gamma motor neurons being spared in the spinal cord of SMA mice (Powis and
Gillingwater 2016). It was reported that additionally to the actual atrophy of motor neurons
an impairment in their neuronal circuitry is visible as assessed by the number of
glutamatergic inputs from interneurons signaling on motor neurons, although whether this
is the cause or rather the consequence of motor neuron soma impairment is under debate
(Mentis et al. 2011, Gogliotti et al. 2012). We studied the effect of NCALD reduction on
spinal motor neuronal circuitry in PND10 mice by determining the average number of
VGlut1 positive inputs per motor neuron soma in lumbar spinal cord sections (Fig. 26). We
confirmed that SMA motor neurons had significantly less VGlut1+ inputs than HET
controls, particularly those neurons with soma volume greater than 5000µm3. Although our
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analysis did not involve a systematic motor neuron counting, we observed in the analyzed
population that in SMA animals the average motor neuron volume was smaller than in HET
due to a higher proportion of smaller neurons (<5000µm3). NCALD reduction did not
increase the average motor neuron volume in SMA-Ncaldko/wt animals, rather the opposite,
as the proportion of smaller motor neurons increased (SMA: 3445 ± 1803 µm3, SMA-
Ncaldko/wt: 3096 ± 1453 µm3, HET: 4173 ± 1996 µm3. Mean ± SD) (Fig. 26b). However,
NCALD reduction resulted in a significant increase of the mean number of VGlut1+ inputs
number per motor neuron soma, suggesting an improvement to the motor neuronal
circuitry (Fig. 26a). This effect correlated with the NCALD reduction independently of SMN
deficiency, as in the HET-Ncaldko/wt animals the number of VGlut+ inputs was the highest
and was significantly increased in comparison to HET littermates (SMA: 14.3 ± 0.4, SMA-
Ncaldko/wt: 17.6 ± 0.5, HET: 19.2 ± 0.9, HET-Ncaldko/wt: 27 ± 0.9. Mean ± SEM). It is possible
that the effect of NCALD reduction is even stronger in sensory neurons as NCALD
expression is supposedly higher in those neurons. As we observed that lower NCALD
levels are associated with increased branching in zebrafish, it is possible that also the
axons of sensory neurons show this phenotype, resulting in more synaptic contacts on the
motor neuron soma.
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Fig. 26: Evaluation of glutamatergic inputs on spinal motor neuron soma in SMA-Ncaldko/wt mice
a) Representative images and quantification of glutamatergic inputs on motor neuron soma. Mean number of
VGlut1+ inputs pro motor neuron was increased in spinal cords derived from PND10 SMA-Ncaldko/wt mice
(SMA= 14.3 ± 10, SMA-Ncaldko/wt =17.6 ± 9. Mean ± SD). Spinal cord sections were stained with antibodies
against ChAT (magenta) to visualize motor neuron soma and VGlut1 (green) to visualize glutamatergic inputs.
Scale bar, 25 µm. b) The distribution of cell volume values within a genotype (left panel) and mean values for
individual animals (right panel). The motor neuron volume is smaller in SMA animals that in HET controls and
is not increased by NCALD reduction, on the contrary, it is further decreased. Bars depict the values within the
25-75% range, whiskers cover the 5-95% range. c) Despite smaller volume of motor neuron soma, the higher
number of VGlut1+ inputs per motor neurons translated to a steep increase in the input/µm3 ratio in SMA-
Ncaldko/wt mice.
For each genotype, three animals were analyzed and 100 motor neurons were analyzed per animal. The
analysis was performed double-blinded (the genotypes were disguised during the image acquisition and the
data analysis). Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant,
***P<0.001.
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5.2.8 Muscle fiber size is not changed in the EDL of SMA-Ncaldko/wt mice
Historically, in SMA the motor neuron degeneration was acknowledged as the primary
disease mechanism and the target for treatment, while muscle weakness and paralysis in
SMA were viewed as secondary effects (Dubowitz 2009, Hamilton and Gillingwater 2013,
Simone et al. 2016). Recent decades, however, have advanced the knowledge of the
intricate interaction between motor neurons and the muscles they innervate. Therefore,
many studies attempted to elucidate whether the severe reduction of muscle fiber size
observed in SMA mice is indeed secondary to defective neuromuscular transmission or
possibly the result of intrinsic muscle abnormalities (Ruiz et al. 2010, Lee et al. 2011).
Cellular and molecular analyses unraveled a number of abnormalities in myofibers from
SMA patients and mouse models: enhanced degeneration, altered expression of
myogenic genes crucial for muscle development (MyoD and myogenin) and myotube
formation deficits (Braun et al. 1995, Boyer et al. 2014, Bricceno et al. 2014). Recent
studies addressed also the question about the temporal relation between muscular and
motoneuronal defects and found quite unexpectedly that SMA-related muscle defects
occur early in the disease progression and independently of motor neuron cell death: when
the extent of cell death was assessed by the degree of apoptosis (evaluated histologically
by H&E stainings and TUNEL assays) and DNA fragmentation, in the muscle the damage
was visible already at birth (on PND0) and increased till PND8, while on PND5 no loss of
motor neurons or any other pathologies in the ventral horns of the spinal cord could be
observed and only on PND8 DNA fragmentation was visible in spinal cord (Fayzullina and
Martin 2014).
The debate about muscle-intrinsic defects in SMA was based largely on an early study
which showed that SMN restoration specifically in muscle tissue did not ameliorate the
SMA phenotype as assessed by lifespan and motor performance, in contrast to neuronal
SMN expression (Gavrilina et al. 2008). However, the SMN expression in muscle was
controlled by the human actin promoter that is not active in satellite cells and myoblasts,
which were both reported to show impairment upon low SMN levels (Nicole et al. 2003,
Shafey et al. 2005).
To test whether NCALD reduction exert a positive effect on the muscle, we analyzed the
diameter of muscle fibers in Extensor digitorum longus (EDL), a hind limb muscle which
was reported to be affected in the SMA mice and importantly, to respond to therapy
(Naryshkin et al. 2014) (Fig. 27).
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Fig. 27: Analysis of the muscle fiber size in the EDL of PND10 mice
a) Representative images of H&E stainings of 7 µm paraffin sections of the EDL muscle. The difference in
muscle fiber size is clearly visible between SMA and HET animals. Scale bar, 50 µm. b) The quantification of
muscle fiber size shows no difference between SMA and SMA-Ncaldko/wt mice which both showed lower values
than HET animals. Interestingly, the muscle fiber size was significantly increased in HET-Ncaldko/wt compared
to HET littermates. c) Mean values presented as bars for individual mice show little degree of variability within
genotype. Mean ± SD.
For each genotype three animals were analyzed and 100 muscle fiber were measured per animal. The analysis
was performed double-blinded (the genotypes were disguised during the image acquisition and the data
analysis). Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant, **P<0.01,
***P<0.001.
The fact that in no improvement could be observed in muscle fiber size can be explained
by extremely low NCALD expression in this tissue, as we could not detect NCALD by
Western blotting in various muscles (see Fig. 19). Moreover, in the severe SMA model
under study the skeletal muscle is affected early in the disease, as some abnormalities
were reported already at birth (Fayzullina and Martin 2014). Another hypothesis is that
SMN levels in the muscle are too low and the resulting muscle-specific defects too severe
so that the Ncaldko/wt-mediated improvement at the MN soma and the NMJ does not
translate to the muscle in the severe SMA animals. This hypothesis was further tested in
5.3.6.
5.2.9 SMA-Ncaldko/wt mice suffer from impairment of peripheral organs outside of CNS
The fact that we could see improvement of some motor neuronal characteristics of the
SMA phenotype upon NCALD reduction, but not of the overall phenotype as monitored by
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survival and weight, is partially explained by the fact that this SMA model is known to be
severely affected and shows impairment of multiple organs apart from the neuromuscular
system, particularly heart, lungs and intestine, as well as liver, pancreas and kidneys
(Ackermann et al. 2013, Schreml et al. 2013, Bowerman et al. 2014). Histological sections
of the intestine confirmed this hypothesis, showing for both SMA and SMA-Ncaldko/wt mice
reduced number and frequently changed shape of villi (many were blunt-ended), edema
in the lamina propria and occasional dilation of the lacteals (Fig. 28), which were all
reported abnormalities in SMA animals, and absent in the HET littermates (Schreml et al.
2013). In line with these intestinal defects, diarrhea was frequently observed in SMA and
SMA-Ncaldko/wt animals.
Fig. 28: The intestinal impairment in the severe SMA mouse model
Representative images of H&E stainings of 7 µm paraffin sections from the small intestine of PND10 SMA,
SMA-Ncaldko/wt, HET and HET-Ncaldko/wt animals. The intestine of both SMA and SMA-Ncaldko/wt mice shows
abnormalities such as decreased number of villi and edema in the lamina propria (marked by back
arrowheads). Scale bar, 50 µm. Three animals per each genotype were analyzed.
Another cause of this selective phenotype improvement might be the predominantly
neuronal specificity of NCALD expression, which likely does not extend to other tissues
affected in SMA (see Fig. 19). Therefore, we decided to analyze how NCALD reduction
affects SMA phenotype in an intermediate mouse model where the impairment of most
organs is at least moderately ameliorated and the survival is prolonged to 3-4 weeks.
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5.3 Intermediate SMA mouse model with NCALD reduction – an SMN-ASO
approach
As other work performed in our group proved that protective modifiers identified in humans
have the potential to improve survival of an intermediate SMA model (Hosseinibarkooie
2016), we applied this model to test whether the protective effect of NCALD reduction is
possibly greater provided that SMN levels are sufficiently increased. Importantly, also in
the SMN1-deleted asymptomatic individuals (see Fig. 5) there are four SMN2 copies
present, and not only two as in the severe SMA model.
The model we used is generated by a treatment with subphenotypic doses of an antisense
oligonucleotide (SMN-ASO) (Hua et al. 2011). The SMN-ASO (in the following chapters
referred to as ASO) is directed against an intronic splicing silencer (ISS) present in intron
7 of SMN2 and by masking this ISS it leads to an increase of SMN expression from SMN2
transgene in the mice (Fig. 29).
Fig. 29: SMN-ASO mode of action
The SMN-ASO targets the 10-27 bp of SMN2 intron 7 and blocks the binding of the hnRNP to the ISS. As a
results, exon 7 is not skipped during splicing but gets included in the SMN2 transcript, eventually giving rise to
more full-length SMN protein (adapted from SMA center at the University Medical Center Utrecht).
5.3.1 SMN-ASO injection increased SMN levels in the liver and spinal cord in SMA+ASO
mice
We injected the SMN-ASO subcutaneously twice on two consecutive days to neonatal
mice (on PND1 and 2). Each injection consisted of the same dosis of 30 µg of SMN-ASO
at a concentration of 10 µg/µl. We confirmed by Western blot of tissues from PND10 mice
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that ASO injection elevated SMN levels, particularly strongly in the liver, in comparison to
uninjected mice of the same genotype. The effect of ASO injection was also visible in
spinal cord, albeit to a lesser degree. Importantly, the SMN-ASO exerted a comparable
effect on the SMN levels in both tested genotypes (Fig. 30).
Fig. 30: SMN-ASO injection increased SMN levels in liver and spinal cord
Tissue lysates were prepared from three animals per genotype. The SMN levels increased ~2fold in the spinal
cord and up to 5fold in the liver which is in line with previous studies that reported an accumulation of SMN-
ASO in the liver (Hua et al. 2011, Hosseinibarkooie et al. 2016).
Statistical analysis was performed using two-tailed student’s t-test. n.s. not significant, *P<0.05, ***P<0.001.
Next, the injected animals of all four genotypes were subjected to identical analyses as
the uninjected ones: their lifespan and weight progression were evaluated as well as the
motoric performance with the tube test and righting reflex test. The anatomical analyses
of spinal motor neurons, NMJs in the TVA muscle and muscle fibers in the EDL muscle,
as well as the intestinal sections were conducted on PND21 as this represented a
symptomatic time point, similar to the PND10 in the uninjected mice.
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5.3.2 Phenotypic analysis of SMA-Ncaldko/wt +ASO mice: survival and weight
As expected, the SMN-ASO injection prolonged the mean survival of SMA animals
irrespective of the Ncald genotype (Fig. 31). However, there was a rather huge variability
between as well as within litters: the survival ranged from 8-9 days (and therefore not
improved in comparison to uninjected) to >200 days. This broad distribution reflects the
variability visible in the uninjected SMA mice as the weakest with confirmed genotype died
on PND8 and the strongest survived to PND 21-22 without ASO injection. Another feasible
factors accounting for this variability are presumably some variation in ASO administration
(despite preparation of larger batches of ASO solution of photometrically confirmed
concentration) as well as variable quality of maternal care, possibly also affected by the
number of animals in a litter.
Fig. 31: Survival and weight studies of SMA+ASO and SMA-Ncaldko/wt+ASO mice
a) Most SMA+ASO and SMA-Ncaldko/wt+ASO mice survived 3-4 weeks, however, some animals which
survived post weaning showed a much longer lifespan (20% of SMA+ASO and 8% of SMA-Ncaldko/wt+ASO).
The mean survival of short-living SMA+ASO mice was 19.2 ± 7.8 d, n=16, and of shorter-living SMA-
Ncaldko/wt+ASO mice was 19.1 ± 6.7 d, n=22. The mean survival of long-living mice SMA+ASO mice was
269.6 ± 92.9 d, n=6; the small population of long-living SMA-Ncaldko/wt+ASO mice survived on average 177.5
± 152 d, n=2. Mean ± SD. b) Body weight did not differ significantly between of SMA+ASO and SMA-
Ncaldko/wt+ASO mice and body weight of both groups was significantly smaller from both HET+ASO groups,
but increased in comparison to uninjected animals. The peak of the body weight was reached around PND15.
Significance of the survival curves was assessed with the Mantel-Kox log-rank test.
For statistical analysis of the weight studies two-way ANOVA with Tukey correction for multiple comparison
was applied. *P<0.05, **P<0.01, ***P<0.001.
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5.3.3 Phenotypic analysis of SMA-Ncaldko/wt +ASO mice: motoric tests
The motoric tests described in 4.2.5.9-10 were also applied to assess the motoric
performance of SMA+ASO and SMA-Ncaldko/wt+ASO mice. Similar to the results obtained
in uninjected SMA, the differences between genotypes were not very pronounced. Still,
some relations observed in the uninjected mice could be recapitulated under SMN-ASO
injection.
The results of the righting reflex test showed that except for very early time point (PND2),
SMA-Ncaldko/wt+ASO animals needed on average more time to right themselves than
SMA+ASO littermates, though this difference reached significancy only on PND7 (Fig.
32a). Again, the motoric performance of SMA-Ncaldko/wt+ASO mice was significantly worse
than of HET+ASO animals starting from PND6 till PND10. The overall tendency shown by
the righting reflex test was in agreement with results from uninjected mice (see Fig. 22a).
In the tube test (Fig. 32b) we could not observe any significant difference between the
performance of SMA+ASO and SMA-Ncaldko/wt+ASO mice, except on PND2, which is not
a representative time point, as neonatal pups do not show much movement or muscle
strength at this age. Notably, animals of both genotypes showed a steep decline in the
tube test score from PND10, likely as the muscle weakness was combined with heavier
body weight than in uninjected animals (see Fig. 31b). On the PND13 the difference to
HET controls was highly significant in SMA+ASO mice (P<0.001) and on PND14 this
significance was given for both SMA+ASO and SMA-Ncaldko/wt+ASO mice.
As these results could be potentially biased by the fact that in the SMA+ASO group some
animals (n=6) survived significantly longer than 4 weeks, as opposed to SMA-
Ncaldko/wt+ASO mice, where only two animals showed longer survival, we re-analyzed the
results in subgroups: short-living SMA+ASO / long-living SMA+ASO / short-living SMA-
Ncaldko/wt+ASO / HET+ASO. In the righting reflex test (Fig. 32c), the long-living SMA+ASO
mice showed a tendency towards better performance than the short-living ones, although
the results did not reach statistical significance, likely because of a small group size. When
only short-living animals were compared, there was no significant difference between
SMA+ASO and SMA-Ncaldko/wt+ASO mice. In the tube test (Fig. 32d), the long-living
SMA+ASO mice performed better only till PND7, but again, these results were not
statistically significant.
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Fig. 32: Evaluation of motoric skills of SMA-Ncaldko/wt+ASO mice
a) The righting reflex test showed a similar trend as observed for uninjected SMA-Ncaldko/wt mice. b) The
results of the tube test were not different between SMA+ASO and SMA-Ncaldko/wt+ASO mice. The significance
is indicated for SMA-Ncaldko/wt+ASO mice in comparison to SMA+ASO (black stars) or HET+ASO (green stars)
littermates, except PND13 in the tube test, which represents SMA+ASO mice in comparison to HET+ASO.
SMA+ASO, n= 23, SMA-Ncaldko/wt+ASO, n=23, HET+ASO, n= 34, HET-Ncaldko/wt+ASO, n=34. c) The re-
analyzed results of the righting reflex test were for short-living and long-living SMA+ASO animals. Short-living
SMA+ASO, n=17, short-living SMA+ASO, n=6, short-living SMA-Ncaldko/wt+ASO, n=21. The two long-living
SMA-Ncaldko/wt+ASO animals were excluded. d)
For both motoric tests two-way ANOVA with Tukey correction for multiple comparisons was applied. *P<0.05,
**P<0.01, ***P<0.001. The significance is indicated for SMA-Ncaldko/wt mice in comparison to SMA (black stars)
or HET (green stars) littermates.
5.3.4 Neuromuscular junctions of SMA-Ncaldko/wt +ASO mice are more mature and have
a larger area of AChR clusters
The first structure evaluated histologically in SMA-Ncaldko/wt+ASO mice was the
neuromuscular junction, as defects of this synapse were reported to be the key SMA
associated phenotype in severe and intermediate mouse models (Murray et al. 2010,
Bogdanik et al. 2015, Hosseinibarkooie et al. 2016). First, we quantified the area covered
by AChR clusters (recognized by Bungarotoxin) in the TVA muscle of ASO-injected
PND21 mice: the AChR area was increased in the in SMA-Ncaldko/wt+ASO mice compared
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to SMA+ASO (Fig. 33b), recapitulating the effect observed in uninjected SMA-Ncaldko/wt
mice (see Fig. 24). This effect was visible only on the SMA background as there was no
difference between HET+ASO and HET-Ncaldko/wt+ASO mice (Fig. 33b). Furthermore, on
PND21 we were able to assess not only the area of AChR clusters but also the NMJ
maturation. In the first three weeks of postnatal development, the NMJ structure changes
from a uniformly stained plaque through an intermediate stage when some folded regions
are stained more intensively suggesting a more complex three-dimensional architecture
of the endplate up to a fully mature “pretzel” form with clearly visible perforations (Tintignac
et al. 2015). We assessed the maturation of NMJs in PND21 animals along recently
published criteria where NMJs with three or more perforations were qualified as mature
and those with less than three perforations as immature (Bogdanik et al. 2015). Analysis
of NMJ maturation showed a significant improvement in SMA-Ncaldko/wt+ASO animals
when compared to SMA+ASO. This effect of NCALD knock-down was also prominent
between the groups of HET+ASO and HET-Ncaldko/wt+ASO animals (see Fig. 33c).
Therefore, NCALD knock-down leads not only to an increased area of AChR, but facilitates
the NMJ development as well. These findings strengthen the role of NCALD as a negative
regulator of neuromuscular system and support the hypothesis that suppressing NCALD
might be advantageous in diseases where the neuromuscular system is impaired in its
development or maturation. Further studies of NCALD suppression in other disease
models, e.g. in ALS mice, could elucidate the potential of NCALD as a cross-disease
modifier.
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Fig. 33: NMJ size and maturation are improved in SMA-Ncaldko/wt+ASO animals
a) Representative images and b) quantification of mean Bungarotoxin-positive NMJ area in the TVA of PND21
animals of all four genotypes under study, stained with an antibody against NF (green) and Bungarotoxin (BTX,
magenta) to visualize the AChR clusters. Scale bar, 10 µm. In the quantification all values per genotype are
presented as whisker bars (upper part) and additionally, all values per animal are presented in a bar graph
(lower part). The mean NMJ area of SMA-Ncaldko/wt+ASO mice is significantly larger than in SMA+ASO
littermates but does not reach the levels of HET+ASO animals. c) The maturation of NMJs in PND21 injected
animals was evaluated by the number of perforations per endplate: SMA+ASO mice showed the highest and
HET-Ncaldko/wt+ASO mice the lowest proportion of immature endplates. The NMJ maturation in SMA-
Ncaldko/wt+ASO mice was not significantly different from that of HET+ASO animals.
For all genotypes at least three animals were analyzed, 100-120 NMJs were measured per animal. The
analysis was performed double-blinded. Statistical analysis was performed using two-tailed student’s t-test.
***P<0.001.
5.3.5 The number of glutamatergic inputs on MN soma and the MN cell size are
increased in SMA-Ncaldko/wt+ASO mice
As NCALD reduction increased the number of glutamatergic synapses on spinal motor
neurons, but not the cell soma in the uninjected mice, it was of interest whether by
elevating SMN levels in the spinal cord the positive effect of lower NCALD gets enhanced.
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Therefore, we performed similar analysis of the VGlut1+ inputs on motor neuron soma as
in 5.2.7. As expected, the motor neurons from SMA+ASO received significantly less inputs
than those from HET+ASO mice. We could recapitulate the positive effect of NCALD
reduction as observed in the severe SMA mice as the number of glutamatergic inputs on
motor neurons from the SMA-Ncaldko/wt+ASO mice was significantly higher in comparison
to SMA+ASO littermates (Fig. 34b). However, as the number of VGlut1+ inputs in
HET+ASO animals doubled from PND10 to PND21 (from ~19 on PND10 to ~40 on
PND21+ASO), possibly augmented by the ASO injection, the SMA-Ncaldko/wt+ASO mice
did not reach the levels of HET+ASO. Notably, in this intermediate SMA model reducing
NCALD also resulted in a significant increase in the cell volume of motor neurons (Fig.
34c). The greater phenotypic variability of the intermediate ASO-mediated SMA model
was reflected in the huge distribution of mean motor neuron cell volumes between
individual animals (Fig. 34d).
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Fig. 34: Number of VGlut1+ inputs and motor neuron size are increased in SMA-Ncaldko/wt+ASO animals
a) Representative images and b) quantification of glutamatergic inputs on motor neuron soma in PND21 ASO-
injected mice. Spinal cord sections were stained with antibodies against ChAT (magenta) to visualize motor
neuron soma and VGlut1 (green) to visualize glutamatergic inputs. Scale bar, 20 µm. Mean number of VGlut1+
inputs pro motor neuron was increased in spinal cords derived from SMA-Ncaldko/wt+ASO mice (SMA+ASO=
24.0±14.9, SMA-Ncaldko/wt+ASO =30.3±18.4, HET+ASO= 40.9±21.2, HET-Ncaldko/wt+ASO =27.3±18.2).
Mean±SD. c) The distribution of cell volume values within a genotype and d) mean values for individual
animals. The motor neuron volume is smaller in SMA+ASO animals that in HET+ASO controls and is increased
by NCALD reduction. Mean ±SD.
For each genotype, three animals were analyzed and 50 motor neurons were analyzed per animal. The
analysis was performed double-blinded (the genotypes were disguised during the image acquisition and the
data analysis). Statistical analysis was performed using two-tailed student’s t-test. *P<0.05, **P<0.01,
***P<0.001.
5.3.6 Muscle fiber size is increased in the EDL muscle of PND21 SMA-Ncaldko/wt+ASO
mice
In uninjected SMA-Ncaldko/wt mice, NCALD reduction increased the NMJ Bungarotoxin-
positive area in the TVA muscle as well as the number of glutamatergic inputs on motor
neuron soma in the spinal cord, showing that structurally both the central as well as distal
synapses were enhanced (see Fig. 24 and 26). The structural improvement, however, did
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not involve the muscle tissue, as the muscle fiber size remained strongly reduced in SMA-
Ncaldko/wt mice (see Fig. 27). The possible reason could be the intrinsic, motor neuron
independent defects of muscle tissue caused by low SMN levels (Fayzullina and Martin
2014). Hypothetically, if SMN levels were elevated in the muscle by a systemic SMN-ASO
injection, then the positive impact of NCALD reduction visible at the neuronal site might
potentially advance to the muscle tissue. We tested this hypothesis by evaluating the
muscle fiber size in the EDL muscle of PND21 SMN+ASO injected mice (Fig. 35).
Fig. 35: Analysis of muscle fiber size in the EDL muscle of PND21 mice
a) Representative images of H&E stainings of 7 µm paraffin sections of the EDL muscle. The difference in
muscle fiber size is prominent between SMA+ASO and HET+ASO animals. Scale bar, 50 µm. b) The
quantification of muscle fiber size shows an increase in SMA-Ncaldko/wt+ASO mice in comparison to SMA+ASO
littermates. Unexpectedly, the muscle fiber size was significantly decreased in HET-Ncaldko/wt+ASO compared
to HET+ASO littermates. c) Mean values presented as bars for individual mice show higher variability within
the ASO-injected heterozygous animals. Mean ± SD.
For each genotype four animals were analyzed and 100 muscle fiber were measured per animal. The analysis
was performed double-blinded (the genotypes were disguised during the image acquisition and the data
analysis). Statistical analysis was performed using two-tailed student’s t-test. ***P<0.001.
The mean muscle fiber size was highly significantly reduced in SMN+ASO mice when
compared to HET+ASO littermates. Notably, it was increased in SMA-Ncaldko/wt+ASO in
comparison to the SMN+ASO mice, although it did not reach the HET-ASO mice levels.
This observation highlights the importance of peripheral SMN restoration for the protective
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modifiers to fully exert their function: while in the severe uninjected SMA-Ncaldko/wt mice
the muscle fiber size was unchanged compared to SMA, elevating SMN was sufficient for
the structural improvement of the NMJ size (see Fig. 33) to manifest itself also in the target
tissue.
5.3.7 The impairment of the gastrointestinal tract is not rescued by reduced NCALD
levels
Although numerous SMA hallmarks were improved in SMA-Ncaldko/wt+ASO, their survival
and body weight remained reduced. The reason for this could be that NCALD reduction
affects predominantly the neuromuscular system, but fails to rescue non-neuronal defects.
As previously, the morphology of the small intestine was studied as tantamount for the
general phenotype of the mice. As PND21 represented a late stage of the disease in the
intermediate model, severe changes were visible in SMA+ASO mice: reduced villi number,
edema of the lamina propria and frequent intracytoplasmatic vacuoles at the tips of the villi
(Fig. 36).
Fig. 36: Intestine impairment is still visible in SMA+ASO mice.
Representative images of H&E stainings of 7 µm paraffin sections from the intestine of PND21 SMA+ASO,
SMA-Ncaldko/wt +ASO, HET+ASO and HET-Ncaldko/wt +ASO animals. In the intestine of both SMA and SMA-
Ncaldko/wt mice the villi are less abundant and show a blunt morphology, in contrast to the longitudinal shape
of villi in HET+ASO and HET-Ncaldko/wt +ASO animals. The red arrowheards mark the edema in the lamina
propria absent in HET+ASO littermates. Scale bar, 50 µm. Three animals per each genotype were analyzed.
The observed phenotypic characteristics of the SMA-Ncaldko/wt and HET-Ncaldko/wt mice,
analyzed in the severe SMA mouse model on PND10 and in the intermediate SMN-ASO
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mediated model on PND21 analyzed, are summarized in Table 13; a group defined in a
column by genotype and treatment has always been compared to identically treated
littermates carrying the same genetic composition of Smn and SMN2, but lacking the
allele: SMA-Ncaldko/wt against SMA and HET-Ncaldko/wt against HET. Overall,
independently of the severity of the SMA model, NCALD reduction ameliorated many
defects mediated by SMN deficiency: when the SMN levels were elevated by SMN-ASO
injection, all analyzed neuromuscular structures showed an improvement. Surprisingly, the
effect of NCALD reduction on HET animals was more complex and will be discussed in
detail in chapter 6.4.
Table 13: The summary of the characteristics of SMA-Ncaldko/wt and HET-Ncaldko/wt analyzed in the
severe and intermediate SMA mouse model.
Upwards arrows indicate an increase, downwards arrows – a decrease and right-bound arrows – no
significant change.
5.4 SMA mouse model with NCALD reduction – an Ncald-ASO approach
As we anticipated that NCALD reduction might be have some translational potential for
SMA therapy, we intended to reduce NCALD by an exogenously administered compound.
To achieve an in vivo knock-down of genes in model organisms and ultimately in patients,
the technology of antisense oligonucleotides (ASOs) has proved very suitable and is
already advanced in therapies against SMA and other diseases (Aartsma-Rus and van
Ommen 2010, Chiriboga et al. 2016). The antisense oligonucleotides against Ncald were
developed in close cooperation with an industrial partner, Ionis Pharmaceuticals
(Carlsbad, California), who has a vast expertise in developing therapeutic ASOs, with SMA
as the most prominent example (Hua et al. 2008, Hua et al. 2010, Hua et al. 2011, Rigo et
al. 2012). As the targeted tissue was central nervous system, Ionis Pharmaceuticals
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developed ASOs with the mixed 2’ MOE chemistry, where the center residues are
phosphorothioate oligodeoxyribonucleotides and the several terminal residues carry a
methoxyethoxy substitution on the 2’ position of ribose, as this provides better tolerability
and uptake into CNS (Chery and Naar 2016). Different ASO sequences were tested in
adult wildtype mice by bolus injection and the knock-down efficiency was evaluated by
qRT-PCR (Fig. 37b,c).
Fig. 37: A screen of different ASO sequences against Ncald performed by Ionis Pharmaceuticals
a) 22 ASO sequences have been tested by administering 500 µg ASO via an i.c.v. bolus to adult wildtype
mice. Except for six, all ASOs were targeting the 3’UTR of Ncald gene. The mice were sacrificed 2 weeks after
injection. Ncald knock-down in the brain b) and spinal cord c) was evaluated by qRT-PCR. The two ASOs
which achieved the highest Ncald knock-down were ASO673663 and ASO673672 (highlighted with black
arrowheads), the latter giving a strong knock-down in both organs tested.
The two ASOs which achieved the greatest NCALD reduction in brain and spinal cord were
selected for further tests in neonatal mice, as any interventions against SMA have the
greatest chance of improving the phenotype when undertaken early in life, preferentially
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before the onset of symptoms. The tests should assess ASO tolerability and efficiency, as
well as determine the optimal amount of ASO, the best injection protocol and the right time
point of injection.
First, we injected two litters of wild-type pups intracerebroventricularly (i.c.v.) with different
doses of two independent ASOs (673663 and 673672, further referred to as ASO1 and
ASO2, respectively) and assessed the degree of NCALD knock-down in the brain and the
spinal cord (Fig. 38a). As it was crucial that Ncald-ASOs are well tolerated when injected
into neonatal SMA mice, in the next step we i.c.v. injected two larger litters (n=8 for ASO1
and n=10 for ASO2) of SMA and HET mice, each litter with variable doses of respective
ASO (at least 2 animals per dose), and we evaluated the NCALD knock-down by Western
blots. Of the 8 mice injected with ASO1, two injected with the higher doses (30 µg and 60
µg) died immediately post injection, while all 10 pups injected with ASO2 survived till
PND8. In line with the preliminary tests performed by Ionis Pharmaceuticals, ASO2
achieved a stronger NCALD knock-down in brain and also in the spinal cord (Fig. 38c).
Fig. 38: NCALD knock-down by i.c.v. Ncald-ASO injection in wildtype and SMA mice
a) Western blot of brain and spinal cord lysates of wildtype mice i.c.v. injected with Ncald-ASO1 or 2 on PND1
and sacrificed on PND8. For both ASO sequences, the highest dosis (60µg) reduced NCALD in the brain and
also, although to a lesser degree, in the spinal cord. The quantification of NCALD knock-down is indicated for
each sample as proportion to uninjected control on the same blot. b) Western blot of brain and spinal cord
lysates of SMA mice i.c.v. injected with different doses of ASO1 on PND1 and sacrificed on PND8. Two mice
died within 24h after injection. c) Western blot of brain and spinal cord lysates of SMA mice i.c.v. injected with
different doses of ASO2 on PND1 and sacrificed on PND8 showed NCALD knock-down in the brain at higher
doses and in the spinal cord at lower doses. All mice survived ASO2 injection.
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As generally NCALD knock-down in the spinal cord after single injection was not very
pronounced irrespective of the injected dose, we attempted to maximize the effect by
injecting ASO2 on two consecutive days. We injected SMA and HET neonatal mice on
days PND1 and 2 and tested different double injection regimens (detailed description in
Fig. 39): two i.c.v. injections, two s.c. injections and one i.c.v. plus one s.c. We reasoned
that in the neonatal mice the permeability of the blood-brain barrier might allow the ASO
to reach the target tissue even if injected subcutaneously. Double intracerebroventricular
injection was too invasive as even mice injected with control ASO (676226, further referred
to as ASOctrl) succumbed to the intervention. However, one pup injected with 2x i.c.v.
ASO2 survived and could be dissected on PND10. Unexpectedly, the combined 1x i.c.v
plus 1x s.c. injection regimen mediated a stronger NCALD knock-down than 2x i.c.v. (Fig.
39a), which was confirmed in a bigger number of animals (Fig. 39b).
Fig. 39: Efficient NCALD knock-down by combined i.c.v. and s.c. injection of ASO2 against Ncald in
SMA mice
a) Western blots of brain and spinal cord lysates of SMA mice injected twice with 60µg Ncald-ASO2 on PND1
and 2 and sacrificed on PND10. Each of the following ASO2 injection regimens was tested on two pups: 2x
i.c.v. (lane 1), 1x i.c.v. + 1x s.c (lane 2), 2x s.c. (lanes 3 ad 4). Additionally, two mice were injected 2x i.c.v.
with 60µg of ASOctrl. From each of the first two regimens one pup died post injection and both mice injected
2x i.c.v. with 60µg of ASOctrl died, therefore lysates from 1x i.c.v. ASOctrl injected mice were used as controls
(lanes 5 and 6). The quantification of NCALD knock-down is indicated for each sample as proportion to
uninjected control on the same blot. b) Western blot of brain lysates from four mice injected with 2x 60 µg
ASO2 or ASOctrl, 1x i.c.v.on PND2 and 1x s.c. on PND3. ASO2 mediated > 60% NCALD knock-down in
comparison to ASOctrl.
Statistical analysis was performed using two-tailed student’s t-test.***P<0.001.
Therefore, we continued with the 1x i.c.v. + 1x s.c. ASO2 injection strategy in next litters.
Unfortunately, we observed a relatively high toxicity of the active compound which resulted
in death within the 24 hours post injection in >30% of mice, where the more efficient ASO2
exerted also a more toxic effect (Fig. 40a). The toxicity occurred in a dose dependent way,
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while the maximal tested amount of 60 µg ASO was also the most toxic. However, we did
not observe this increased mortality for animals injected in the same manner with ASOctrl,
so that the injection per se could be excluded as the death cause. As the ASOctrl of the
same chemistry and injected in the same manner did not show a lethal effect, and
complete Ncald ko/ko mice do not show an increased perinatal mortality, it is possible that
Ncald-ASOs have some off-target effects on a crucial neuronal gene. In an extreme case
of a 10-pup-litter all 8 injected with the active compound were dead on the following day,
while the two ASOctrl injected pups survived till PND10. It is also unlikely that NCALD
reduction alone would have such an extreme effect as complete Ncald ko/ko mice are viable
to adulthood.
We reasoned that possibly the ASO2 dosis is too high and may be toxic for the neonatal
mice, therefore we tested a series of ASO2 concentrations; NCALD reduction was ASO2
dose-dependent and visible only at doses ≥ 2x 50 µg (Fig. 40b).
As i.c.v. injection of ASO2 too appeared to be the reason of the lethality, we decided to
inject ASO2 only subcutaneously and instead inject ASO1 intracerebroventricularly. In the
spinal cord the injection of ASO cocktail achieved a knock-down of NCALD up to 30%;
surprisingly, there was no advantage of injecting both ASOs compared to injecting only
ASO1 (Fig. 40c). Therefore, we decided to continue injecting with ASO1 only;
unfortunately, also ASO1 injection was associated with increased mortality, as 30% mice
injected i.c.v. with ASO1 died shortly afterwards (Fig. 40a).
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Fig. 40: Increased mortality following the injection of Ncald-ASOs
a) Survival curve of mice injected i.c.v. and s.c. with Ncald-ASOs. Both ASOs increased the mortality directly
post injection (15 mice out of 50 injected with ASO1 and 17 mice out of 57 injected with ASO2 died before
PND10). PND10 was set as cut-off, as the surviving animals were dissected at this age to evaluate the NCALD
knock-down. b) Western blot and quantification of spinal cord lysates from mice injected with a series of ASO2
concentrations (i.c.v. on PND2 and s.c. on PND3). c) Western blot and quantification of spinal cord lysates
from mice injected with ASO cocktail (s.c. ASO2 + i.cv. ASO1), ASO1 or ASOctrl  (sc. on PND1 + i.c.v. on
PND3).
Two (b) or three animals (c) were injected identically for one Western blot experiment. Mean ± SEM. Statistical
analysis was performed using two-tailed student’s t-test.
All in all, we could show a satisfactory NCALD knock-down using ASO compounds,
however, their therapeutic potential requires great caution due to observed high toxicity;
the safety profile and clinical effect need to be assessed in more detail.
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6 Discussion
6.1 Different strategies to reduce NCALD in vivo in SMA mice
Neurocalcin delta (NCALD) was identified as a protective SMA modifier in humans.
Preliminary work in cellular and non-mammalian models showed that reducing NCALD
ameliorated defects mediated by SMN deficiency: particularly, the neuronal outgrowth
which is strongly reduced in SMN-deficient cells and zebrafish (McWhorter et al. 2003,
Kwon et al. 2011) was restored to control levels when NCALD was concomitantly
downregulated. The work presented here attempted to answer the question whether
NCALD reduction can rescue the SMA phenotype in mice. Studies of SMA mouse models
contributed enormously to the understanding of the disease pathology: by unraveling NMJ
defects as one of the earliest SMA symptoms (Kariya et al. 2008), the developmental
synaptopathy of the neuromuscular junctions has been identified as the primary pathology
both in severe and mild SMA mouse models and, most importantly, in SMA patients
(Murray et al. 2008, Bogdanik et al. 2015, Harding et al. 2015). SMA mice serve also as a
platform to test potential therapeutics against this devastating disorder which are reviewed
in (Kaczmarek et al. 2015). By studying the effect of NCALD reduction in SMA mice we
aimed at answering two questions: first, which SMA symptoms are potentially rescued by
NCALD reduction, and second, to explore the therapeutic potential of NCALD knock-down.
In order to do so, we had to find the optimal method to reduce NCALD in vivo: in the scope
of this work, three different approaches have been tested and each has shown certain
advantages but also some caveats.
Our first strategy to reduce NCALD involved generating a novel mouse line carrying an
shRNA that by RNA interference would likely promote the degradation of Ncald transcript
(Kleinhammer et al. 2011). The shRNA would be expressed only upon induction, while the
inducer (Doxycycline) can be either added to the medium in vitro or conveniently
administered in vivo in food or drinking water. This strategy of inducible and incomplete
depletion of a gene product is particularly suitable when a gene knock-out would result in
embryonic death (McJunkin et al. 2011). Moreover, by merely reducing the levels of a
protein of interest the human phenotype can be recapitulated more faithfully, as is the case
in the asymptomatic individuals, where NCALD is not completely absent, but expressed at
lower levels. The greatest challenge of this approach lies in the identification of potent
shRNA sequences, and indeed, we had difficulties identifying an shRNA sequence that
would strongly downregulate endogenous NCALD in a mouse cell line. Only when we
overexpressed Ncald cDNA in a cell line that does not express NCALD endogenously, we
could find two efficient shRNA sequences. As also identification of a strong siRNA for
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transient NCALD knock-down in mouse cell lines proved difficult, it is feasible that Ncald
mRNA takes on a secondary structure which is not easily targeted by RNAi (Gutschner et
al. 2011).
Second, as the complete Ncaldko/ko mouse line has become available and turned out to be
both viable and fertile, we decided to adapt our strategy accordingly and instead of the
shRNA transgene to use the heterozygous Ncaldko/wt mice as a model of NCALD depletion,
which we crossed with the SMA mice. The great advantage of a genetic knock-out model
is a consistent degree of protein reduction between individual animals while an exogenous
treatment inevitably introduces additional variability. A genetic model is best suited for
initial assessment of candidate modifier genes for a disease, however, it has obviously
little translational potential. Moreover, most likely virtually any knock-out mouse line has
its own phenotype arising from the disruption of the cellular homeostasis. In the case of
the Ncaldko/ko mice, their phenotypical analysis has revealed numerous changes of mainly
neurological and metabolic nature (Jackson Laboratory 2016). It remains unclear how
many of these changes are already present in the Ncaldko/wt animals and have an effect
on the SMA-Ncaldko/wt mice that is independent of SMN deficiency. NCALD reduction had
a readily noticeable impact on the adipose tissue and body weight (5.2.3), still further
analysis of the Ncaldko/wt and Ncaldko/ko animals is required to fully comprehend the function
of NCALD.
Third, we attempted to deplete NCALD using exogenous compounds with a direct
therapeutic potential, antisense oligonucleotides (ASOs). ASOs have the ability to target
RNA in a sequence-specific way and depending on the locus they bind to, they can either
silence gene expression by a variety of mechanisms or alter the splicing (Bennett and
Swayze 2010). The ASOs we used here represent the second generation of antisense
compounds with the mixed 2’ MOE chemistry: the center residues are phosphorothioate
oligodeoxyribonucleotides, while the several terminal residues carry a methoxyethoxy
substitution on the 2’ position of ribose. This combination increased hybridization affinity
and potency, as well as resistance to nuclease cleavage; it also improved the tolerability
profile by decreasing the proinflammatory effects (Chery and Naar 2016). Due to their
large molecular weight and size, ASOs do not cross the blood brain barrier, therefore
targeting ASO to neuronal tissue involves intrathecal or intracerebreventricular
administration. In our tests of Ncald-ASO we observed that the 2’MOE chemistry
(assessed from control ASO) was well tolerated despite the invasive nature of i.c.v.
injection. When Ncald-ASOs were administered i.c.v., they mediated an NCALD knock-
down in the CNS even up to 30% of control level (5.4). Unfortunately, an apparent
sequence-related toxicity of Ncald-ASOs resulted in increased mortality. One possible way
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to overcome this drawback would be to test yet another ASO sequence; this approach is
currently in progress. Another way to achieve a milder injection would be the use of a fine
glass capillary needle in order to minimize the damage to the sensitive brain tissue
(Glascock et al. 2011); also this refinement is under investigation.
Testing modifier genes in SMA mouse models has previously required laborious
generation of new mouse lines carrying the modifying variants. Conveniently, a growing
number of knock-out lines has become available for the scientific community to study the
functional basis of human diseases (Rosen et al. 2015). In the future, functional genomic
screens in mammalian animal models, e.g. in mouse, might be facilitated by the break-
through gene editing technique using the endonuclease CRISPR/Cas9, especially as the
libraries of verified guide RNA sequence are already being generated for many common
laboratory species (Hsu et al. 2014). The advantages of the CRISPR/Cas9 mediated gene
editing are its specificity, as specific gene variants can be tested instead of disease models
only phenocopying a particular disorder, and rapidness, through bypassing the typical ES
cell targeting step and directly targeting zygotes to generate transgenic lines (Paquet et
al. 2016). This technique has already proven helpful in targeting difficult genes that failed
in previous attempts (Schick et al. 2016). It harbors also a therapeutic potential for treating
genetic disorders by correcting (even postnatally) the causative mutations while the gene
remains expressed in its natural context which is an advantage in comparison to viral gene
delivery (Long et al. 2016).
6.2 Effect of NCALD reduction on the motor neurons of SMA animals
The motor neurons are widely accepted as the primary cell type affected by SMN
deficiency, although the reason of their susceptibility to low SMN levels is not fully clear
and remains the subject of many studies in the SMA research (Saal et al. 2014, Fallini et
al. 2016). One possible explanation could be that motor neurons express lower SMN from
SMN2 that other cell populations in the spinal cord due to a particularly inefficient splicing
of exon 7 (Ruggiu et al. 2012). Other hypotheses view the high energy demand of neurons
as critical for their vulnerability, especially as mitochondrial dysfunction has been reported
in SMA (Malkki 2016), as well as the polarity of neurons which is coupled with their high
demand of local translation (Liu-Yesucevitz et al. 2011, Fallini et al. 2016).
NCALD was previously identified as localizing to axons of sensory and hippocampal
neurons (Yamatani et al. 2010); additionally, our group could pinpoint the localization of
NCALD to the soma and growth cones of motor neurons (Svenja Schneider, unpublished
data). With this important indication that NCALD may play a role in the tissue of interest,
we studied two characteristics of motor neurons that are impaired under low SMN levels:
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axonal length and number of glutamatergic inputs on the motor neuron soma as a
component of spinal motoneuronal circuitry (Rossoll et al. 2003, Mentis et al. 2011).
Yamanati and colleagues identified NCALD and another protein of the NCS family –
VILIP1 – in a proteomic screen as highly upregulated during axon development, which
suggested a prominent function of neuronal calcium sensors in the growing axon.
Furthermore, both NCALD and VILIP1 localized to the growth cone which is a dynamic
structure orchestrating the axonal growth (Tamariz and Varela-Echavarria 2015).
Overexpression studies showed detrimental effect of excessive NCALD on neurite
outgrowth – thus highlighting that an alteration of NCALD levels is able to affect the
homeostasis of axon development (Yamatani et al. 2010). We showed that NCALD
suppression counteracts the axonal outgrowth impairment in SMA, strengthening the
evidence of NCALD as an important regulator of axonal growth (5.2.5). The mechanism
how this happens remains elusive; it is feasible, however, that the reported interaction of
NCALD with tubulin and actin, two key components of the cytoskeleton, plays a role as the
growth cone and axonal growth are directly dependent on the dynamics of the cytoskeleton
(Gordon-Weeks and Fournier 2014). Another hypothesis would involve a possible
restoration of Ca2+ homeostasis, which is known to be altered in SMA, by altering the Ca2+
sensing (Ruiz et al. 2010). The precise nature of Ca2+ disturbance is SMA is still under
discussion, as human and mouse studies yield incongruous results (McGivern et al. 2013),
therefore intensive research would be required to verify this hypothesis.
Recently, disturbed neuronal circuits are increasingly recognized as contributing to and
potentially even initiating various neurodegenerative disorders, e.g. Parkinson’s and
Huntington’s disease (Palop et al. 2006). Importantly, as also other cell types directly
interacting with motor neurons, such as interneurons and astrocytes, were reported to
show alterations when SMN is depleted, not only cell-autonomous effects, but the entire
neuronal network needs to be taken into consideration in SMA research (Zhou et al. 2016).
This is particularly relevant for motor neurons, as their function is not only dependent on
intrinsic qualities, but also reflects the excitatory and inhibitory inputs that the motor
neurons receive: when the overall numbers or firing frequency of these inputs or the ratio
of excitatory to inhibitory ones are changed, this directly affects the activity of the target
neuron and ultimately its output – in this case the activation of skeletal muscle (Kitzmann
2010). In SMA, it has been shown that specifically the excitatory, but not the inhibitory
inputs are reduced (Simon 2016). The excitatory inputs are prevalently of glutamatergic
nature and provide the motor neuron with sensory information with respect to touch,
proprioception, mechanoreception and nociception as well as integrate information from
different levels of CNS (cortex, brain stem and spinal cord). We analyzed the glutamatergic
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inputs on spinal motor neurons by immunohistochemical staining of spinal cord sections
and in both SMA models under study: the severe and the intermediate one, we could
observe that reducing NCALD lead to the increase of the number of glutamatergic inputs
on motor neuron soma (see 5.2.7 and 5.3.5), implicating that the positive effect of lower
NCALD levels is not limited to motor neurons but is capable of modifying the spinal
circuitry. Other studies found that the loss of excitatory inputs accompanied by a block in
their synaptic transmission leads to hyperexcitability of motor neurons (Simon et al. 2016).
This manifested in an alteration of two intrinsic membrane properties: input resistance and
time constant, that were reported to be increased in SMA motor neurons. As other
neuronal sensor proteins have been shown to play a role in membrane trafficking and
calcium channel regulation (Burgoyne and Haynes 2010, Weiss et al. 2010), and defective
clustering of calcium channels has been reported to disturb the excitability of SMA motor
neurons (Jablonka et al. 2007), one could envisage that reducing NCALD possibly
interferes with these SMA defects and restores some provisory balance at the membrane.
The limitation of the anatomical studies is that when an increase in excitatory inputs to
motor neurons is detected by immunolabeling, this does not necessarily implicate an
actual increase in glutamate release. Therefore, electrophysiological analysis of the
properties of SMA motor neurons along the methodology presented in (Mentis et al. 2011,
Gogliotti et al. 2012) would be technically challenging, yet highly interesting in order to
make a conclusive statement about the functional impact of NCALD reduction.
6.3 Effect of NCALD reduction on the NMJs of SMA animals
Traditionally, SMA was perceived as motor neuron disorder, however since the
identification of SMN1 as the disease determining gene and SMN2 as the main modifying
gene (Lefebvre et al. 1995), our understanding of the nature of this disease has vastly
increased, largely due to in vivo studies conducted in SMA mouse models. In particular,
defects of the neuromuscular junction have been identified as an early pathology,
preceding the death of motor neuron (Ling et al. 2012). The pathological alterations of
NMJs in SMA are both of structural and functional nature and include impaired maturation
(Kariya et al. 2008), neurofilament aggregation (Cifuentes-Diaz et al. 2002), disturbance
of calcium homeostasis (Ruiz et al. 2010) and impaired neurotransmitter release (Kong et
al. 2009). The axonal degeneration and resulting impairment of neurotransmission happen
long before motor neuron cell death: even at end stage of the disease only 25-30% motor
neurons in spinal cord are lost (Cifuentes-Diaz et al. 2002). Although muscle weakness
and finally paralysis are prominent SMA symptoms, NMJ denervation is rather moderate
and varies strongly between muscles: specific muscles in the head, neck and trunk have
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been shown to be more affected that those of distal extremities (Ling et al. 2012). This
phenotype appears also to vary between mouse models as the Taiwanese SMA mice
show a different profile of muscles affected by denervation: a vast majority of analyzed
muscles showed minimal levels of denervation in SMA animals when compared to HET
and exclusively Flexor digitorum brevis 2 and 3 (FDB-2/3) muscles showed severe and
progressive denervation (Lin et al. 2016).
The development of NMJ is dependent on motor nerves reaching the muscle fibers;
interestingly, some AChR clusters are formed already before the neuronal contact in a
process termed “prepatterning” (Lin et al. 2008). However, aneural AChR disappear before
birth and only the innervated ones remain and grow in size (Yang et al. 2001). At this stage
of development, most AChR are of the “fetal” subtype (Mishina et al. 1986); furthermore,
they show a high degree of polyinnervation as in neonatal muscle a single AChR cluster
can be contacted by ~10 motor axons (Tapia et al. 2012). The final formation of NMJ
occurs in rodents in the first three weeks of life when multiple innervation is reduced to a
single motor axon, fetal AChRs are replaced with the adult form, the subsynaptic foldings
of the membrane are formed and the size and density of AChR cluster increased and
changes shape from a uniform plaque to an elaborate pretzel (Tintignac et al. 2015).
For the reliable transmission of the nerve impulse, the postsynaptic membrane must be
organized with the help of numerous proteins. The master organizer of postsynaptic
differentiation is the agrin-MusK pathway, where agrin, a heparan sulfate proteoglycan
derived from the innervating motor axon, activates the muscle-specific kinase (MuSK) via
a coreceptor low-density lipoprotein receptor-related protein 4 (Lrp4); furthermore, also
downstream of tyrosine kinases-7 (Dok-7) and 43 kDa receptor-associated protein of the
synapse (rapsyn) are necessary for NMJ formation (Zong et al. 2012). Mutations in genes
encoding these key structural proteins result in congenital myasthenic syndromes (Ferraro
et al. 2012). Importantly, splicing of agrin has been reported to be misregulated when SMN
is depleted and thus may contribute to the initiation of NMJ pathology in SMA (Zhang et
al. 2013). Although the NMJ development has been extensively studied, still not much is
known about how SMN depletion affects the development of this intricately regulated
synapse as most studies are limited to anatomical assessment (Goulet et al. 2013).
In our analysis of SMA-Ncaldko/wt mice, whether in the severe model or upon SMN-ASO
injection, we assessed the effect of NCALD reduction by evaluating merely the size of NMJ
in the TVA muscle. In both SMA models of variable severity NCALD reduction resulted in
an increased NMJ area, however, not reaching the levels observed in HET littermates
(5.2.6 and 5.3.4). Furthermore, when we evaluated the maturity in SMN-ASO injected
animals, we could see that also this hallmark was improved upon decreased NCALD
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levels. Especially the time-course study of NMJ size offered interesting conclusions: while
in SMA mice no NMJ growth over time could be observed, reducing NCALD enabled the
NMJ structure to grow and (at least partially) mature. It would be highly interesting to
investigate the molecular basis of this structural amelioration, e.g. by studying the
expression of synaptogenesis genes which were reported to be dysregulated in SMA
(Zhang et al. 2013). Indeed, a recent study reported that downregulation of synaptic
proteins such as synaptotagmin-1 and -2 and synaptic vesicle protein 2B corresponded to
defects in neurotransmission, such as highly reduced evoked release, altered short-term
plasticity and inability to modulate normally the number of functional release sites; notable,
the reduction of these synaptic protein was correlated to the vulnerability of a given muscle
and is potentially determinant for the selective sensitivity of muscles in SMA (Tejero et al.
2016). Also examining the functional consequences of the observed morphological
alterations using electrophysiological methods would give us more insight into the
protective mechanism of NCALD reduction (Arnold et al. 2014). In this way, we could
analyze the effect of NCALD reduction on whole motor units, i.e. axon and its innervated
muscle fibers: either by the compound muscle action potential (CMAP), which summates
the electrical activity of all motor units in one muscle, or by motor unit number estimation
(MUNE).
Due to its peripheral location NMJ is speculated as an attractive target for therapeutic
agents (Boido and Vercelli 2016). As NMJs showed a consistent improvement upon
genetic reduction of NCALD, it is worthwhile testing whether the same effect can be
achieved by exogenous agents, such as Ncald-ASOs (5.4); in particular, determining
whether the intervention requires a systemic or a CNS administration would potentially
enhance the therapeutic value of this novel strategy.
6.4 Why did NCALD reduction have no effect on the lifespan of SMA mice?
While initially SMA was viewed as a disease of motor neurons, studies of mouse models
revealed that other types of neurons (e.g. excitatory interneurons) but also various
peripheral organs and systems were affected by SMN deficiency, e.g. bone, heart,
intestine, liver, pancreas and vascular system (Khatri et al. 2008, Bevan et al. 2010, Mentis
et al. 2011, Sahashi et al. 2013, Schreml et al. 2013, Bowerman et al. 2014, Simon et al.
2016, Somers et al. 2016). The fact that motor neurons are particularly, but not exclusively
susceptible to low SMN gave rise to the so called threshold theory: in mouse studies it was
observed that with decreasing SMN levels, motor neurons show defects as the first tissue,
but once SMN deficiency has passed a certain threshold, heart and other susceptible
organs start to develop a disease phenotype, until finally all tissues are affected (Sleigh et
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al. 2011). However, this inner organ impairment has been observed mainly in severe SMA
mouse models and in humans impairment of internal organs has been reported only for
severely affected, so called type 0 patients who often have only one SMN2 copy (Hamilton
and Gillingwater 2013). Due to its housekeeping function, SMN deficiency has been
reported to disrupt many essential cellular processes, such as apoptosis, autophagy and
recently endocytosis (Anderton et al. 2013, Custer and Androphy 2014, Hosseinibarkooie
et al. 2016). Therefore, the positive impact of NCALD reduction that was visible in the
motor neurons, their glutamatergic inputs and at the NMJ level in severe SMA mice could
not translate to an overall phenotypic improvement, when SMN deficiency continued to
impair peripheral tissues (5.2.9 and 5.3.7). The importance of peripheral SMN delivery is
highlighted by studies which reported that increasing SMN exclusively in the periphery is
sufficient to extend the lifespan of severe SMA mice (Hua et al. 2015, Hammond et al.
2016).
The fact that NCALD reduction did not increase survival in the severe SMA mice is in
concordance with similar studies of other SMA modifiers: stathmin and chondrolectin,
which showed promising effect in vitro and in lower model organisms but failed to achieve
a rescue in vivo (Wen et al. 2013, Sleigh et al. 2014). Another study reported an improved
survival by reducing IGF-1R, however, this was mediated by increasing SMN levels (Biondi
et al. 2015). Also when SMN levels were increased exogenously by SMN-ASO injection,
additionally overexpressing PLS3 has mediated significant survival rescue
(Hosseinibarkooie et al. 2016). So far, only one study reported an SMN-independent
survival of a severe SMA mouse model upon genetic inhibition of JNK3, a neuron-specific
kinase implicated in neurodegeneration which was shown to be activated in spinal cords
from SMA patients and mice: complete knock-out of Jnk3 in SMAΔ7 mice lead to a
systemic rescue of SMA phenotype including lifespan without changing SMN levels
(Genabai et al. 2015).
As NCALD reduction ameliorated specifically neuronal pathologies in the severe SMA
mice, but without a rescue of muscular and peripheral defects (5.2.8-9), we hypothesized
that the positive effect of reduced NCALD is visible above a certain high threshold of SMN,
similarly to the levels observed in asymptomatic individuals from Utah family. However,
when SMN was increased by low-dose SMN-ASO injection, we observed no survival
increase upon concomitant NCALD reduction (5.3.2). Histological studies of
gastrointestinal tract revealed defects (although presumably of variable severity due to
different SMN levels) in both the severe and the intermediate SMA model under study
(5.2.9 and 5.3.7), therefore we concluded that likely this multi-organ impairment accounts
for the reduced lifespan. This is contrary to another modifier studied in our group, PLS3,
which, when overexpressed, could extend the lifespan of the intermediate model precisely
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by ameliorating the disease phenotype in peripheral organs: intestine, heart and lung
(Hosseinibarkooie et al. 2016). However, the PLS3 overexpression was driven by a
ubiquitous transgene and positively affected the actin dynamics (Ackermann et al. 2013),
whereas NCALD expression is mainly restricted to neuronal tissue (see 5.2.1).
The fact that heterozygous knock-out of Ncald did not prolong the survival of SMA mice
raises the question whether the mouse models we used are good representation of the
phenotype observed in SMN1-deleted asymptomatic individuals. Notably, these
individuals all carry four SMN2 copies which would theoretically associate with a mild SMA
phenotype without a reduced life expectancy (SMA type 3 or 4), as opposed to the mouse
models under study, which both showed reduced survival. Whether there is a threshold of
SMN levels that still shows reduced survival which could be rescued by reducing NCALD
remains unclear but is rather unlikely as it has been shown that increasing SMN levels
above a certain threshold has dramatic and not gradual effect on survival (Osborne et al.
2012). Similarly, when only half of SMN-ASO dosis (1x 30 µg) was injected to SMA animals
on the mixed background, the decreased survival was completely rescued but these mild
SMA mice still displayed motoric impairment (Riessland et al. under review). Importantly,
when NCALD was reduced in the mild SMA model, a clear improvement of the motoric
phenotype was visible, which likely resembles better the situation of the asymptomatic
individuals.
The observation that NCALD downregulation coincided with the asymptomatic phenotype
was made in lymphoblastoid cell lines, however, it is not possible to determine the NCALD
level in the spinal motor neurons, which are the actual tissue of interest, in living human
subjects. This impediment could be overcome with technique of inducible pluripotent stem
cell, which can be generated from available fibroblasts and subsequently differentiated
into motor neurons; our group has already successfully applied this method to study the
SMA modifier PLS3 (Heesen et al. 2016).
While considering potential therapeutic approaches for SMA, a differentiation must be
made between severe and milder types. For severe SMA mouse models and for SMA type
1 patients, the survival rescue is crucial as death (or long-term dependence on ventilator
support) presents the endpoint in clinical studies and for these groups, an increase of SMN
levels seems to be an indispensable therapeutic step. While defects in peripheral organs
have a major contribution to the mortality in SMA mouse models (with the sudden cardiac
arrest being a likely cause of death), in SMA patients impairment of inner organs is a rare
event observed only in the most severe cases (Palladino et al. 2011, Hamilton and
Gillingwater 2013), which implicates the limitations of animal models of human diseases.
Studies of SMN-independent modifiers that act downstream of SMN might be highly
relevant for therapy development, in case the approach to supplement SMN protein does
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not bring the desired full rescue in all patients; this is particularly important for therapies
that rely on the SMN2 expression, e.g. ASO that correct the SMN2 splicing. Therefore, it
is feasible that agents which specifically improve the neuromuscular system of the SMA
mice might be useful as potential therapeutics in human patients, particularly as
candidates for combinatorial therapies. Recent proof-of-principle study showed that once
SMN levels were elevated early in the disease progression, modifiers such as PLS3 can
mediate a long-term survival rescue (Hosseinibarkooie et al. 2016). This view is favorable
for NCALD reduction as a potential SMA therapy, especially for patients with slower
disease progression but with significant motor dysfunction, who are in need of therapies
enhancing the regeneration of the neuromuscular system (Iascone et al. 2015).
6.5 Effect of NCALD reduction on HET animals
Our studies of NCALD reduction in two SMA mouse models of variable severity quite
clearly showed that by decreasing NCALD levels some, altough not a complete,
phenotypic rescue can be achieved. Paradoxically, the effect of NCALD reduction in HET
animals was not unequivocally positive. As we observed in zebrafish studies, reducing
Ncald resulted in increased EPSP amplitude and frequency and in enhanced neuronal
branching (Riessland et al. under review); the latter could be recapitulated in mouse motor
neurons (5.2.5). It is feasible that abnormally increased branching translates to a higher
synaptic drive on motor neurons which might potentially disturb their normal development.
In turn, aberrant motor neuronal signaling might impair the development of the endplate
and the muscle as the target tissue (Favero et al. 2015).
In uninjected HET-Ncaldko/wt mice we observed the following alterations in comparison to
HET littermates: the average number of glutamatergic inputs on motor neuron soma was
increased without an effect of cell volume, which resulted in a higher ratio of inputs per
µm3 (5.2.7). Interestingly, while the NMJ size was not changed, an increase in muscle fiber
size was visible (5.2.6 and 8). Strikingly, in HET-Ncaldko/wt+ASO animals analyzed at an
older age (on PND21), the reverse phenotype was observed: both the number of VGlut1+
inputs and the mean muscle fiber size were decreased when compared to HET+ASO
littermates (5.3.5 and 6). It is feasible that excessive glutamatergic inputs disturb the
homeostasis between excitatory and inhibitory signaling at the motor neuron soma and
eventually results in a defect at the target tissue.
Taken together, these results strongly suggest that reducing NCALD in a healthy setting
disrupts the fine balance of the neuromuscular system, which positions NCALD as an
important regulator of the transmission of the signal from the nerve to the muscle.
Interestingly, in HET-Ncaldko/wt mice the size of NMJ was not altered either in uninjected
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PND10 or in SMN-ASO injected PND21 animals, implicating that under sufficient levels of
SMN the effect of NCALD reduction is mediated not by increasing NMJ size, but likely by
modifying the neurotransmission as shown in zebrafish (Riessland et al. under review);
further electrophysiological studies in mice are needed to conclusively delineate this
mechanism.
The possible explanation of the neuromuscular alterations observed in HET-Ncaldko/wt
would be that if HET animals are viewed as representing a physiologically normal
neuromuscular system, then by abrogating NCALD, a protein which is anticipated as
relevant for neuronal functioning, whether through neurotransmission, synaptic vesicle
recycling or neuronal activity, a disturbance of the homeostasis is to be expected.
However, as SMN depletion causes a major imbalance in multiple cellular processes,
concomitant NCALD reduction is able to restore some provisional balance, particularly in
the neuromuscular system (Fig. 41).
Fig. 41: A model of restored neuromuscular homeostasis under concomitant depletion of SMN and
NCALD
The consequences of SMN deficiency are widely studied in SMA patients and SMA mouse models (Burghes
and Beattie 2009). So far, little is known about the consequences of NCALD reduction. Our results show that
many characteristics of the neuromuscular system which are defective in SMA can be partially corrected by
concominant NCALD reduction.
6.6 Clinical relevance of neuronal calcium sensors
Changes in intracellular calcium have an enormous impact on neuronal cells: they are
essential to trigger neurotransmitter release (Sudhof 2012) but also for other processes
such as synaptic plasticity and activity-dependent transcription (Berridge 1998).
Importantly, dysregulation of Ca2+ has been long implicated as a key contributor to
neurodegeneration, e.g. an increase in intracellular Ca2+ can induce a change in
mitochondrial Ca2+ and subsequently enhance oxidative stress by production of reactive
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oxygen species and ultimately activate apoptotic cascade and trigger cell death (Naia et
al. 2016).
In order to translate the changes of this single ion into such a plethora of cellular effects,
a special class of neuronal calcium sensors (NCS) has evolved (Burgoyne 2007). The
NCS proteins do not possess an intrinsic enzymatic activity; instead, upon an increase of
Ca2+ levels they undergo conformational change and are then able to interact with their
specific target proteins which allows processing subtle Ca2+ changes into cellular function
(Burgoyne and Haynes 2015). The functions of these proteins are only beginning to be
understood and so is their clinical relevance. Our finding that targeting NCALD is able to
modify the SMA phenotype is in line with previous reports linking other NCS proteins to
various neurodegenerative disorders which will be discussed in the following.
Many NCS proteins have been implicated in the etiology of Alzheimer’s disease (AD) as
potentially linked to the Ca2+-hypothesis of AD where the abnormal metabolism of amyloid
beta (Aβ) induces a change in Ca2+ homeostasis, which initiates first the decline in memory
and then massive changes in Ca2+-levels and finally increased neuronal cell death
(Popugaeva et al. 2016). The Aβ-mediated rise in intracellular Ca2+ has been shown to
regulate the binding of calsenilin, a KChIP subfamily of NCS, to presenilin-2, which in turn
leads to increase apoptosis and APP production (Jang et al. 2011). Additionally, the NCS
protein VILIP1 has been shown to associate with amyloid plaques and to enhance tau
phosphorylation which is a well-known hallmark of AD brains (Schnurra et al. 2001);
VILIP1 protein levels were increased in the cerebrospinal fluid of AS patients although
paradoxically, VILIP1 mRNA was down-regulated in AD and correlated to the degree of
cognitive impairment (Lee et al. 2008). In conclusion of numerous studies, neurons
expressing VILIP1 seem to be particularly vulnerable against Aβ-induced disturbances of
Ca2+-homeostasis and die early on in the disease (Braunewell 2012). Notably, NCALD has
been reported to be differentially expressed in mice lacking Bleomycin hydrolase (BLMH),
a protein involved in the metabolism of homocysteine and linked to AD (Suszynska-
Zajczyk et al. 2014).
The work of Dragisevic and colleagues has linked NCS-1, the evolutionary oldest member
of the NCS family, to the Parkinson’s disease (PD) as it is upregulated in the substantia
nigra of PD patients. NCS1 is constitutively membrane-bound and in a complex with
Cav1.3 L-type-Ca2+ channel and the dopamine D2 autoreceptor has been shown to tune
the adaptive response of substantia nigra neurons dopaminergic agonists. This lead to the
suggestion that targeting NCS1 might be a way to modify the vulnerability of substantia
nigra neurons to neurodegeneration (Dragicevic et al. 2014).
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6.7 Two independently identified SMA modifiers: NCALD and PLS3 act on
endocytosis as a common pathway which is impaired in SMA
The fact that NCALD reduction ameliorated the SMA phenotype across species: in
nematode, zebrafish and mouse, provided a hint towards an evolutionary conserved
mechanism (Riessland et al. under review). Presumably, the protective effect of NCALD
reduction is mediated by an interaction partner of NCALD; however, so far only few
proteins interacting with NCALD have been identified (Fig. 42). We focused our attention
on the reported NCALD interaction with clathrin (Ivings et al. 2002), as clathrin has been
widely studied in the context of clathrin-mediated endocytosis (Rodemer and Haucke
2008) and NCALD was also identified within synaptic vesicles (Wilhelm et al. 2014).
Furthermore, the Ca2+ dynamics at the presynaptic terminals is crucial for the regulation
of endo- and exocytosis of neurotransmitters (Sudhof 2012). We showed that the NCALD-
clathrin interaction is Ca2+ dependent; specifically, the binding occurred only when Ca2+
was absent (Riessland et al. under review).
The examination of the effect of NCALD reduction on the endocytic uptake in the context
of SMA was performed in the NMJs of the TVA muscle in PND10 animals identical with
those analyzed in 5.2: SMA, SMA-Ncaldko/wt, HET and HET-Ncaldko/wt, using a FM1-43 dye
as recently described in (Hosseinibarkooie et al. 2016). When the nerve was stimulated
under conditions simulating clathrin-mediated endocytosis, in the NMJs of SMA animals
the dye uptake was significantly reduced in comparison to HET littermates, but
concomitant NCALD reduction restored the uptake to control levels (Riessland et al. under
review).
The importance of endocytosis impairment in SMA is further underlined by the fact that
also overexpression of PLS3, which has been identified as protective modifier for SMA in
humans (Oprea et al. 2008), could rescue the deficient endocytosis in SMA mice
(Hosseinibarkooie et al. 2016). Notably, other proteins acting directly in endocytosis have
been reported in a screen for SMA modifiers in C. elegans (Dimitriadi et al. 2016). Taken
together, these findings recognize endocytosis as a common pathway impacted by both
SMA modifiers: NCALD and PLS3.
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Fig. 42: A map of known interaction partners of NCS proteins
NCALD has been shown to interact with the following proteins: NCS-1, clathrin, tubulin and actin, CAPS (Ca2+
dependent activator protein for secretion), GluR6 (glutamate receptor 6), GUCY2D (guanylate cyclase 2D),
S100b (S100 protein beta) and PDE (phosphodiesterase 1A); detailed information to other NCS proteins can
be found in (Ivings et al. 2002, Burgoyne and Haynes 2012).
Interestingly, other NCS proteins have been demonstrated to play a role in a very specific
kind of endocytosis indispensable for synaptic plasticity, namely the receptor endocytosis
(Kerrigan et al. 2012). The hippocalcin together with calmodulin regulates the trafficking of
NMDA receptors (Jo et al. 2010), while NCS-1 interacts with protein C kinase 1 (PICK1)
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and IP3 in order to control the synaptic removal of the AMPA receptors by endocytosis (Jo
et al. 2008). Interestingly, hippocalcin, which shares 91% homology with NCALD
(Braunewell and Klein-Szanto 2009), has been shown to interact with the AP2 adaptor
complex subunit to promote the clathrin-mediated endocytosis of AMPA receptors (Palmer
et al. 2005). The recruitment of clathrin displaced hippocalcin, suggesting a similar
antagonistic interaction between hippocalcin and clathrin as we hypothesize for NCALD in
the context of SMA. In normal physiological conditions, after neurotransmitter release
clathrin binds to synaptic membrane to participate in vesicle recycling (Takei and Haucke
2001, Soykan et al. 2016). As local Ca2+ is elevated after vesicle release, this induces
conformational change of NCALD and release of clathrin to perform its endocytic function.
In SMA, voltage-dependent Ca2+ influx is reduced and prevents the clathrin release, thus
inhibiting clathrin from vesicle coating. However, when NCALD is reduced (as in
asymptomatic individuals), even at low intracellular Ca2+ more clathrin is released to
mediate efficient endocytosis (Fig. 43) (Riessland et al. under review).
Fig. 43: Proposed mode of NCALD acting on the endocytosis at the synaptic membrane
Under normal physiological conditions of Ca2+ homeostasis, NCALD does not impair the clathrin-mediated
endocytosis (CME). In SMA, however, the Ca2+ homeostasis and subsequently the CME are disturbed, but
can be restored to normal function when NCALD is depleted, as in asymptomatic individuals (Riessland et al.
under review).
6.8 Future outlook
While we succeeded in verifying the positive effect of reduced NCALD levels in various
cellular systems and across species (nematode, zebrafish and mouse) and identified
endocytosis as the key mechanism how NCALD reduction ameliorates SMA phenotype,
the studies have opened new research avenues to follow:
1) as the Ncaldko/ko mouse line is readily available, an unbiased interactome study
using proteomics approach with neuronal tissue can be conducted in order to see
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the possible effect of Ncald knock-out on the binding partners, their stability and
function;
2) since NCALD has three active EF-hand motifs with calcium binding ability, it is still
possible that the calcium signaling is modified in the Ncaldko/ko animals; further
studies including calcium imaging or investigation of the downstream signaling
pathways would shed more light on this process;
3) considering the weight loss phenotype in the HET-Ncaldko/wt and HET-Ncaldko/ko,
presumably the lipid metabolism is changed; further characterization of lipid and
glucose profile in the blood of Ncaldko/ko mice can be a starting point to elucidate
the role of NCALD in lipid metabolism;
4) it is worthwhile to investigate a possible effect of Ncald knock-out on the signaling
of other closely related member of NCS family like VILIP1-3 and hippocalcin;
5) since NCALD has been shown to be upregulated in a mouse model of Alzheimer’s
disease (Suszynska-Zajczyk et al. 2014), Ncaldko/ko mouse model might be applied
to study the effect of NCALD reduction on AD and on other neurodegenerative
diseases;
6) so far, our analysis of genetic NCALD reduction was restricted to the
neuromuscular system; considering apparent behavioral abnormalities, studies of
other neuron populations, particularly in the brain, are presently performed to better
understand the neuronal consequences of NCALD depletion;
7) a milder model of SMA which does not show a reduced survival but merely a motor
phenotype is currently analyzed using electrophysiological recordings (CMAP) in
order to investigate the long-term effect of NCALD reduction under lower SMN
levels;
8) utilizing Ncald-ASOs as potential SMA therapeutics needs further optimization,
especially to improve the safety profile;
9) as both NCALD and PLS3 were shown to improve the SMA phenotype, combining
their protective potential in a new Ncaldko/wt; PLS3tg/tg mouse line is an exciting
opportunity to study a potential synergistic effect of both modifiers in vivo.
116
7 References
1. Aartsma-Rus, A. and G. J. van Ommen (2010). "Progress in therapeutic antisense applications
for neuromuscular disorders." Eur J Hum Genet 18(2): 146-153.
2. Ackermann, B., S. Krober, L. Torres-Benito, A. Borgmann, M. Peters, S. M. Hosseini Barkooie,
R. Tejero, M. Jakubik, J. Schreml, J. Milbradt, T. F. Wunderlich, M. Riessland, L. Tabares and B.
Wirth (2013). "Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves
neuromuscular junction functionality." Hum Mol Genet 22(7): 1328-1347.
3. Akten, B., M. J. Kye, T. Hao le, M. H. Wertz, S. Singh, D. Nie, J. Huang, T. T. Merianda, J. L.
Twiss, C. E. Beattie, J. A. Steen and M. Sahin (2011). "Interaction of survival of motor neuron (SMN)
and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits." Proc Natl Acad Sci U
S A 108(25): 10337-10342.
4. Anderton, R. S., B. P. Meloni, F. L. Mastaglia and S. Boulos (2013). "Spinal muscular atrophy
and the antiapoptotic role of survival of motor neuron (SMN) protein." Mol Neurobiol 47(2): 821-
832.
5. Angelozzi, C., F. Borgo, F. D. Tiziano, A. Martella, G. Neri and C. Brahe (2008). "Salbutamol
increases SMN mRNA and protein levels in spinal muscular atrophy cells." J Med Genet 45(1): 29-
31.
6. Arkblad, E., M. Tulinius, A. K. Kroksmark, M. Henricsson and N. Darin (2009). "A population-
based study of genotypic and phenotypic variability in children with spinal muscular atrophy." Acta
Paediatr 98(5): 865-872.
7. Armstrong, C. M. and F. Bezanilla (1974). "Charge movement associated with the opening and
closing of the activation gates of the Na channels." J Gen Physiol 63(5): 533-552.
8. Arnold, W. D., P. N. Porensky, V. L. McGovern, C. C. Iyer, S. Duque, X. Li, K. Meyer, L.
Schmelzer, B. K. Kaspar, S. J. Kolb, J. T. Kissel and A. H. Burghes (2014). "Electrophysiological
Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept." Ann Clin Transl Neurol 1(1):
34-44.
9. Avila, A. M., B. G. Burnett, A. A. Taye, F. Gabanella, M. A. Knight, P. Hartenstein, Z. Cizman, N.
A. Di Prospero, L. Pellizzoni, K. H. Fischbeck and C. J. Sumner (2007). "Trichostatin A increases
SMN expression and survival in a mouse model of spinal muscular atrophy." J Clin Invest 117(3):
659-671.
10. Benjamini, Y. and Y. Hochberg (1995). "Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing " [Royal Statistical Society, Wiley] 57(1): 289-300.
11. Bennett, C. F. and E. E. Swayze (2010). "RNA targeting therapeutics: molecular mechanisms
of antisense oligonucleotides as a therapeutic platform." Annu Rev Pharmacol Toxicol 50: 259-293.
12. Berridge, M. J. (1998). "Neuronal calcium signaling." Neuron 21(1): 13-26.
13. Bevan, A. K., K. R. Hutchinson, K. D. Foust, L. Braun, V. L. McGovern, L. Schmelzer, J. G.
Ward, J. C. Petruska, P. A. Lucchesi, A. H. Burghes and B. K. Kaspar (2010). "Early heart failure
in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN
delivery." Hum Mol Genet 19(20): 3895-3905.
14. Biogen and Ionis Pharmaceuticals (2016). Biogen and Ionis Pharmaceuticals Report
Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-
Onset Spinal Muscular Atrophy CAMBRIDGE, Mass. & CARLSBAD, Calif. , Biogen Media.
15. Biondi, O., J. Branchu, A. Ben Salah, L. Houdebine, L. Bertin, F. Chali, C. Desseille, L. Weill,
G. Sanchez, C. Lancelin, S. Aid, P. Lopes, C. Pariset, S. Lecolle, J. Cote, M. Holzenberger, C.
117References
Chanoine, C. Massaad and F. Charbonnier (2015). "IGF-1R Reduction Triggers Neuroprotective
Signaling Pathways in Spinal Muscular Atrophy Mice." J Neurosci 35(34): 12063-12079.
16. Biondi, O., J. Branchu, G. Sanchez, C. Lancelin, S. Deforges, P. Lopes, C. Pariset, S. Lecolle,
J. Cote, C. Chanoine and F. Charbonnier (2010). "In vivo NMDA receptor activation accelerates
motor unit maturation, protects spinal motor neurons, and enhances SMN2 gene expression in
severe spinal muscular atrophy mice." J Neurosci 30(34): 11288-11299.
17. Bogdanik, L. P., M. A. Osborne, C. Davis, W. P. Martin, A. Austin, F. Rigo, C. F. Bennett and
C. M. Lutz (2015). "Systemic, postsymptomatic antisense oligonucleotide rescues motor unit
maturation delay in a new mouse model for type II/III spinal muscular atrophy." Proc Natl Acad Sci
U S A 112(43): E5863-5872.
18. Boido, M. and A. Vercelli (2016). "Neuromuscular Junctions as Key Contributors and
Therapeutic Targets in Spinal Muscular Atrophy." Front Neuroanat 10: 6.
19. Bordet, T., B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N. P. Akentieva, A. S.
Evers, D. F. Covey, M. A. Ostuni, J. J. Lacapere, C. Massaad, M. Schumacher, E. M. Steidl, D.
Maux, M. Delaage, C. E. Henderson and R. M. Pruss (2007). "Identification and characterization of
cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis."
J Pharmacol Exp Ther 322(2): 709-720.
20. Bowerman, M., C. L. Anderson, A. Beauvais, P. P. Boyl, W. Witke and R. Kothary (2009). "SMN,
profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis."
Mol Cell Neurosci 42(1): 66-74.
21. Bowerman, M., A. Beauvais, C. L. Anderson and R. Kothary (2010). "Rho-kinase inactivation
prolongs survival of an intermediate SMA mouse model." Hum Mol Genet 19(8): 1468-1478.
22. Bowerman, M., J. P. Michalski, A. Beauvais, L. M. Murray, Y. DeRepentigny and R. Kothary
(2014). "Defects in pancreatic development and glucose metabolism in SMN-depleted mice
independent of canonical spinal muscular atrophy neuromuscular pathology." Hum Mol Genet
23(13): 3432-3444.
23. Bowerman, M., L. M. Murray, A. Beauvais, B. Pinheiro and R. Kothary (2011). "A critical smn
threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated
with a distinct neuromuscular junction pathology." Neuromuscul Disord 22(3): 263-276.
24. Bowerman, M., L. M. Murray, J. G. Boyer, C. L. Anderson and R. Kothary (2012). "Fasudil
improves survival and promotes skeletal muscle development in a mouse model of spinal muscular
atrophy." BMC Med 10: 24.
25. Bowerman, M., D. Shafey and R. Kothary (2007). "Smn depletion alters profilin II expression
and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity." J Mol
Neurosci 32(2): 120-131.
26. Boyer, J. G., M. O. Deguise, L. M. Murray, A. Yazdani, Y. De Repentigny, C. Boudreau-Lariviere
and R. Kothary (2014). "Myogenic program dysregulation is contributory to disease pathogenesis
in spinal muscular atrophy." Hum Mol Genet 23(16): 4249-4259.
27. Bradford, M. M. (1976). "A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding." Anal Biochem 72: 248-254.
28. Braun, S., B. Croizat, M. C. Lagrange, J. M. Warter and P. Poindron (1995). "Constitutive
muscular abnormalities in culture in spinal muscular atrophy." Lancet 345(8951): 694-695.
29. Braunewell, K. H. (2012). "The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease-
old wine in new bottles." Front Mol Neurosci 5: 20.
118
30. Braunewell, K. H. and A. J. Klein-Szanto (2009). "Visinin-like proteins (VSNLs): interaction
partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+ -sensor
proteins." Cell Tissue Res 335(2): 301-316.
31. Bricceno, K. V., T. Martinez, E. Leikina, S. Duguez, T. A. Partridge, L. V. Chernomordik, K. H.
Fischbeck, C. J. Sumner and B. G. Burnett (2014). "Survival motor neuron protein deficiency
impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics."
Hum Mol Genet 23(18): 4745-4757.
32. Briese, M., B. Esmaeili, S. Fraboulet, E. C. Burt, S. Christodoulou, P. R. Towers, K. E. Davies
and D. B. Sattelle (2009). "Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal
muscular atrophy gene, results in locomotor dysfunction and reduced lifespan." Hum Mol Genet
18(1): 97-104.
33. Brzustowicz, L. M., T. Lehner, L. H. Castilla, G. K. Penchaszadeh, K. C. Wilhelmsen, R. Daniels,
K. E. Davies, M. Leppert, F. Ziter, D. Wood and et al. (1990). "Genetic mapping of chronic
childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3." Nature 344(6266): 540-541.
34. Burghes, A. H. and C. E. Beattie (2009). "Spinal muscular atrophy: why do low levels of survival
motor neuron protein make motor neurons sick?" Nat Rev Neurosci 10(8): 597-609.
35. Burglen, L., S. Lefebvre, O. Clermont, P. Burlet, L. Viollet, C. Cruaud, A. Munnich and J. Melki
(1996). "Structure and organization of the human survival motor neurone (SMN) gene." Genomics
32(3): 479-482.
36. Burgoyne, R. D. (2007). "Neuronal calcium sensor proteins: generating diversity in neuronal
Ca2+ signalling." Nat Rev Neurosci 8(3): 182-193.
37. Burgoyne, R. D. and L. P. Haynes (2010). "Neuronal calcium sensor proteins: emerging roles
in membrane traffic and synaptic plasticity." F1000 Biol Rep 2.
38. Burgoyne, R. D. and L. P. Haynes (2012). "Understanding the physiological roles of the
neuronal calcium sensor proteins." Mol Brain 5(1): 2.
39. Burgoyne, R. D. and L. P. Haynes (2015). "Sense and specificity in neuronal calcium signalling."
Biochim Biophys Acta 1853(9): 1921-1932.
40. Burnett, B. G., E. Munoz, A. Tandon, D. Y. Kwon, C. J. Sumner and K. H. Fischbeck (2009).
"Regulation of SMN protein stability." Mol Cell Biol 29(5): 1107-1115.
41. Calixto, A., D. Chelur, I. Topalidou, X. Chen and M. Chalfie (2010). "Enhanced neuronal RNAi
in C. elegans using SID-1." Nat Methods 7(7): 554-559.
42. Cashman, N. R., H. D. Durham, J. K. Blusztajn, K. Oda, T. Tabira, I. T. Shaw, S. Dahrouge and
J. P. Antel (1992). "Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor
neurons." Dev Dyn 194(3): 209-221.
43. Chang, H. C., D. N. Dimlich, T. Yokokura, A. Mukherjee, M. W. Kankel, A. Sen, V. Sridhar, T.
A. Fulga, A. C. Hart, D. Van Vactor and S. Artavanis-Tsakonas (2008). "Modeling spinal muscular
atrophy in Drosophila." PLoS One 3(9): e3209.
44. Charlesworth, G., P. R. Angelova, F. Bartolome-Robledo, M. Ryten, D. Trabzuni, M. Stamelou,
A. Y. Abramov, K. P. Bhatia and N. W. Wood (2015). "Mutations in HPCA cause autosomal-
recessive primary isolated dystonia." Am J Hum Genet 96(4): 657-665.
45. Chery, J. and A. Naar (2016). "RNA therapeutics: RNAi and antisense mechanisms and clinical
applications." Postdoc J 4(7): 35-50.
119References
46. Chiriboga, C. A., K. J. Swoboda, B. T. Darras, S. T. Iannaccone, J. Montes, D. C. De Vivo, D.
A. Norris, C. F. Bennett and K. M. Bishop (2016). "Results from a phase 1 study of nusinersen
(ISIS-SMN(Rx)) in children with spinal muscular atrophy." Neurology 86(10): 890-897.
47. Cifuentes-Diaz, C., S. Nicole, M. E. Velasco, C. Borra-Cebrian, C. Panozzo, T. Frugier, G. Millet,
N. Roblot, V. Joshi and J. Melki (2002). "Neurofilament accumulation at the motor endplate and
lack of axonal sprouting in a spinal muscular atrophy mouse model." Hum Mol Genet 11(12): 1439-
1447.
48. Cobben, J. M., H. Scheffer, M. De Visser, G. Van der Steege, J. B. Verhey, J. Osinga, M. Burton,
R. G. Mensink, P. M. Grootscholten, L. P. Ten Kate and C. H. Buys (1996). "Prenatal prediction of
spinal muscular atrophy. Experience with linkage studies and consequences of present SMN
deletion analysis." Eur J Hum Genet 4(4): 231-236.
49. Cobben, J. M., G. van der Steege, P. Grootscholten, M. de Visser, H. Scheffer and C. H. Buys
(1995). "Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal
muscular atrophy." Am J Hum Genet 57(4): 805-808.
50. Coque, E., C. Raoul and M. Bowerman (2014). "ROCK inhibition as a therapy for spinal
muscular atrophy: understanding the repercussions on multiple cellular targets." Front Neurosci 8:
271.
51. Custer, S. K. and E. J. Androphy (2014). "Autophagy dysregulation in cell culture and animals
models of spinal muscular atrophy." Mol Cell Neurosci 61: 133-140.
52. Di Sole, F., K. Vadnagara, O. W. Moe and V. Babich (2012). "Calcineurin homologous protein:
a multifunctional Ca2+-binding protein family." Am J Physiol Renal Physiol 303(2): F165-179.
53. Dimitriadi, M., A. Derdowski, G. Kalloo, M. S. Maginnis, P. O'Hern, B. Bliska, A. Sorkac, K. C.
Nguyen, S. J. Cook, G. Poulogiannis, W. J. Atwood, D. H. Hall and A. C. Hart (2016). "Decreased
function of survival motor neuron protein impairs endocytic pathways." Proc Natl Acad Sci U S A
113(30): E4377-4386.
54. Dimitriadi, M., A. Derdowski, G. Kalloo, M. S. Maginnis, P. O'Hern, B. Bliska, A. Sorkac, K. C.
Nguyen, S. J. Cook, G. Poulogiannis, W. J. Atwood, D. H. Hall and A. C. Hart (2016). "Decreased
function of survival motor neuron protein impairs endocytic pathways." Proc Natl Acad Sci U S A.
55. Dimitriadi, M., M. J. Kye, G. Kalloo, J. M. Yersak, M. Sahin and A. C. Hart (2013). "The
neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate
defects in spinal muscular atrophy models." J Neurosci 33(15): 6557-6562.
56. Dimitriadi, M., J. N. Sleigh, A. Walker, H. C. Chang, A. Sen, G. Kalloo, J. Harris, T. Barsby, M.
B. Walsh, J. S. Satterlee, C. Li, D. Van Vactor, S. Artavanis-Tsakonas and A. C. Hart (2010).
"Conserved genes act as modifiers of invertebrate SMN loss of function defects." PLoS Genet
6(10): e1001172.
57. Doktor, T. K., Y. Hua, H. S. Andersen, S. Broner, Y. H. Liu, A. Wieckowska, M. Dembic, G. H.
Bruun, A. R. Krainer and B. S. Andresen (2016). "RNA-sequencing of a mouse-model of spinal
muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns." Nucleic Acids
Res.
58. Dragicevic, E., C. Poetschke, J. Duda, F. Schlaudraff, S. Lammel, J. Schiemann, M. Fauler, A.
Hetzel, M. Watanabe, R. Lujan, R. C. Malenka, J. Striessnig and B. Liss (2014). "Cav1.3 channels
control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons." Brain 137(Pt
8): 2287-2302.
59. Drapeau, P., R. R. Buss, D. W. Ali, P. Legendre and R. L. Rotundo (2001). "Limits to the
development of fast neuromuscular transmission in zebrafish." J Neurophysiol 86(6): 2951-2956.
120
60. Dubowitz, V. (1964). "Infantile Muscular Atrophy. A Prospective Study with Particular Reference
to a Slowly Progressive Variety." Brain 87: 707-718.
61. Dubowitz, V. (1999). "Very severe spinal muscular atrophy (SMA type 0): an expanding clinical
phenotype." Eur J Paediatr Neurol 3(2): 49-51.
62. Dubowitz, V. (2009). "Ramblings in the history of spinal muscular atrophy." Neuromuscul Disord
19(1): 69-73.
63. Dunning, M. J., N. L. Barbosa-Morais, A. G. Lynch, S. Tavare and M. E. Ritchie (2008).
"Statistical issues in the analysis of Illumina data." BMC Bioinformatics 9: 85.
64. Duque, S., B. Joussemet, C. Riviere, T. Marais, L. Dubreil, A. M. Douar, J. Fyfe, P. Moullier, M.
A. Colle and M. Barkats (2009). "Intravenous administration of self-complementary AAV9 enables
transgene delivery to adult motor neurons." Mol Ther 17(7): 1187-1196.
65. El-Khodor, B. F., N. Edgar, A. Chen, M. L. Winberg, C. Joyce, D. Brunner, M. Suarez-Farinas
and M. P. Heyes (2008). "Identification of a battery of tests for drug candidate evaluation in the
SMNDelta7 neonate model of spinal muscular atrophy." Exp Neurol 212(1): 29-43.
66. Evans, M. J. and M. H. Kaufman (1981). "Establishment in culture of pluripotential cells from
mouse embryos." Nature 292(5819): 154-156.
67. Fallini, C., G. J. Bassell and W. Rossoll (2012). "Spinal muscular atrophy: the role of SMN in
axonal mRNA regulation." Brain Res 1462: 81-92.
68. Fallini, C., P. G. Donlin-Asp, J. P. Rouanet, G. J. Bassell and W. Rossoll (2016). "Deficiency of
the Survival of Motor Neuron Protein Impairs mRNA Localization and Local Translation in the
Growth Cone of Motor Neurons." J Neurosci 36(13): 3811-3820.
69. Farooq, F., F. Abadia-Molina, D. MacKenzie, J. Hadwen, F. Shamim, S. O'Reilly, M. Holcik and
A. MacKenzie (2013). "Celecoxib increases SMN and survival in a severe spinal muscular atrophy
mouse model via p38 pathway activation." Hum Mol Genet 22(17): 3415-3424.
70. Farooq, F., F. A. Molina, J. Hadwen, D. MacKenzie, L. Witherspoon, M. Osmond, M. Holcik and
A. MacKenzie (2011). "Prolactin increases SMN expression and survival in a mouse model of
severe spinal muscular atrophy via the STAT5 pathway." J Clin Invest 121(8): 3042-3050.
71. Fatt, P. and B. Katz (1951). "An analysis of the end-plate potential recorded with an intracellular
electrode." J Physiol 115(3): 320-370.
72. Favero, M., A. Cangiano and G. Busetto (2015). "Lesson from the neuromuscular junction: role
of pattern and timing of nerve activity in synaptic development." Neural Regen Res 10(5): 686-688.
73. Fayzullina, S. and L. J. Martin (2014). "Skeletal muscle DNA damage precedes spinal motor
neuron DNA damage in a mouse model of Spinal Muscular Atrophy (SMA)." PLoS One 9(3):
e93329.
74. Feldkotter, M., V. Schwarzer, R. Wirth, T. F. Wienker and B. Wirth (2002). "Quantitative
analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier
testing and prediction of severity of spinal muscular atrophy." Am J Hum Genet 70(2): 358-368.
75. Ferraro, E., F. Molinari and L. Berghella (2012). "Molecular control of neuromuscular junction
development." J Cachexia Sarcopenia Muscle 3(1): 13-23.
76. Finkel, R. S., M. P. McDermott, P. Kaufmann, B. T. Darras, W. K. Chung, D. M. Sproule, P. B.
Kang, A. R. Foley, M. L. Yang, W. B. Martens, M. Oskoui, A. M. Glanzman, J. Flickinger, J. Montes,
S. Dunaway, J. O'Hagen, J. Quigley, S. Riley, M. Benton, P. A. Ryan, M. Montgomery, J. Marra, C.
121References
Gooch and D. C. De Vivo (2014). "Observational study of spinal muscular atrophy type I and
implications for clinical trials." Neurology 83(9): 810-817.
77. Fischer, U., Q. Liu and G. Dreyfuss (1997). "The SMN-SIP1 complex has an essential role in
spliceosomal snRNP biogenesis." Cell 90(6): 1023-1029.
78. Flanagan-Steet, H., M. A. Fox, D. Meyer and J. R. Sanes (2005). "Neuromuscular synapses
can form in vivo by incorporation of initially aneural postsynaptic specializations." Development
132(20): 4471-4481.
79. Foust, K. D., X. Wang, V. L. McGovern, L. Braun, A. K. Bevan, A. M. Haidet, T. T. Le, P. R.
Morales, M. M. Rich, A. H. Burghes and B. K. Kaspar (2010). "Rescue of the spinal muscular
atrophy phenotype in a mouse model by early postnatal delivery of SMN." Nat Biotechnol 28(3):
271-274.
80. Gabanella, F., M. E. Butchbach, L. Saieva, C. Carissimi, A. H. Burghes and L. Pellizzoni (2007).
"Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and
preferentially affect a subset of spliceosomal snRNPs." PLoS One 2(9): e921.
81. Garbes, L., M. Riessland, I. Holker, R. Heller, J. Hauke, C. Trankle, R. Coras, I. Blumcke, E.
Hahnen and B. Wirth (2009). "LBH589 induces up to 10-fold SMN protein levels by several
independent mechanisms and is effective even in cells from SMA patients non-responsive to
valproate." Hum Mol Genet 18(19): 3645-3658.
82. Gavrilina, T. O., V. L. McGovern, E. Workman, T. O. Crawford, R. G. Gogliotti, C. J. DiDonato,
U. R. Monani, G. E. Morris and A. H. Burghes (2008). "Neuronal SMN expression corrects spinal
muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic
effect." Hum Mol Genet 17(8): 1063-1075.
83. Genabai, N. K., S. Ahmad, Z. Zhang, X. Jiang, C. A. Gabaldon and L. Gangwani (2015).
"Genetic inhibition of JNK3 ameliorates spinal muscular atrophy." Hum Mol Genet 24(24): 6986-
7004.
84. Gilliam, T. C., L. M. Brzustowicz, L. H. Castilla, T. Lehner, G. K. Penchaszadeh, R. J. Daniels,
B. C. Byth, J. Knowles, J. E. Hislop, Y. Shapira and et al. (1990). "Genetic homogeneity between
acute and chronic forms of spinal muscular atrophy." Nature 345(6278): 823-825.
85. Glascock, J. J., E. Y. Osman, T. H. Coady, F. F. Rose, M. Shababi and C. L. Lorson (2011).
"Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection
in mice." J Vis Exp(56).
86. Gogliotti, R. G., K. A. Quinlan, C. B. Barlow, C. R. Heier, C. J. Heckman and C. J. Didonato
(2012). "Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor
defects are a consequence, not a cause, of motor neuron dysfunction." J Neurosci 32(11): 3818-
3829.
87. Gomez, M., E. De Castro, E. Guarin, H. Sasakura, A. Kuhara, I. Mori, T. Bartfai, C. I. Bargmann
and P. Nef (2001). "Ca2+ signaling via the neuronal calcium sensor-1 regulates associative learning
and memory in C. elegans." Neuron 30(1): 241-248.
88. Gordon-Weeks, P. R. and A. E. Fournier (2014). "Neuronal cytoskeleton in synaptic plasticity
and regeneration." J Neurochem 129(2): 206-212.
89. Goulet, B. B., R. Kothary and R. J. Parks (2013). "At the "junction" of spinal muscular atrophy
pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression." Curr
Mol Med 13(7): 1160-1174.
90. Greene, L. A. and A. S. Tischler (1976). "Establishment of a noradrenergic clonal line of rat
adrenal pheochromocytoma cells which respond to nerve growth factor." Proc Natl Acad Sci U S A
73(7): 2424-2428.
122
91. Grzeschik, S. M., M. Ganta, T. W. Prior, W. D. Heavlin and C. H. Wang (2005). "Hydroxyurea
enhances SMN2 gene expression in spinal muscular atrophy cells." Ann Neurol 58(2): 194-202.
92. Gutschner, T., M. Baas and S. Diederichs (2011). "Noncoding RNA gene silencing through
genomic integration of RNA destabilizing elements using zinc finger nucleases." Genome Res
21(11): 1944-1954.
93. Haddad, H., C. Cifuentes-Diaz, A. Miroglio, N. Roblot, V. Joshi and J. Melki (2003). "Riluzole
attenuates spinal muscular atrophy disease progression in a mouse model." Muscle Nerve 28(4):
432-437.
94. Hadwen, J., D. MacKenzie, F. Shamim, K. Mongeon, M. Holcik, A. MacKenzie and F. Farooq
(2014). "VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates
disease phenotype in severe spinal muscular atrophy mouse models." Orphanet J Rare Dis 9: 4.
95. Hahnen, E., R. Forkert, C. Marke, S. Rudnik-Schoneborn, J. Schonling, K. Zerres and B. Wirth
(1995). "Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal
muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals."
Hum Mol Genet 4(10): 1927-1933.
96. Hamilton, G. and T. H. Gillingwater (2013). "Spinal muscular atrophy: going beyond the motor
neuron." Trends Mol Med 19(1): 40-50.
97. Hammond, S. M., G. Hazell, F. Shabanpoor, A. F. Saleh, M. Bowerman, J. N. Sleigh, K. E.
Meijboom, H. Zhou, F. Muntoni, K. Talbot, M. J. Gait and M. J. Wood (2016). "Systemic peptide-
mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy." Proc
Natl Acad Sci U S A 113(39): 10962-10967.
98. Harding, B. N., S. Kariya, U. R. Monani, W. K. Chung, M. Benton, S. W. Yum, G. Tennekoon
and R. S. Finkel (2015). "Spectrum of neuropathophysiology in spinal muscular atrophy type I." J
Neuropathol Exp Neurol 74(1): 15-24.
99. Haucke, V., E. Neher and S. J. Sigrist (2011). "Protein scaffolds in the coupling of synaptic
exocytosis and endocytosis." Nat Rev Neurosci 12(3): 127-138.
100. Haynes, L. P., H. V. McCue and R. D. Burgoyne (2012). "Evolution and functional diversity of
the Calcium Binding Proteins (CaBPs)." Front Mol Neurosci 5: 9.
101. Heesen, L., M. Peitz, L. Torres-Benito, I. Holker, K. Hupperich, K. Dobrindt, J. Jungverdorben,
S. Ritzenhofen, B. Weykopf, D. Eckert, S. M. Hosseini-Barkooie, M. Storbeck, N. Fusaki, R. Lonigro,
R. Heller, M. J. Kye, O. Brustle and B. Wirth (2016). "Plastin 3 is upregulated in iPSC-derived
motoneurons from asymptomatic SMN1-deleted individuals." Cell Mol Life Sci 73(10): 2089-2104.
102. Hidaka, H. and K. Okazaki (1993). "Neurocalcin family: a novel calcium-binding protein
abundant in bovine central nervous system." Neurosci Res 16(2): 73-77.
103. Hitz, C., W. Wurst and R. Kuhn (2007). "Conditional brain-specific knockdown of MAPK using
Cre/loxP regulated RNA interference." Nucleic Acids Res 35(12): e90.
104. Hoffmann, J. (1893). "Über chronische spinale Muskelatrophie im Kindesalter, auf familiärer
Basis." Dtsch Z Nervenheilk(3): 427-470.
105. Hosseinibarkooie, S., M. Peters, L. Torres-Benito, R. H. Rastetter, K. Hupperich, A. Hoffmann,
N. Mendoza-Ferreira, A. Kaczmarek, E. Janzen, J. Milbradt, T. Lamkemeyer, F. Rigo, C. F. Bennett,
C. Guschlbauer, A. Buschges, M. Hammerschmidt, M. Riessland, M. J. Kye, C. S. Clemen and B.
Wirth (2016). "The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired
Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype." Am J Hum Genet 99(3):
647-665.
123References
106. Hsieh-Li, H. M., J. G. Chang, Y. J. Jong, M. H. Wu, N. M. Wang, C. H. Tsai and H. Li (2000).
"A mouse model for spinal muscular atrophy." Nat Genet 24(1): 66-70.
107. Hsu, P. D., E. S. Lander and F. Zhang (2014). "Development and applications of CRISPR-
Cas9 for genome engineering." Cell 157(6): 1262-1278.
108. Hua, Y., Y. H. Liu, K. Sahashi, F. Rigo, C. F. Bennett and A. R. Krainer (2015). "Motor neuron
cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic
mouse models." Genes Dev 29(3): 288-297.
109. Hua, Y., K. Sahashi, G. Hung, F. Rigo, M. A. Passini, C. F. Bennett and A. R. Krainer (2010).
"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse
model." Genes Dev 24(15): 1634-1644.
110. Hua, Y., K. Sahashi, F. Rigo, G. Hung, G. Horev, C. F. Bennett and A. R. Krainer (2011).
"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy
mouse model." Nature 478(7367): 123-126.
111. Hua, Y., T. A. Vickers, H. L. Okunola, C. F. Bennett and A. R. Krainer (2008). "Antisense
masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice."
Am J Hum Genet 82(4): 834-848.
112. Iascone, D. M., C. E. Henderson and J. C. Lee (2015). "Spinal muscular atrophy: from tissue
specificity to therapeutic strategies." F1000Prime Rep 7: 04.
113. Iino, S., S. Kobayashi and H. Hidaka (1998). "Neurocalcin-immunopositive nerve terminals in
the muscle spindle, Golgi tendon organ and motor endplate." Brain Res 808(2): 294-299.
114. Isaksson, H. S., B. Sorbe and T. K. Nilsson (2014). "Whole genome expression profiling of
blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and
NOP14." Oncotarget 5(12): 4040-4049.
115. Ivings, L., S. R. Pennington, R. Jenkins, J. L. Weiss and R. D. Burgoyne (2002). "Identification
of Ca2+-dependent binding partners for the neuronal calcium sensor protein neurocalcin delta:
interaction with actin, clathrin and tubulin." Biochem J 363(Pt 3): 599-608.
116. Jablonka, S., M. Beck, B. D. Lechner, C. Mayer and M. Sendtner (2007). "Defective Ca2+
channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular
atrophy." J Cell Biol 179(1): 139-149.
117. Jablonka, S., B. Schrank, M. Kralewski, W. Rossoll and M. Sendtner (2000). "Reduced survival
motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for
spinal muscular atrophy type III." Hum Mol Genet 9(3): 341-346.
118. Jackson Laboratory (2016, 27.09.2016). "Ncaldtm1.1(KOMP)Vlcg."
http://www.informatics.jax.org/allele/key/827975#phenotypes Retrieved 05.10.2016, 2016.
119. Jang, C., J. K. Choi, Y. J. Na, B. Jang, W. Wasco, J. D. Buxbaum, Y. S. Kim and E. K. Choi
(2011). "Calsenilin regulates presenilin 1/gamma-secretase-mediated N-cadherin epsilon-cleavage
and beta-catenin signaling." FASEB J 25(12): 4174-4183.
120. Jo, J., S. Heon, M. J. Kim, G. H. Son, Y. Park, J. M. Henley, J. L. Weiss, M. Sheng, G. L.
Collingridge and K. Cho (2008). "Metabotropic glutamate receptor-mediated LTD involves two
interacting Ca(2+) sensors, NCS-1 and PICK1." Neuron 60(6): 1095-1111.
121. Jo, J., G. H. Son, B. L. Winters, M. J. Kim, D. J. Whitcomb, B. A. Dickinson, Y. B. Lee, K. Futai,
M. Amici, M. Sheng, G. L. Collingridge and K. Cho (2010). "Muscarinic receptors induce LTD of
NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95." Nat Neurosci 13(10):
1216-1224.
124
122. Kaczmarek, A., S. Schneider, B. Wirth and M. Riessland (2015). "Investigational therapies for
the treatment of spinal muscular atrophy." Expert Opin Investig Drugs 24(7): 867-881.
123. Kariya, S., T. Obis, C. Garone, T. Akay, F. Sera, S. Iwata, S. Homma and U. R. Monani (2014).
"Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction
maturation." J Clin Invest 124(2): 785-800.
124. Kariya, S., G. H. Park, Y. Maeno-Hikichi, O. Leykekhman, C. Lutz, M. S. Arkovitz, L. T.
Landmesser and U. R. Monani (2008). "Reduced SMN protein impairs maturation of the
neuromuscular junctions in mouse models of spinal muscular atrophy." Hum Mol Genet 17(16):
2552-2569.
125. Kashima, T. and J. L. Manley (2003). "A negative element in SMN2 exon 7 inhibits splicing in
spinal muscular atrophy." Nat Genet 34(4): 460-463.
126. Kerrigan, T. L., J. W. Daniel, P. L. Regan and K. Cho (2012). "The role of neuronal calcium
sensors in balancing synaptic plasticity and synaptic dysfunction." Front Mol Neurosci 5: 57.
127. Khatri, I. A., U. S. Chaudhry, M. G. Seikaly, R. H. Browne and S. T. Iannaccone (2008). "Low
bone mineral density in spinal muscular atrophy." J Clin Neuromuscul Dis 10(1): 11-17.
128. Kitzmann, P. H. (2010). Animal Models of Spasticity. . Spasticity: Diagnosis and Management.
A. E. E. P. Brashear, Demos Medical Publishing: 419-437.
129. Kleinhammer, A., J. Deussing, W. Wurst and R. Kuhn (2011). "Conditional RNAi in mice."
Methods 53(2): 142-150.
130. Kleinhammer, A., W. Wurst and R. Kuhn (2011). "Constitutive and conditional RNAi
transgenesis in mice." Methods 53(4): 430-436.
131. Kobayashi, M., T. Masaki, K. Hori, Y. Masuo, M. Miyamoto, H. Tsubokawa, H. Noguchi, M.
Nomura and K. Takamatsu (2005). "Hippocalcin-deficient mice display a defect in cAMP response
element-binding protein activation associated with impaired spatial and associative memory."
Neuroscience 133(2): 471-484.
132. Kong, L., X. Wang, D. W. Choe, M. Polley, B. G. Burnett, M. Bosch-Marce, J. W. Griffin, M. M.
Rich and C. J. Sumner (2009). "Impaired synaptic vesicle release and immaturity of neuromuscular
junctions in spinal muscular atrophy mice." J Neurosci 29(3): 842-851.
133. Kubler, E. and H. Riezman (1993). "Actin and fimbrin are required for the internalization step
of endocytosis in yeast." Embo J 12(7): 2855-2862.
134. Kugelberg, E. and L. Welander (1956). "Heredofamilial juvenile muscular atrophy simulating
muscular dystrophy." AMA Arch Neurol Psychiatry 75(5): 500-509.
135. Kuroda, Y., I. Ohashi, T. Saito, J. Nagai, K. Ida, T. Naruto, M. Iai and K. Kurosawa (2014).
"Refinement of the deletion in 8q22.2-q22.3: the minimum deletion size at 8q22.3 related to
intellectual disability and epilepsy." Am J Med Genet A 164A(8): 2104-2108.
136. Kwon, J. E., E. K. Kim and E. J. Choi (2011). "Stabilization of the survival motor neuron protein
by ASK1." FEBS Lett 585(9): 1287-1292.
137. Ladant, D. (1995). "Calcium and membrane binding properties of bovine neurocalcin delta
expressed in Escherichia coli." J Biol Chem 270(7): 3179-3185.
138. Le, T. T., L. T. Pham, M. E. Butchbach, H. L. Zhang, U. R. Monani, D. D. Coovert, T. O.
Gavrilina, L. Xing, G. J. Bassell and A. H. Burghes (2005). "SMNDelta7, the major product of the
centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular
atrophy and associates with full-length SMN." Hum Mol Genet 14(6): 845-857.
125References
139. Lee, J. M., K. Blennow, N. Andreasen, O. Laterza, V. Modur, J. Olander, F. Gao, M. Ohlendorf
and J. H. Ladenson (2008). "The brain injury biomarker VLP-1 is increased in the cerebrospinal
fluid of Alzheimer disease patients." Clin Chem 54(10): 1617-1623.
140. Lee, Y. I., M. Mikesh, I. Smith, M. Rimer and W. Thompson (2011). "Muscles in a mouse model
of spinal muscular atrophy show profound defects in neuromuscular development even in the
absence of failure in neuromuscular transmission or loss of motor neurons." Dev Biol 356(2): 432-
444.
141. Lefebvre, S., L. Burglen, S. Reboullet, O. Clermont, P. Burlet, L. Viollet, B. Benichou, C.
Cruaud, P. Millasseau, M. Zeviani and et al. (1995). "Identification and characterization of a spinal
muscular atrophy-determining gene." Cell 80(1): 155-165.
142. Li, C. H. and P. K. S. Tam (1998). "An iterative algorithm for minimum cross entropy
thresholding." Pattern Recognition Letters 19: 771-776.
143. Lin, S., L. Landmann, M. A. Ruegg and H. R. Brenner (2008). "The role of nerve- versus
muscle-derived factors in mammalian neuromuscular junction formation." J Neurosci 28(13): 3333-
3340.
144. Lin, T. L., T. H. Chen, Y. Y. Hsu, Y. H. Cheng, B. T. Juang and Y. J. Jong (2016). "Selective
Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino
Antisense Oligonucleotides." PLoS One 11(4): e0154723.
145. Linder, C. C. (2006). "Genetic variables that influence phenotype." ILAR J 47(2): 132-140.
146. Ling, K. K., R. M. Gibbs, Z. Feng and C. P. Ko (2012). "Severe neuromuscular denervation of
clinically relevant muscles in a mouse model of spinal muscular atrophy." Hum Mol Genet 21(1):
185-195.
147. Ling, K. K., M. Y. Lin, B. Zingg, Z. Feng and C. P. Ko (2010). "Synaptic defects in the spinal
and neuromuscular circuitry in a mouse model of spinal muscular atrophy." PLoS One 5(11):
e15457.
148. Liu-Yesucevitz, L., G. J. Bassell, A. D. Gitler, A. C. Hart, E. Klann, J. D. Richter, S. T. Warren
and B. Wolozin (2011). "Local RNA translation at the synapse and in disease." J Neurosci 31(45):
16086-16093.
149. Long, C., L. Amoasii, A. A. Mireault, J. R. McAnally, H. Li, E. Sanchez-Ortiz, S. Bhattacharyya,
J. M. Shelton, R. Bassel-Duby and E. N. Olson (2016). "Postnatal genome editing partially restores
dystrophin expression in a mouse model of muscular dystrophy." Science 351(6271): 400-403.
150. Lorson, C. L. and E. J. Androphy (2000). "An exonic enhancer is required for inclusion of an
essential exon in the SMA-determining gene SMN." Hum Mol Genet 9(2): 259-265.
151. Lorson, C. L., E. Hahnen, E. J. Androphy and B. Wirth (1999). "A single nucleotide in the SMN
gene regulates splicing and is responsible for spinal muscular atrophy." Proc Natl Acad Sci U S A
96(11): 6307-6311.
152. Lotti, F., W. L. Imlach, L. Saieva, E. S. Beck, T. Hao le, D. K. Li, W. Jiao, G. Z. Mentis, C. E.
Beattie, B. D. McCabe and L. Pellizzoni (2012). "An SMN-dependent U12 splicing event essential
for motor circuit function." Cell 151(2): 440-454.
153. Lunn, M. R. and C. H. Wang (2008). "Spinal muscular atrophy." Lancet 371(9630): 2120-2133.
154. Macia, E., M. Ehrlich, R. Massol, E. Boucrot, C. Brunner and T. Kirchhausen (2006).
"Dynasore, a cell-permeable inhibitor of dynamin." Dev Cell 10(6): 839-850.
126
155. Makhortova, N. R., M. Hayhurst, A. Cerqueira, A. D. Sinor-Anderson, W. N. Zhao, P. W.
Heiser, A. C. Arvanites, L. S. Davidow, Z. O. Waldon, J. A. Steen, K. Lam, H. D. Ngo and L. L.
Rubin (2011). "A screen for regulators of survival of motor neuron protein levels." Nat Chem Biol
7(8): 544-552.
156. Malkki, H. (2016). "Neuromuscular disease: Mitochondrial dysfunction could precipitate motor
neuron loss in spinal muscular atrophy." Nat Rev Neurol 12(10): 556.
157. Mattis, V. B., A. D. Ebert, M. Y. Fosso, C. W. Chang and C. L. Lorson (2009). "Delivery of a
read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal
model." Hum Mol Genet 18(20): 3906-3913.
158. McGivern, J. V., T. N. Patitucci, J. A. Nord, M. E. Barabas, C. L. Stucky and A. D. Ebert (2013).
"Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor
production." Glia 61(9): 1418-1428.
159. McGovern, V. L., A. Massoni-Laporte, X. Wang, T. T. Le, H. T. Le, C. E. Beattie, M. M. Rich
and A. H. Burghes (2015). "Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity
in the 7 SMA Mouse." PLoS One 10(7): e0132364.
160. McJunkin, K., A. Mazurek, P. K. Premsrirut, J. Zuber, L. E. Dow, J. Simon, B. Stillman and S.
W. Lowe (2011). "Reversible suppression of an essential gene in adult mice using transgenic RNA
interference." Proc Natl Acad Sci U S A 108(17): 7113-7118.
161. McWhorter, M. L., U. R. Monani, A. H. Burghes and C. E. Beattie (2003). "Knockdown of the
survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and
pathfinding." J Cell Biol 162(5): 919-931.
162. Melki, J., S. Abdelhak, P. Sheth, M. F. Bachelot, P. Burlet, A. Marcadet, J. Aicardi, A. Barois,
J. P. Carriere, M. Fardeau and et al. (1990). "Gene for chronic proximal spinal muscular atrophies
maps to chromosome 5q." Nature 344(6268): 767-768.
163. Melki, J., S. Lefebvre, L. Burglen, P. Burlet, O. Clermont, P. Millasseau, S. Reboullet, B.
Benichou, M. Zeviani, D. Le Paslier and et al. (1994). "De novo and inherited deletions of the 5q13
region in spinal muscular atrophies." Science 264(5164): 1474-1477.
164. Mentis, G. Z., D. Blivis, W. Liu, E. Drobac, M. E. Crowder, L. Kong, F. J. Alvarez, C. J. Sumner
and M. J. O'Donovan (2011). "Early functional impairment of sensory-motor connectivity in a mouse
model of spinal muscular atrophy." Neuron 69(3): 453-467.
165. Mercuri, E., E. Bertini, S. Messina, A. Solari, A. D'Amico, C. Angelozzi, R. Battini, A.
Berardinelli, P. Boffi, C. Bruno, C. Cini, F. Colitto, M. Kinali, C. Minetti, T. Mongini, L. Morandi, G.
Neri, S. Orcesi, M. Pane, M. Pelliccioni, A. Pini, F. D. Tiziano, M. Villanova, G. Vita and C. Brahe
(2007). "Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular
atrophy." Neurology 68(1): 51-55.
166. Miller, N., H. Shi, A. S. Zelikovich and Y. C. Ma (2016). "Motor Neuron Mitochondrial
Dysfunction in Spinal Muscular Atrophy." Hum Mol Genet.
167. Mishina, M., T. Takai, K. Imoto, M. Noda, T. Takahashi, S. Numa, C. Methfessel and B.
Sakmann (1986). "Molecular distinction between fetal and adult forms of muscle acetylcholine
receptor." Nature 321(6068): 406-411.
168. Moffat, J., D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepfer, G. Hinkle, B. Piqani, T. M.
Eisenhaure, B. Luo, J. K. Grenier, A. E. Carpenter, S. Y. Foo, S. A. Stewart, B. R. Stockwell, N.
Hacohen, W. C. Hahn, E. S. Lander, D. M. Sabatini and D. E. Root (2006). "A lentiviral RNAi library
for human and mouse genes applied to an arrayed viral high-content screen." Cell 124(6): 1283-
1298.
127References
169. Monani, U. R. and D. C. De Vivo (2014). "Neurodegeneration in spinal muscular atrophy: from
disease phenotype and animal models to therapeutic strategies and beyond." Future Neurol 9(1):
49-65.
170. Monani, U. R., M. T. Pastore, T. O. Gavrilina, S. Jablonka, T. T. Le, C. Andreassi, J. M.
DiCocco, C. Lorson, E. J. Androphy, M. Sendtner, M. Podell and A. H. Burghes (2003). "A transgene
carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with
severe (type I) spinal muscular atrophy." J Cell Biol 160(1): 41-52.
171. Monani, U. R., M. Sendtner, D. D. Coovert, D. W. Parsons, C. Andreassi, T. T. Le, S. Jablonka,
B. Schrank, W. Rossoll, T. W. Prior, G. E. Morris and A. H. Burghes (2000). "The human
centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and
results in a mouse with spinal muscular atrophy." Hum Mol Genet 9(3): 333-339.
172. Mullis, K., F. Faloona, S. Scharf, R. Saiki, G. Horn and H. Erlich (1986). "Specific enzymatic
amplification of DNA in vitro: the polymerase chain reaction." Cold Spring Harb Symp Quant Biol
51 Pt 1: 263-273.
173. Murray, L., T. H. Gillingwater and R. Kothary (2014). "Dissection of the transversus abdominis
muscle for whole-mount neuromuscular junction analysis." J Vis Exp(83): e51162.
174. Murray, L. M., L. H. Comley, D. Thomson, N. Parkinson, K. Talbot and T. H. Gillingwater
(2008). "Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic
pathology at the neuromuscular junction in mouse models of spinal muscular atrophy." Hum Mol
Genet 17(7): 949-962.
175. Murray, L. M., K. Talbot and T. H. Gillingwater (2010). "Review: neuromuscular synaptic
vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy."
Neuropathol Appl Neurobiol 36(2): 133-156.
176. Nadeau, J. H. (2001). "Modifier genes in mice and humans." Nat Rev Genet 2(3): 165-174.
177. Nagy, A., L. Mar and G. Watts (2009). "Creation and use of a cre recombinase transgenic
database." Methods Mol Biol 530: 365-378.
178. Naia, L., I. L. Ferreira, E. Ferreiro and A. C. Rego (2016). "Mitochondrial Ca2+ handling in
Huntington's and Alzheimer's diseases - Role of ER-mitochondria crosstalk." Biochem Biophys Res
Commun.
179. Naryshkin, N. A., M. Weetall, A. Dakka, J. Narasimhan, X. Zhao, Z. Feng, K. K. Ling, G. M.
Karp, H. Qi, M. G. Woll, G. Chen, N. Zhang, V. Gabbeta, P. Vazirani, A. Bhattacharyya, B. Furia,
N. Risher, J. Sheedy, R. Kong, J. Ma, A. Turpoff, C. S. Lee, X. Zhang, Y. C. Moon, P. Trifillis, E. M.
Welch, J. M. Colacino, J. Babiak, N. G. Almstead, S. W. Peltz, L. A. Eng, K. S. Chen, J. L. Mull, M.
S. Lynes, L. L. Rubin, P. Fontoura, L. Santarelli, D. Haehnke, K. D. McCarthy, R. Schmucki, M.
Ebeling, M. Sivaramakrishnan, C. P. Ko, S. V. Paushkin, H. Ratni, I. Gerlach, A. Ghosh and F.
Metzger (2014). "Motor neuron disease. SMN2 splicing modifiers improve motor function and
longevity in mice with spinal muscular atrophy." Science 345(6197): 688-693.
180. Nicole, S., B. Desforges, G. Millet, J. Lesbordes, C. Cifuentes-Diaz, D. Vertes, M. L. Cao, F.
De Backer, L. Languille, N. Roblot, V. Joshi, J. M. Gillis and J. Melki (2003). "Intact satellite cells
lead to remarkable protection against Smn gene defect in differentiated skeletal muscle." J Cell Biol
161(3): 571-582.
181. Nolle, A., A. Zeug, J. van Bergeijk, L. Tonges, R. Gerhard, H. Brinkmann, S. Al Rayes, N.
Hensel, Y. Schill, D. Apkhazava, S. Jablonka, J. O'Mer, R. K. Srivastav, A. Baasner, P. Lingor, B.
Wirth, E. Ponimaskin, R. Niedenthal, C. Grothe and P. Claus (2012). "The spinal muscular atrophy
disease protein SMN is linked to the Rho-kinase pathway via profilin." Hum Mol Genet 20(24): 4865-
4878.
128
182. Nyabi, O., M. Naessens, K. Haigh, A. Gembarska, S. Goossens, M. Maetens, S. De Clercq,
B. Drogat, L. Haenebalcke, S. Bartunkova, I. De Vos, B. De Craene, M. Karimi, G. Berx, A. Nagy,
P. Hilson, J. C. Marine and J. J. Haigh (2009). "Efficient mouse transgenesis using Gateway-
compatible ROSA26 locus targeting vectors and F1 hybrid ES cells." Nucleic Acids Res 37(7): e55.
183. Oh, D. Y., J. H. Cho, S. Y. Park, Y. S. Kim, Y. J. Yoon, S. H. Yoon, K. C. Chung, K. S. Lee
and J. S. Han (2008). "A novel role of hippocalcin in bFGF-induced neurite outgrowth of H19-7
cells." J Neurosci Res 86(7): 1557-1565.
184. Ollion, J., J. Cochennec, F. Loll, C. Escude and T. Boudier (2013). "TANGO: a generic tool for
high-throughput 3D image analysis for studying nuclear organization." Bioinformatics 29(14): 1840-
1841.
185. Oprea, G. E., S. Krober, M. L. McWhorter, W. Rossoll, S. Muller, M. Krawczak, G. J. Bassell,
C. E. Beattie and B. Wirth (2008). "Plastin 3 is a protective modifier of autosomal recessive spinal
muscular atrophy." Science 320(5875): 524-527.
186. Osborne, M., D. Gomez, Z. Feng, C. McEwen, J. Beltran, K. Cirillo, B. El-Khodor, M. Y. Lin, Y.
Li, W. M. Knowlton, D. D. McKemy, L. Bogdanik, K. Butts-Dehm, K. Martens, C. Davis, R. Doty, K.
Wardwell, A. Ghavami, D. Kobayashi, C. P. Ko, S. Ramboz and C. Lutz (2012). "Characterization
of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse
models." Hum Mol Genet 21(20): 4431-4447.
187. Oskoui, M., G. Levy, C. J. Garland, J. M. Gray, J. O'Hagen, D. C. De Vivo and P. Kaufmann
(2007). "The changing natural history of spinal muscular atrophy type 1." Neurology 69(20): 1931-
1936.
188. Otsu, N. (1979). "A threshold selection method from gray-level histograms." IEEE Trans. Sys.,
Man., Cyber. 9: 62-66.
189. Palladino, A., L. Passamano, A. Taglia, P. D'Ambrosio, M. Scutifero, M. R. Cecio, E. Picillo,
E. Viggiano, V. Torre, F. De Luca, G. Nigro and L. Politano (2011). "Cardiac involvement in patients
with spinal muscular atrophies." Acta Myol 30(3): 175-178.
190. Palmer, C. L., W. Lim, P. G. Hastie, M. Toward, V. I. Korolchuk, S. A. Burbidge, G. Banting,
G. L. Collingridge, J. T. Isaac and J. M. Henley (2005). "Hippocalcin functions as a calcium sensor
in hippocampal LTD." Neuron 47(4): 487-494.
191. Palop, J. J., J. Chin and L. Mucke (2006). "A network dysfunction perspective on
neurodegenerative diseases." Nature 443(7113): 768-773.
192. Paquet, D., D. Kwart, A. Chen, A. Sproul, S. Jacob, S. Teo, K. M. Olsen, A. Gregg, S. Noggle
and M. Tessier-Lavigne (2016). "Efficient introduction of specific homozygous and heterozygous
mutations using CRISPR/Cas9." Nature 533(7601): 125-129.
193. Park, G. H., Y. Maeno-Hikichi, T. Awano, L. T. Landmesser and U. R. Monani (2010).
"Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell
autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric
(SMN2) gene." J Neurosci 30(36): 12005-12019.
194. Passini, M. A., J. Bu, A. M. Richards, C. Kinnecom, S. P. Sardi, L. M. Stanek, Y. Hua, F. Rigo,
J. Matson, G. Hung, E. M. Kaye, L. S. Shihabuddin, A. R. Krainer, C. F. Bennett and S. H. Cheng
(2011). "Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe
spinal muscular atrophy." Sci Transl Med 3(72): 72ra18.
195. Pellizzoni, L. (2007). "Chaperoning ribonucleoprotein biogenesis in health and disease."
EMBO Rep 8(4): 340-345.
196. Pellizzoni, L., N. Kataoka, B. Charroux and G. Dreyfuss (1998). "A novel function for SMN, the
spinal muscular atrophy disease gene product, in pre-mRNA splicing." Cell 95(5): 615-624.
129References
197. Popugaeva, E., E. Pchitskaya and I. Bezprozvanny (2016). "Dysregulation of neuronal calcium
homeostasis in Alzheimer's disease - A therapeutic opportunity?" Biochem Biophys Res Commun.
198. Porensky, P. N., C. Mitrpant, V. L. McGovern, A. K. Bevan, K. D. Foust, B. K. Kaspar, S. D.
Wilton and A. H. Burghes (2012). "A single administration of morpholino antisense oligomer rescues
spinal muscular atrophy in mouse." Hum Mol Genet 21(7): 1625-1638.
199. Powis, R. A. and T. H. Gillingwater (2016). "Selective loss of alpha motor neurons with sparing
of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular
atrophy." J Anat 228(3): 443-451.
200. Prior, T. W., A. R. Krainer, Y. Hua, K. J. Swoboda, P. C. Snyder, S. J. Bridgeman, A. H.
Burghes and J. T. Kissel (2009). "A positive modifier of spinal muscular atrophy in the SMN2 gene."
Am J Hum Genet 85(3): 408-413.
201. Prior, T. W., K. J. Swoboda, H. D. Scott and A. Q. Hejmanowski (2004). "Homozygous SMN1
deletions in unaffected family members and modification of the phenotype by SMN2." Am J Med
Genet 130A(3): 307-310.
202. Riessland, M., B. Ackermann, A. Forster, M. Jakubik, J. Hauke, L. Garbes, I. Fritzsche, Y.
Mende, I. Blumcke, E. Hahnen and B. Wirth (2010). "SAHA ameliorates the SMA phenotype in two
mouse models for spinal muscular atrophy." Hum Mol Genet 19(8): 1492-1506.
203. Riessland, M., L. Brichta, E. Hahnen and B. Wirth (2006). "The benzamide M344, a novel
histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular
atrophy cells." Hum Genet 120(1): 101-110.
204. Riessland, M., A. Kaczmarek, S. Schneider, K. J. Swoboda, H. Löhr, C. Bradler, V. Grysko,
M. Dimitriadi, S. M. Hosseini Barkooie, L. Torres-Benito, M. Peters, A. Upadhyay, N. Biglari, S.
Kröber, I. Hölker, L. Garbes, C. Gilissen, A. Hoischen, G. Nürnberg, P. Nürnberg, M. Walter, F.
Rigo, F. C. Bennett, M. J. Kye, A. C. Hart, M. Hammerschmidt, P. Kloppenburg and B. Wirth (under
review). "Neurocalcin delta suppression rescues spinal muscular atrophy across species." Nature
Medicine in review.
205. Rigo, F., Y. Hua, A. R. Krainer and C. F. Bennett (2012). "Antisense-based therapy for the
treatment of spinal muscular atrophy." J Cell Biol 199(1): 21-25.
206. Rodemer, C. and V. Haucke (2008). "Clathrin/AP-2-dependent endocytosis: a novel
playground for the pharmacological toolbox?" Handb Exp Pharmacol(186): 105-122.
207. Rosen, B., J. Schick and W. Wurst (2015). "Beyond knockouts: the International Knockout
Mouse Consortium delivers modular and evolving tools for investigating mammalian genes." Mamm
Genome 26(9-10): 456-466.
208. Rossoll, W., S. Jablonka, C. Andreassi, A. K. Kroning, K. Karle, U. R. Monani and M. Sendtner
(2003). "Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and
localization of beta-actin mRNA in growth cones of motoneurons." J Cell Biol 163(4): 801-812.
209. Roudier, M. P., B. R. Winters, I. Coleman, H. M. Lam, X. Zhang, R. Coleman, L. Chery, L. D.
True, C. S. Higano, B. Montgomery, P. H. Lange, L. A. Snyder, S. Srivastava, E. Corey, R. L.
Vessella, P. S. Nelson, A. Uren and C. Morrissey (2016). "Characterizing the molecular features of
ERG-positive tumors in primary and castration resistant prostate cancer." Prostate 76(9): 810-822.
210. Rudkowska, I., L. Perusse, C. Bellis, J. Blangero, J. P. Despres, C. Bouchard and M. C. Vohl
(2015). "Interaction between Common Genetic Variants and Total Fat Intake on Low-Density
Lipoprotein Peak Particle Diameter: A Genome-Wide Association Study." J Nutrigenet
Nutrigenomics 8(1): 44-53.
130
211. Ruggiu, M., V. L. McGovern, F. Lotti, L. Saieva, D. K. Li, S. Kariya, U. R. Monani, A. H. Burghes
and L. Pellizzoni (2012). "A role for SMN exon 7 splicing in the selective vulnerability of motor
neurons in spinal muscular atrophy." Mol Cell Biol 32(1): 126-138.
212. Ruiz, R., J. J. Casanas, L. Torres-Benito, R. Cano and L. Tabares (2010). "Altered intracellular
Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice." J Neurosci 30(3):
849-857.
213. Saal, L., M. Briese, S. Kneitz, M. Glinka and M. Sendtner (2014). "Subcellular transcriptome
alterations in a cell culture model of spinal muscular atrophy point to widespread defects in axonal
growth and presynaptic differentiation." RNA 20(11): 1789-1802.
214. Sahashi, K., K. K. Ling, Y. Hua, J. E. Wilkinson, T. Nomakuchi, F. Rigo, G. Hung, D. Xu, Y. P.
Jiang, R. Z. Lin, C. P. Ko, C. F. Bennett and A. R. Krainer (2013). "Pathological impact of SMN2
mis-splicing in adult SMA mice." EMBO Mol Med 5(10): 1586-1601.
215. Schick, J. A., C. Seisenberger, J. Beig, A. Burger, V. Iyer, V. Maier, S. Perera, B. Rosen, W.
C. Skarnes and W. Wurst (2016). "CRISPR-Cas9 enables conditional mutagenesis of challenging
loci." Sci Rep 6: 32326.
216. Schmid, A. and C. J. DiDonato (2007). "Animal models of spinal muscular atrophy." J Child
Neurol 22(8): 1004-1012.
217. Schnurra, I., H. G. Bernstein, P. Riederer and K. H. Braunewell (2001). "The neuronal calcium
sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's
disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors
and Alzheimer's disease?" Neurobiol Dis 8(5): 900-909.
218. Schrank, B., R. Gotz, J. M. Gunnersen, J. M. Ure, K. V. Toyka, A. G. Smith and M. Sendtner
(1997). "Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular
atrophy, leads to massive cell death in early mouse embryos." Proc Natl Acad Sci U S A 94(18):
9920-9925.
219. Schreij, A. M., E. A. Fon and P. S. McPherson (2016). "Endocytic membrane trafficking and
neurodegenerative disease." Cell Mol Life Sci 73(8): 1529-1545.
220. Schreml, J., M. Riessland, M. Paterno, L. Garbes, K. Rossbach, B. Ackermann, J. Kramer, E.
Somers, S. H. Parson, R. Heller, A. Berkessel, A. Sterner-Kock and B. Wirth (2013). "Severe SMA
mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585."
Eur J Hum Genet 21(6): 643-652.
221. See, K., P. Yadav, M. Giegerich, P. S. Cheong, M. Graf, H. Vyas, S. G. Lee, S. Mathavan, U.
Fischer, M. Sendtner and C. Winkler (2014). "SMN deficiency alters Nrxn2 expression and splicing
in zebrafish and mouse models of spinal muscular atrophy." Hum Mol Genet 23(7): 1754-1770.
222. Sen, A., D. N. Dimlich, K. G. Guruharsha, M. W. Kankel, K. Hori, T. Yokokura, S. Brachat, D.
Richardson, J. Loureiro, R. Sivasankaran, D. Curtis, L. S. Davidow, L. L. Rubin, A. C. Hart, D. Van
Vactor and S. Artavanis-Tsakonas (2013). "Genetic circuitry of Survival motor neuron, the gene
underlying spinal muscular atrophy." Proc Natl Acad Sci U S A 110(26): E2371-2380.
223. Shababi, M., C. L. Lorson and S. S. Rudnik-Schoneborn (2014). "Spinal muscular atrophy: a
motor neuron disorder or a multi-organ disease?" J Anat 224(1): 15-28.
224. Shafey, D., P. D. Cote and R. Kothary (2005). "Hypomorphic Smn knockdown C2C12
myoblasts reveal intrinsic defects in myoblast fusion and myotube morphology." Exp Cell Res
311(1): 49-61.
225. Shi, X., C. Ma, Q. Zhu, D. Yuan, M. Sun, X. Gu, G. Wu, T. Lv and Y. Song (2016). "Upregulation
of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and
repression of NCALD in non-small-cell lung cancer." Oncotarget 7(18): 25558-25575.
131References
226. Simon, C. M., A. M. Janas, F. Lotti, J. C. Tapia, L. Pellizzoni and G. Z. Mentis (2016). "A Stem
Cell Model of the Motor Circuit Uncouples Motor Neuron Death from Hyperexcitability Induced by
SMN Deficiency." Cell Rep 16(5): 1416-1430.
227. Simone, C., A. Ramirez, M. Bucchia, P. Rinchetti, H. Rideout, D. Papadimitriou, D. B. Re and
S. Corti (2016). "Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and
therapeutic implications?" Cell Mol Life Sci 73(5): 1003-1020.
228. Singh, N. N., M. Shishimorova, L. C. Cao, L. Gangwani and R. N. Singh (2009). "A short
antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in
spinal muscular atrophy." RNA Biol 6(3): 341-350.
229. Sintusek, P., F. Catapano, N. Angkathunkayul, E. Marrosu, S. H. Parson, J. E. Morgan, F.
Muntoni and H. Zhou (2016). "Histopathological Defects in Intestine in Severe Spinal Muscular
Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment." PLoS One 11(5):
e0155032.
230. Sleigh, J. N., A. Barreiro-Iglesias, P. L. Oliver, A. Biba, T. Becker, K. E. Davies, C. G. Becker
and K. Talbot (2014). "Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in
vivo models of spinal muscular atrophy." Hum Mol Genet 23(4): 855-869.
231. Sleigh, J. N., T. H. Gillingwater and K. Talbot (2011). "The contribution of mouse models to
understanding the pathogenesis of spinal muscular atrophy." Dis Model Mech 4(4): 457-467.
232. Somers, E., R. D. Lees, K. Hoban, J. N. Sleigh, H. Zhou, F. Muntoni, K. Talbot, T. H.
Gillingwater and S. H. Parson (2016). "Vascular Defects and Spinal Cord Hypoxia in Spinal
Muscular Atrophy." Ann Neurol 79(2): 217-230.
233. Somers, E., M. Riessland, J. Schreml, B. Wirth, T. H. Gillingwater and S. H. Parson (2013).
"Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in
skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy." Neurosci
Lett 544: 100-104.
234. Soykan, T., T. Maritzen and V. Haucke (2016). "Modes and mechanisms of synaptic vesicle
recycling." Curr Opin Neurobiol 39: 17-23.
235. Stevens, C. F. (2003). "Neurotransmitter release at central synapses." Neuron 40(2): 381-388.
236. Sudhof, T. C. (2012). "Calcium control of neurotransmitter release." Cold Spring Harb Perspect
Biol 4(1): a011353.
237. Sumner, C. J., T. N. Huynh, J. A. Markowitz, J. S. Perhac, B. Hill, D. D. Coovert, K. Schussler,
X. Chen, J. Jarecki, A. H. Burghes, J. P. Taylor and K. H. Fischbeck (2003). "Valproic acid increases
SMN levels in spinal muscular atrophy patient cells." Ann Neurol 54(5): 647-654.
238. Sun, Y., M. Grimmler, V. Schwarzer, F. Schoenen, U. Fischer and B. Wirth (2005). "Molecular
and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy."
Hum Mutat 25(1): 64-71.
239. Suszynska-Zajczyk, J., M. Luczak, L. Marczak and H. Jakubowski (2014).
"Hyperhomocysteinemia and bleomycin hydrolase modulate the expression of mouse brain
proteins involved in neurodegeneration." J Alzheimers Dis 40(3): 713-726.
240. Suszynska-Zajczyk, J., M. Luczak, L. Marczak and H. Jakubowski (2014).
"Hyperhomocysteinemia and Bleomycin Hydrolase Modulate the Expression of Mouse Brain
Proteins Involved in Neurodegeneration." J Alzheimers Dis.
241. Suszynska-Zajczyk, J., M. Luczak, L. Marczak and H. Jakubowski (2014). "Inactivation of the
paraoxonase 1 gene affects the expression of mouse brain proteins involved in neurodegeneration."
J Alzheimers Dis 42(1): 247-260.
132
242. Swoboda, K. J., C. B. Scott, T. O. Crawford, L. R. Simard, S. P. Reyna, K. J. Krosschell, G.
Acsadi, B. Elsheik, M. K. Schroth, G. D'Anjou, B. LaSalle, T. W. Prior, S. L. Sorenson, J. A.
Maczulski, M. B. Bromberg, G. M. Chan, J. T. Kissel and N. Project Cure Spinal Muscular Atrophy
Investigators (2010). "SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled
trial of L-carnitine and valproic acid in spinal muscular atrophy." PLoS One 5(8): e12140.
243. Swoboda, K. J., C. B. Scott, S. P. Reyna, T. W. Prior, B. LaSalle, S. L. Sorenson, J. Wood, G.
Acsadi, T. O. Crawford, J. T. Kissel, K. J. Krosschell, G. D'Anjou, M. B. Bromberg, M. K. Schroth,
G. M. Chan, B. Elsheikh and L. R. Simard (2009). "Phase II open label study of valproic acid in
spinal muscular atrophy." PLoS One 4(5): e5268.
244. Takei, K. and V. Haucke (2001). "Clathrin-mediated endocytosis: membrane factors pull the
trigger." Trends Cell Biol 11(9): 385-391.
245. Tamariz, E. and A. Varela-Echavarria (2015). "The discovery of the growth cone and its
influence on the study of axon guidance." Front Neuroanat 9: 51.
246. Tapia, J. C., J. D. Wylie, N. Kasthuri, K. J. Hayworth, R. Schalek, D. R. Berger, C. Guatimosim,
H. S. Seung and J. W. Lichtman (2012). "Pervasive synaptic branch removal in the mammalian
neuromuscular system at birth." Neuron 74(5): 816-829.
247. Tejero, R., M. Lopez-Manzaneda, S. Arumugam and L. Tabares (2016). "Synaptotagmin-2,
and -1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy." Hum
Mol Genet.
248. Thomas, K. R. and M. R. Capecchi (1987). "Site-directed mutagenesis by gene targeting in
mouse embryo-derived stem cells." Cell 51(3): 503-512.
249. Thyagarajan, B., E. C. Olivares, R. P. Hollis, D. S. Ginsburg and M. P. Calos (2001). "Site-
specific genomic integration in mammalian cells mediated by phage phiC31 integrase." Mol Cell
Biol 21(12): 3926-3934.
250. Tintignac, L. A., H. R. Brenner and M. A. Ruegg (2015). "Mechanisms Regulating
Neuromuscular Junction Development and Function and Causes of Muscle Wasting." Physiol Rev
95(3): 809-852.
251. Torres-Benito, L., M. F. Neher, R. Cano, R. Ruiz and L. Tabares (2011). "SMN requirement
for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals."
PLoS One 6(10): e26164.
252. Torres, R. M. and R. Kühn (1997). Laboratory protocols for conditional gene targeting. Oxford
; New York, Oxford Uninversity Press.
253. Valenzuela, D. M., A. J. Murphy, D. Frendewey, N. W. Gale, A. N. Economides, W. Auerbach,
W. T. Poueymirou, N. C. Adams, J. Rojas, J. Yasenchak, R. Chernomorsky, M. Boucher, A. L.
Elsasser, L. Esau, J. Zheng, J. A. Griffiths, X. Wang, H. Su, Y. Xue, M. G. Dominguez, I. Noguera,
R. Torres, L. E. Macdonald, A. F. Stewart, T. M. DeChiara and G. D. Yancopoulos (2003). "High-
throughput engineering of the mouse genome coupled with high-resolution expression analysis."
Nat Biotechnol 21(6): 652-659.
254. Venkataraman, V., T. Duda, S. Ravichandran and R. K. Sharma (2008). "Neurocalcin delta
modulation of ROS-GC1, a new model of Ca(2+) signaling." Biochemistry 47(25): 6590-6601.
255. Vercauteren, F. G., G. Flores, W. Ma, J. G. Chabot, L. Geenen, S. Clerens, A. Fazel, J. J.
Bergeron, L. K. Srivastava, L. Arckens and R. Quirion (2007). "An organelle proteomic method to
study neurotransmission-related proteins, applied to a neurodevelopmental model of
schizophrenia." Proteomics 7(19): 3569-3579.
256. Vezain, M., P. Saugier-Veber, E. Goina, R. Touraine, V. Manel, A. Toutain, S. Fehrenbach, T.
Frebourg, F. Pagani, M. Tosi and A. Martins (2010). "A rare SMN2 variant in a previously
133References
unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the
clinical severity of spinal muscular atrophy." Hum Mutat 31(1): E1110-1125.
257. Villalobos, C. and R. Andrade (2010). "Visinin-like neuronal calcium sensor proteins regulate
the slow calcium-activated afterhyperpolarizing current in the rat cerebral cortex." J Neurosci
30(43): 14361-14365.
258. Vitte, J. M., B. Davoult, N. Roblot, M. Mayer, V. Joshi, S. Courageot, F. Tronche, J. Vadrot, M.
H. Moreau, F. Kemeny and J. Melki (2004). "Deletion of murine Smn exon 7 directed to liver leads
to severe defect of liver development associated with iron overload." Am J Pathol 165(5): 1731-
1741.
259. Viviano, J., A. Krishnan, H. Wu and V. Venkataraman (2016). "Data on the calcium-induced
mobility shift of myristoylated and non-myristoylated forms of neurocalcin delta." Data Brief 7: 630-
633.
260. von Kleist, L., W. Stahlschmidt, H. Bulut, K. Gromova, D. Puchkov, M. J. Robertson, K. A.
MacGregor, N. Tomilin, A. Pechstein, N. Chau, M. Chircop, J. Sakoff, J. P. von Kries, W. Saenger,
H. G. Krausslich, O. Shupliakov, P. J. Robinson, A. McCluskey and V. Haucke (2011). "Role of the
clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition."
Cell 146(3): 471-484.
261. Wang, C. H., J. Xu, T. A. Carter, B. M. Ross, M. K. Dominski, C. A. Bellcross, G. K.
Penchaszadeh, T. L. Munsat and T. C. Gilliam (1996). "Characterization of survival motor neuron
(SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy." Hum Mol Genet 5(3):
359-365.
262. Weiss, J. L., H. Hui and R. D. Burgoyne (2010). "Neuronal calcium sensor-1 regulation of
calcium channels, secretion, and neuronal outgrowth." Cell Mol Neurobiol 30(8): 1283-1292.
263. Wen, H. L., C. H. Ting, H. C. Liu, H. Li and S. Lin-Chao (2013). "Decreased stathmin
expression ameliorates neuromuscular defects but fails to prolong survival in a mouse model of
spinal muscular atrophy." Neurobiol Dis 52: 94-103.
264. Werdnig, G. (1891). "Two early infantile hereditary cases of progressive muscular atrophy
simulating dystrophy, but on a neural basis. ." Arch Neurol 25(3): 276-278.
265. Westerfield, M., J. V. McMurray and J. S. Eisen (1986). "Identified motoneurons and their
innervation of axial muscles in the zebrafish." J Neurosci 6(8): 2267-2277.
266. Wettenhall, J. M. and G. K. Smyth (2004). "limmaGUI: a graphical user interface for linear
modeling of microarray data." Bioinformatics 20(18): 3705-3706.
267. Wiederschain, D., S. Wee, L. Chen, A. Loo, G. Yang, A. Huang, Y. Chen, G. Caponigro, Y. M.
Yao, C. Lengauer, W. R. Sellers and J. D. Benson (2009). "Single-vector inducible lentiviral RNAi
system for oncology target validation." Cell Cycle 8(3): 498-504.
268. Wilhelm, B. G., S. Mandad, S. Truckenbrodt, K. Krohnert, C. Schafer, B. Rammner, S. J. Koo,
G. A. Classen, M. Krauss, V. Haucke, H. Urlaub and S. O. Rizzoli (2014). "Composition of isolated
synaptic boutons reveals the amounts of vesicle trafficking proteins." Science 344(6187): 1023-
1028.
269. Wirth, B., L. Garbes and M. Riessland (2013). "How genetic modifiers influence the phenotype
of spinal muscular atrophy and suggest future therapeutic approaches." Curr Opin Genet Dev 23(3):
330-338.
270. Wirth, B., N. Mendoza-Ferreira and L. Torres-Benito (2016). Spinal Muscular Atrophy Disease
Modifiers. Spinal Muscular Atrophy. C. J. Sumner, S. Paushkin and C. P. Ko, Academic Press.
134
271. Wishart, T. M., C. A. Mutsaers, M. Riessland, M. M. Reimer, G. Hunter, M. L. Hannam, S. L.
Eaton, H. R. Fuller, S. L. Roche, E. Somers, R. Morse, P. J. Young, D. J. Lamont, M.
Hammerschmidt, A. Joshi, P. Hohenstein, G. E. Morris, S. H. Parson, P. A. Skehel, T. Becker, I. M.
Robinson, C. G. Becker, B. Wirth and T. H. Gillingwater (2014). "Dysregulation of ubiquitin
homeostasis and beta-catenin signaling promote spinal muscular atrophy." J Clin Invest 124(4):
1821-1834.
272. Xu, W., S. Cohen-Woods, Q. Chen, A. Noor, J. Knight, G. Hosang, S. V. Parikh, V. De Luca,
F. Tozzi, P. Muglia, J. Forte, A. McQuillin, P. Hu, H. M. Gurling, J. L. Kennedy, P. McGuffin, A.
Farmer, J. Strauss and J. B. Vincent (2014). "Genome-wide association study of bipolar disorder in
Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1." BMC Med
Genet 15: 2.
273. Yamatani, H., T. Kawasaki, S. Mita, N. Inagaki and T. Hirata (2010). "Proteomics analysis of
the temporal changes in axonal proteins during maturation." Dev Neurobiol 70(7): 523-537.
274. Yang, X., S. Arber, C. William, L. Li, Y. Tanabe, T. M. Jessell, C. Birchmeier and S. J. Burden
(2001). "Patterning of muscle acetylcholine receptor gene expression in the absence of motor
innervation." Neuron 30(2): 399-410.
275. Yoshida, M., S. Kitaoka, N. Egawa, M. Yamane, R. Ikeda, K. Tsukita, N. Amano, A. Watanabe,
M. Morimoto, J. Takahashi, H. Hosoi, T. Nakahata, H. Inoue and M. K. Saito (2015). "Modeling the
early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived
iPSCs." Stem Cell Reports 4(4): 561-568.
276. Zerres, K., S. Rudnik-Schoneborn, R. Forkert and B. Wirth (1995). "Genetic basis of adult-
onset spinal muscular atrophy." Lancet 346(8983): 1162.
277. Zerres, K., B. Wirth and S. Rudnik-Schoneborn (1997). "Spinal muscular atrophy--clinical and
genetic correlations." Neuromuscul Disord 7(3): 202-207.
278. Zhang, Z., F. Lotti, K. Dittmar, I. Younis, L. Wan, M. Kasim and G. Dreyfuss (2008). "SMN
deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects
in splicing." Cell 133(4): 585-600.
279. Zhang, Z., A. M. Pinto, L. Wan, W. Wang, M. G. Berg, I. Oliva, L. N. Singh, C. Dengler, Z. Wei
and G. Dreyfuss (2013). "Dysregulation of synaptogenesis genes antecedes motor neuron
pathology in spinal muscular atrophy." Proc Natl Acad Sci U S A 110(48): 19348-19353.
280. Zhou, C., Z. Feng and C. P. Ko (2016). "Defects in Motoneuron-Astrocyte Interactions in Spinal
Muscular Atrophy." J Neurosci 36(8): 2543-2553.
281. Zhou, H., N. Janghra, C. Mitrpant, R. L. Dickinson, K. Anthony, L. Price, I. C. Eperon, S. D.
Wilton, J. Morgan and F. Muntoni (2013). "A novel morpholino oligomer targeting ISS-N1 improves
rescue of severe spinal muscular atrophy transgenic mice." Hum Gene Ther 24(3): 331-342.
282. Zong, Y., B. Zhang, S. Gu, K. Lee, J. Zhou, G. Yao, D. Figueiredo, K. Perry, L. Mei and R. Jin
(2012). "Structural basis of agrin-LRP4-MuSK signaling." Genes Dev 26(3): 247-258.
135Appendix
8 Appendix
The manuscript “Neurocalcin delta suppression rescues spinal muscular atrophy across
species”, under review in Nature Medicine (for reference purposes)
Neurocalcin delta suppression rescues spinal muscular atrophy across species
Markus Riessland,1,2,3,13,14 Anna Kaczmarek,1,2,3,13 Svenja Schneider,1,2,3,13 Kathryn J.
Swoboda,4 Heiko Löhr,5,7 Cathleen Bradler,6,7 Vanessa Grysko,1,2,3 Maria Dimitriadi,8,15
Seyyedmohsen Hosseinibarkooie,1,2,3 Laura Torres-Benito,1,2,3 Miriam Peters,1,2,3
Aaradhita Upadhyay,1,2,3 Nasim Biglari,1,2,3 Sandra Kröber,1,2,3 Irmgard Hölker,1,2,3 Lutz
Garbes,1,2,3 Christian Gilissen,9 Alexander Hoischen,9 Gudrun Nürnberg,7,10 Peter
Nürnberg,7,10 Michael Walter,11 Frank Rigo,12 C. Frank Bennett,12 Min Jeong Kye,1,2 Anne
C. Hart,8 Matthias Hammerschmidt,5,7 Peter Kloppenburg,6,7 and Brunhilde Wirth1,2,3,*
1Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany
2Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany
3Institute for Genetics, University of Cologne, 50674 Cologne, Germany
4MassGeneral Hospital for Children, Boston, MA 02115, USA
5Institute for Zoology - Developmental Biology, University of Cologne, 50674 Cologne,
Germany
6Institute for Zoology - Neurophysiology University of Cologne, 50674 Cologne, Germany
7Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
(CECAD), University of Cologne, 50931 Cologne, Germany
8Department of Neuroscience, Brown University, Providence, Rhode Island, USA
9Department of Human Genetics, Donders Centre for Neuroscience, Radboud University
Medical Center, 6525 Nijmegen, The Netherlands
10Center for Genomics Cologne, University of Cologne, 50931 Cologne, Germany
11Institute of Medical Genetics, University of Tübingen, 72076 Tübingen, Germany
12IONIS Pharmaceuticals, Carlsbad, California, CA 92008, USA
13These authors contributed equally to this work
Present address:
14Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New
York, NY 10065, USA
15Department of Biological and Environmental Sciences, University of Hertfordshire,
Hatfield, AL10 9AB, UK
*Correspondence: brunhilde.wirth@uk-koeln.de
136
ABSTRACT
Homozygous SMN1 gene loss causes spinal muscular atrophy (SMA), the most common
lethal genetic childhood motor neuron disease. SMA patients harbor low SMN expression
from SMN2 copy genes, insufficient to functionally compensate for SMN1 loss. Here, we
identify that the neuronal calcium sensor Neurocalcin delta (NCALD) functions as a
protective SMA modifier in humans and acts as a Ca2+-dependent negative regulator of
endocytosis. Indeed, SMN deficiency impairs endocytosis, which is restored by NCALD
depletion. NCALD depletion also restores pharmacologically induced endocytosis
impairment in zebrafish and effectively ameliorates SMA pathology in severe SMA models
of worm, zebrafish and mouse. Notably, a combinatorial treatment combining antisense
oligonucleotide-mediated SMN elevation and NCALD depletion improves survival rate and
motoric disabilities of severe SMA mice, resembling asymptomatic condition. Thus, our
study identifies a previously unknown protective mechanism against SMA and suggests a
potential therapeutic strategy that might efficiently treat SMA, regardless of severity.
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INTRODUCTION
Genetic modifiers can influence disease-causing mechanisms resulting in incomplete
penetrance(Wirth et al. 2013). Identification of such modifiers is of utmost relevance since
they can uncover novel regulatory networks and pathological mechanisms, and allow
identification of therapeutic pathways. For recessive disorders, the full protection through
modifiers is very rare, making their identification highly challenging.
Spinal muscular atrophy (SMA), a motor neuron disease, is one of the most common and
devastating autosomal recessive disorders, for which no treatment is available yet.
However, various clinical trials using antisense oligonucleotides (ASOs), small molecules
or gene therapy show highly promising ameliorations (Kaczmarek et al. 2015). Most SMA
patients show homozygous absence of exon 7 of the survival motor neuron 1 (SMN1) gene
(Lefebvre et al. 1995), allowing an easy and efficient genetic testing. SMN is an
housekeeping protein involved in snRNP biogenesis (Fischer et al. 1997); full absence
causes embryonic lethality (Hsieh-Li et al. 2000). Only humans have an almost identical
gene copy, SMN2, which, however, produces only 10% correctly spliced full-length
transcript and protein, due to a single silent mutation affecting an exonic splicing enhancer
(Lorson et al. 1999). In SMA patients, SMN2 is the only source of SMN, thus its copy
number (between 1-6) determines SMA severity (Feldkotter et al. 2002). In SMA-I, the
severe and most common form (60%), the majority of patients carry two SMN2 copies and
die within the first two years of life. Most SMA-II patients carry three SMN2 copies and are
never able to walk. In SMA-III, the mild form, most patients carry four SMN2 copies, are
able to walk, but often become wheel-chair bound (Lunn and Wang 2008). Reduced SMN
levels cause spinal motor neuron (MN) dysfunction in all types of SMA (Lunn and Wang
2008). In SMA mouse models impaired maturation and maintenance of neuromuscular
junctions (NMJs) and decreased proprioceptive inputs on MN soma are hallmarks of SMA
(Kariya et al. 2008, Mentis et al. 2011). Additionally, non- neuronal cells and tissues can
also be affected in the severe form (Hamilton and Gillingwater 2013).
Rare SMA-discordant families exist, in which relatives of SMA patients carry a
homozygous SMN1-deletion together with three or four SMN2 copies, but are clinically
asymptomatic (Cobben et al. 1995, Hahnen et al. 1995, Wang et al. 1996, Prior et al.
2004). In seven of these families, we identified the Ca2+-dependent protein Plastin 3
(PLS3) as a protective modifier (Oprea et al. 2008, Heesen et al. 2016). PLS3
overexpression (OE) rescues SMA across species and is specifically upregulated in MNs
of asymptomatic individuals (Oprea et al. 2008, Dimitriadi et al. 2010, Lotti et al. 2012,
Ackermann et al. 2013, Hosseinibarkooie et al. 2016)
Here, we identified Neurocalcin delta (NCALD), a neuronal Ca2+ sensor protein, as a SMA
protective modifier in humans. Based on the function and interacting partners of both SMA
modifiers (PLS3 (Hosseinibarkooie et al. 2016) and NCALD), we identified endocytosis as
a main impaired cellular mechanism in SMA. NCALD acts as a negative regulator of
endocytosis. We demonstrate that NCALD knockdown (KD) in various SMA animal models
rescues the major functional SMA disturbances. Most importantly, a combined therapy
using a low suboptimal SMN-ASO dose and NCALD KD rescues severe SMA in mice,
defining a novel powerful strategy to efficiently treat patients with SMA.
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RESULTS
Identification of NCALD as a potential SMA modifier
In a four-generation Mormon family from Utah, we identified seven individuals carrying
homozygous SMN1 deletions, two affected by SMA-I and five fully asymptomatic, except
an increased photosensitivity (Fig. 1a) (Online Methods for clinical pictures).
Haplotype analysis of SMA regions showed a co-segregation of three different SMA alleles
(Fig. 1a). The two SMA-I patients carried no SMN1 and two SMN2 copies. By contrast, all
five asymptomatic individuals showed homozygous absence of SMN1 and four SMN2
copies, resembling a genotype associated with SMA-III (Feldkotter et al. 2002) (Fig. 1a).
SMN2 sequencing excluded any further variant affecting expression. In lymphoblastoid
cells (LBs), SMN RNA and protein levels were similar to those in typical SMA-III patients,
thus excluding cis and trans-acting factors regulating SMN2. Increased PLS3 levels were
not found (Fig. 1a, GEO: GSE58316). Thus, we conclude that a previously unknown SMA
modifier potentially protects these individuals.
To identify the SMA modifier, we combined linkage with transcriptome-wide differential
expression analysis followed by targeted resequencing. Assuming a dominant mode of
inheritance, a parametric linkage analysis with 14 family members revealed eight positive
peaks with a maximum LOD score of 1.5 (Fig. 1b). In parallel, a transcriptome-wide
differential expression analysis with 12 RNA samples was performed (GEO: GSE58316)
and revealed 17 transcripts significantly differentially regulated in asymptomatic
individuals (Supplementary Table 1). Most importantly, NCALD was the only transcript
localized in one of the eight linked regions on chromosome 8q22.3 (between rs28144 and
rs958381), making it a highly likely candidate. Microarray data were confirmed by RT-
qPCR and Western blot (Fig. 1c,d).
Targeted resequencing of ~3 Mb genomic DNA encompassing NCALD in five family
members and detailed genetic analysis (Supplementary Table 2) revealed various
polymorphisms in NCALD non-coding sequence; these may impact NCALD expression in
protected individuals.
NCALD is a highly conserved neuronal calcium sensor (NCS), primarily involved in
neuronal Ca2+ signaling (Burgoyne and Haynes 2012, Di Sole et al. 2012). NCALD
encodes a small protein containing two pairs of EF-hand domains and an N-terminal
myristoyl anchor that enables a switching from cytosolic to membrane-bound forms in a
Ca2+-dependent manner (Hidaka and Okazaki 1993, Ladant 1995). Both myristoylated and
non-myristoylated forms show Ca2+-dependent mobility shifts (Viviano et al. 2016). NCALD
is highly expressed in cerebral neurons, spinal MNs, and in axonal growth cones (Iino et
al. 1998). NCALD overexpression inhibits neurite outgrowth (Yamatani et al. 2010).
NCALD is important in phototransduction (Venkataraman et al. 2008), which may explain
photosensitivity in asymptomatic individuals. Importantly, NCALD interacts with clathrin
and actin, both of which are involved in endocytosis and synaptic vesicle recycling (Ivings
et al. 2002, Haucke et al. 2011).
NCALD knockdown triggers MN differentiation and restores neurite and axonal
growth in SMA
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First, we analyzed NCALD expression levels during MN differentiation and maturation in
NSC34 cells treated with retinoic acid (RA) (Cashman et al. 1992) and we observed a
steady increase in NCALD amount over time under RA treatment (Fig. 2a). siRNA-
mediated Ncald reduction induced MN differentiation (indicated by HB9-positive staining)
and triggered neurite outgrowth even without RA (Fig. 2b). In contrast, NCALD
overexpression in RA-treated NSC34 cells impaired neurite outgrowth (Supplementary
Fig. 2b,c).
NCALD is highly abundant in axonal growth cones of spinal MNs(Iino et al. 1998). In
addition, we show that it localizes at the presynaptic terminals of NMJs, suggesting a
potential role at the NMJ (Fig. 2c,d).
We found that Ncald KD in Smn deficient NSC34 cells restored impaired neurite outgrowth
to controls levels (Supplementary Fig. 2a). Similar results were obtained in cultured
primary MNs from SMA (Smnko/ko;SMN2tg/0) versus heterozygous (Smnko/wt;SMN2tg/0)
embryos, where reduced axon length was fully restored by siRNA-mediated Ncald KD
(Fig. 2e). These findings indicate that reduced NCALD levels counteract the impaired
axonal development of SMN-deficient MNs.
ncald knockdown restores axonal growth and NMJ functionality in zebrafish smn
morphants
We investigated the modifying effect of ncald in vivo in zebrafish(Flanagan-Steet et al.
2005) by morpholino (MO)-mediated KD of either smn, ncald or both. Consistent with
previous results, smn depletion resulted in motor axon–specific outgrowth defects such as
truncations and ectopic branches (McWhorter et al. 2003, Oprea et al. 2008) (Fig. 3a). KD
of ncald led to enhanced motor axons branching, whereas double smn+ncald KD fully
rescued the truncated motor axon defect associated with Smn deficiency (Fig.
3a,c;Supplementary 3a). KD efficiency was confirmed by Western blot (Fig. 3b). We also
found that OE of human NCALD mRNA in zebrafish caused truncation and branching of
motor axons (Supplementary Fig. 3b), resembling the phenotype of smn morphant
zebrafish (Fig. 3a) similar to NSC34 cells (Supplementary Fig. 2c).
During NMJ maturation the width of the synaptic cleft, which is essential in
neurotransmission (Drapeau et al. 2001) increases. Ultrastructural analysis of synaptic
clefts revealed an impaired NMJ maturation in smn morphants (Fig. 3d,e). The synaptic
cleft of smn morphants was significantly smaller than in controls or ncald morphants, but
fully restored to control level in double smn+ncald KD embryos (Fig. 3d,e).
To test the functionality of neuromuscular synapses between caudal primary MNs and
ventral fast muscle cells (Westerfield et al. 1986), we performed whole-cell patch clamp
recordings from muscle cells during MN stimulation in morphants. We recorded
spontaneous endplate potentials at rest (without stimulation) and during MN stimulation by
NMDA (Supplementary Fig. 3c). In controls, we recorded at rest small endplate potentials
that were primarily not tetrodotoxin (TTX) sensitive (Supplementary Fig. 3d,e). Most
resembled miniature endplate potentials (mEPPs) (Fatt and Katz 1951). During NMDA
stimulation, the mEPP frequency did not significantly increase, but large TTX-sensitive
endplate potentials and muscle action potentials were induced by MN spike evoked
transmission. In smn morphants, a significantly lower spontaneous mEPP frequency and
only occasional action potentials during NMDA stimulation were observed (Fig. 3f). In the
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smn+ncald morphants, the spontaneous mEPP frequency was slightly increased and the
frequency of large NMDA-induced EPP was restored to control levels (Fig. 3f,g). In line
with these data, induced swimming velocity was reduced in smn morphants, but rescued
in smn+ncald morphants (Supplementary Fig. 3f). Together, these results show that
Ncald KD rescues neural circuit function at NMJs of smn morphants.
NCALD loss suppresses defects of C. elegans SMN loss of function animals
C. elegans lacking the SMN ortholog smn-1, referred to here as Cesmn-1, have
neuromuscular defects, including decreased pharyngeal pumping rate (Fig. 3h) (Briese et
al. 2009, Dimitriadi et al. 2010). The C. elegans ortholog of NCALD is encoded by neuronal
calcium sensor-1 (ncs-1) (Gomez et al. 2001). Either ncs-1 KD by RNA interference or
introduction of the ncs-1(qa401) loss of function allele in Cesmn-1 animals, significantly
ameliorated pumping defects (Fig. 3i,j), confirming that NCALD loss ameliorates the SMN
loss-of-function-induced neuromuscular defects across species.
Heterozygous Ncald KO ameliorates motor neuron development in severe SMA
mice
Heterozygous Ncaldko/wt mice are asymptomatic and show >50% reduction of NCALD
expression in spinal cord and brain (Fig. 4a). Homozygous Ncaldko/ko mice are fertile;
however, preliminary reported data (www.mousephenotype.org) and our data show
behavioral abnormalities, vision defects and metabolic impairment. Since asymptomatic
individuals have reduced NCALD levels, we used the heterozygous Ncaldko/wt animals for
experiments herein.
The Ncaldko/wt allele was bred into a severe SMA mouse model (Hsieh-Li et al. 2000) on a
C57BL/6N background. Severe SMA mice show multi-organ failure (Riessland et al. 2010,
Ackermann et al. 2013, Somers et al. 2013) due to very low SMN expression, which could
not be rescued by Ncald KD alone. Both SMA and SMA-Ncaldko/wt mice die at a mean age
of 13 days (Supplementary Fig. 4a). Nonetheless, we found larger NMJs in the
Transversus abdominis muscle (TVA) and elevated proprioceptive inputs on MN soma in
SMA-Ncaldko/wt versus SMA mice (P10) (Fig. 4b,c). Moreover, SMA-Ncaldko/wt mice show
more inputs per MN than SMA mice independent of cell size (Supplementary Fig. 4c). A
comparison of axonal development in cultured primary MNs revealed a large impact of
Ncald reduction on axonal growth and arborization (Fig. 4d), confirming our initial results
with NCALD knockdown (Fig. 2e). Therefore, NCALD reduction counteracts impaired
axonal development and restores NMJ size in SMN-deficient mice.
Combinatorial therapy with a suboptimal low-dose SMN-ASO and reduced Ncald
expression rescues SMA pathogenesis in a severe SMA mouse model
In our study, we combined suboptimal low-dose SMN-ASOs with heterozygous Ncald KD
mice: for three reasons: firstly, asymptomatic individuals carry four SMN2 copies similar
to typical SMA-III patients, but not two SMN2 copies as most SMA-I patients or severe
SMA mice. Secondly, SMA-I patients, currently treated with SMN-ASOs, show only a
moderate SMN elevation and thirdly, genetic modifiers efficiently protect against SMA only
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if a certain SMN level is present (Hosseinibarkooie et al. 2016). Since presymptomatic
subcutaneous (s.c.) injection of high dose SMN-ASO in severely-affected SMA mice fully
rescues SMA (Hua et al. 2011), we opted for a suboptimal dose to ameliorate SMA. We
crossed C57BL/6N Ncaldko/wt;Smnko/wt males with FVB/N Smnko/ko;SMNtg/tg females to
produce 50% C57BL/6N:50% FVB/N (mixed50) offspring (Fig. 5a). Untreated mixed50 SMA
and SMA-Ncaldko/wt mice live 16.5 and 17.0 days, respectively (Fig. 5b). Mixed50 offspring
were injected s.c. with a single suboptimal dose of SMN-ASO at P1. Elevated SMN levels
were obtained in liver, but not in spinal cord or brain (Supplementary Fig. 5a). Survival of
SMA+ASO mice was rescued (Fig. 5b), but their motoric abilities were visibly impaired as
determined by righting reflex and grip strength test (Fig. 5c,d). This suggests that slightly
elevated SMN expression achieved by systemic ASO-treatment rescued non-neuronal
multi-organ impairment (Hosseinibarkooie et al. 2016), but not MN function. In contrast,
Ncald KD in addition to low dose SMN-ASO treatment significantly improved also motoric
abilities (Fig. 5c,d). Analysis of NMJs maturation score at P21 (Bogdanik et al. 2015),
showed that both NMJ size and maturation were markedly restored by Ncald KD as
compared to SMA+ASO mice (Fig. 5e). Ncald KD did not rescue tail necrosis and
impacted slightly weight progression in male mice (Supplementary Fig. 5b-d). Our data
provide clear evidence of the beneficial effect of reduced NCALD on the neuromuscular
system and motoric function in SMA+ASO mice.
Low SMN decreases Ca2+ influx in NSC34 and PC12 cells
Since impaired Ca2+ homeostasis has been reported in SMA(Ruiz et al. 2010), we tested
if lowering SMN levels can modulate voltage-dependent Ca2+ currents (ICa) in MN-like cells.
We performed whole-cell patch-clamp recordings and ratiometric Ca2+ imaging with fura-
2. We recorded ICa of RA-differentiated NSC34 cells that were treated with siRNAs specific
to Smn, Ncald, or Smn+Ncald and analyzed the ICa tail currents with a series of increasing
voltage pulses. In NSC34 cells, Smn depletion significantly reduced the voltage-dependent
Ca2+ influx, which was not restored by additional Ncald reduction (Fig. 6a). Ratiometric
Ca2+ imaging with fura-2 revealed a reduced voltage-dependent Ca2+ influx in SMN-
depleted PC12 cells compared to controls (Supplementary Fig. 6a). These data show
that low SMN levels impair Ca2+ influx, which is not restored by NCALD KD and that
NCALD depletion rescues synaptic transmission by a different mechanism.
Disturbed endocytosis and synaptic vesicle recycling is rescued by NCALD
depletion
We next sought for a common pathway in which both SMA modifiers, NCALD and PLS3,
might operate. Since NCALD binds clathrin(Ivings et al. 2002) directly and PLS3 knockout
in yeast impairs endocytosis (Kubler and Riezman 1993, Ivings et al. 2002), we
hypothesized that low SMN levels may impair endocytosis, which in turn is rescued by
NCALD KD or PLS3 OE. Indeed, we recently identified impaired endocytosis as a
disturbed cellular mechanism affected in SMA, which is rescued by PLS3 OE
(Hosseinibarkooie et al. 2016). Impaired endocytosis and endocytic trafficking have also
been demonstrated in a C. elegans SMA model (Dimitriadi et al. 2016).
Co-immunoprecipitation studies in NSC34 revealed NCALD interaction with clathrin only
in the absence of Ca2+ (Fig. 6b) or at low Ca2+ levels (data not shown). TEM analyses after
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immunogold staining of wt zebrafish sections showed co-localization of Ncald and clathrin
in the presynaptic sites of NMJs (Supplementary Fig. 6b).
To study the effect of NCALD on endocytosis, we applied FITC-dextran internalization
assays in various cell culture systems. In primary fibroblast cell lines derived from SMA
patients, endocytosis rates were strongly reduced compared to controls but restored in
fibroblasts of asymptomatic individuals (Fig. 6c; Supplementary 6c). Moreover, Smn KD
in NSC34 cells significantly reduced FITC-dextran uptake, which was rescued by
concomitant Ncald KD. Ncald KD alone increased the rate of endocytosis by 1.3-fold,
demonstrating that low NCALD levels already facilitate endocytosis (Supplementary Fig.
6f).
Moreover, we analyzed endocytic uptake of FM1-43 in mouse NMJs under stimulation at
5 and 20 Hz as described (Hosseinibarkooie et al. 2016). FM1-43 uptake was markedly
decreased in SMA mice at 5 Hz stimulation (triggering clathrin-dependent endocytosis),
but Ncald reduction fully restored the levels similar to heterozygous mice (Fig. 6d;
Supplementary Fig. 6d). Ncald reduction had no impact at 20 Hz stimulation (triggering
bulk endocytosis), further strengthening the role of NCALD in clathrin-dependent
endocytosis in NMJs (Supplementary Fig. 6e).
Lastly, we investigated in vivo whether endocytosis and the Smn-Ncald-clathrin network is
relevant for SMA using pharmacological inhibition of endocytosis in zebrafish. Using sub-
phenotypical concentrations of smn MO in combination with Pitstop2, an inhibitor of
clathrin (von Kleist et al. 2011), resulted in  more truncated motor axons than in smn MO
alone (Fig. 6e) and a phenotype similar to severe smn KD (4 ng) (Fig. 3a,c). Moreover,
treatment with Dynasore, an inhibitor of the endocytosis-driving GTPase dynamin(Macia
et al. 2006), either alone or in combination with low smn MO resulted in an SMA-like axonal
truncation (Fig. 6e). These defects were rescued by additional treatment with ncald MO
(Fig. 6e; Supplementary 6g). Together, these findings suggest that SMN and clathrin
interact genetically to promote endocytosis and MN axogenesis, whereas NCALD
negatively interferes with an SMN-dependent function of clathrin.
DISCUSSION
Here, we describe NCALD as a novel genetic SMA modifier in humans. Reduced NCALD
expression fully protects individuals from developing SMA, despite lacking SMN1 and
carrying only four SMN2 copies, usually causing SMA-III (Feldkotter et al. 2002). NCALD
reduction acts as genetic suppressor of SMA. We analyzed the impact of NCALD KD on
SMA models across species and found that it ameliorates SMA pathology, counteracting
the disruptive impact of SMN loss on a conserved cellular mechanism in MNs and NMJs.
Clinical trials using ASOs correcting SMN2 splicing are highly promising and close to FDA-
approval (Kaczmarek et al. 2015). However, for SMA-I children, with only two SMN2
copies, these approaches are likely insufficient to fully counteract SMA symptoms. A
combinatorial therapy, elevating SMN and decreasing NCALD (e.g. by ASO treatment),
might bring additional benefit to SMA patients and likely provide a full protection as in
asymptomatic individuals.
In SMA, impaired neurotransmission, disturbed Ca2+ homeostasis, decreased synaptic
vesicle number and reduced F-actin caging of reserve pool synaptic vesicles have been
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reported (Kariya et al. 2008, Murray et al. 2008, Kong et al. 2009, Ruiz et al. 2010). For
repeated neurotransmitter release, subsequent endocytosis is important (Stevens 2003);
furthermore, endo- and exocytosis are regulated by the Ca2+ dynamics within the
presynaptic terminals (Sudhof 2012).
We found that low SMN levels cause reduction of voltage activated Ca2+ influx, in
accordance with recent studies in a zebrafish SMA model and mislocalization of calcium
channels in SMA (Jablonka et al. 2007, See et al. 2014). However, unlike SMA pathology,
Ca2+ influx was not restored by reduced NCALD, suggesting a different counteraction.
Since NCALD binds clathrin and actin, two major players in endocytosis (Ivings et al. 2002,
Haucke et al. 2011), we propose that reduced SMN may disturb endocytosis, possibly due
to decreased Ca2+, whereas NCALD KD subsequently compensates for SMN loss. We
demonstrate in vitro and in ex vivo mouse NMJs that NCALD KD restores impaired
clathrin-dependent endocytosis. Furthermore, chemical endocytosis-inhibition in zebrafish
caused MN axogenesis defects that were reversed upon Ncald suppression. Importantly,
NCALD binds clathrin only at low Ca2+ levels (mimicking unstimulated MNs) but not at high
Ca2+ levels mimicking action potentials in MNs). For SMA MNs, with low Ca2+ levels even
during action potential, we predict that NCALD constantly binds clathrin, thereby inhibiting
its function in recycling. However, low NCALD levels, as in asymptomatic individuals, may
allow free clathrin to act in endocytosis even at reduced Ca2+ levels (Fig. 6f).
Moreover, reduced NCALD amount might be beneficial for other MN or neurodegenerative
disorders with impaired endocytosis and Ca2+-homeostasis, as was shown for
Alzheimer´s, where NCALD is highly upregulated (Suszynska-Zajczyk et al. 2014) or
Parkinson´s, hereditary spastic paraplegia and ALS where impaired endocytic trafficking
was found (Schreij et al. 2016). Therefore, NCALD downregulation might become an
efficient strategy against SMA and other neurodegenerative diseases.
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METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Gene Expression Omnibus: all microarray data are available in GSE58316.
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FIG. LEGENDS
Fig. 1 Genome-wide linkage and transcriptome analysis uncovered NCALD as candidate
modifier of SMA. (a) Pedigree of the Utah family: haplotype analysis of microsatellite
markers in the 5q13 SMA region and SMN1 and SMN2 copies are indicated. Black filled
symbols: SMA-affected individuals, grey filled symbols: asymptomatic SMN1-deleted
individuals and symbols with a dot: SMA carriers. (b) Genome-wide linkage analysis
identified eight regions with positive LOD scores. Black arrow marks 8q22.3 region
containing NCALD. (c) Verification of microarray results (Table S1) of NCALD RNA and
protein in lymphoblastoid (LB) cells. NCALD is represented by two independent probes,
showing a 4-to-5 fold downregulation in the asymptomatic group versus familial SMA-I or
an independent SMA-III group. Three independent experiments including all 17 cell lines
(asymptomatic, N = 5; symptomatic, N = 2; independent SMA-III, N = 10) were performed.
* P ≤ 0.05. (d) Expression analysis of NCALD RNA and proteins in fibroblasts (FB) derived
from the Utah family (asymptomatic, N = 5; symptomatic, N = 2). Three independent
experiments including all seven cell lines were performed. ** P ≤ 0.01; *** P ≤ 0.001. See
also Supplementary Fig. 1 and Table 1.
Fig. 2 NCALD downregulation restores neurite outgrowth defect in SMN-deficient neuronal
cells. (a) Western blot of NSC34 cells treated with 1µM retinoic acid (RA) for 0-120h as a
model of MN differentiation and maturation (n = 3 biological replicates). (b) Ncald siRNA-
treated NSC34 cells show signs of MN differentiation (HB9-positive staining, marked with
white arrows) even in absence of RA (right panel). As positive control, cells were
differentiated with RA and treated with control siRNA (middle panel). Negative control was
treated only with control siRNA (left panel). Scale bar, 100 µm. (c) Representative images
of primary murine MNs cultured 6 days in vitro (DIV) stained with antibodies against
NCALD, tau and CHAT. Note the high expression of NCALD in soma and growth cones
(inset). Scale bar, 50 µm. (d) Exemplary NCALD staining of NMJ in TVA of 3-week-old wt
mice. Postsynaptic terminals stained with Bungarotoxin (magenta) and presynaptic
terminals with SV2 (red, delineated by the dashed line). NCALD (green) localizes to
presynaptic region, based on overlap between SV2 and NCALD, by Pearson`s correlation
of 0.72 ± 0.082 (Z stack, 0.5 µm per stack; n = 4). Scale bar, 5 µm. (e) Primary MNs from
SMA or heterozygous murine embryos were fixed at 8 DIV and stained with anti-
neurofilament. Quantitative analysis of axon length of MNs. SMA: N = 7, control
heterozygotes (HET): N = 6, n = 100 per measurement; *** P ≤0.001; dashed line = mean;
straight line = median. Scale bar, 100 µm. See also Supplementary Fig. 2.
Fig. 3 Ncald reduction corrects the phenotype in Smn-deficient zebrafish and C. elegans.
(a) First 10 motor axons posterior to the yolk globule of 34 hpf zebrafish embryos injected
with respective morpholinos (MO). White arrows mark truncated motor axons. Arrowheads
mark extensive branching in ncald or smn+ncald morphants; green = Znp1 staining. Scale
bar, 100 µm. (b) Western blot of lysates of zebrafish embryos injected with indicated MO.
(c) Quantification of motor axon phenotype. Dashed lines mark the rescue of the truncation
phenotype (**P≤ 0.01). smn+ncald and ncald morphants showed increased branching. n
>500 motor axons per MO injection. (d) TEM images of NMJs of 48 hpf zebrafish embryos
injected with respective MO. White arrows mark synaptic clefts including basal lamina. M
= muscle fiber, T = nerve terminal. Scale bar, 100 nm. (e) Quantification of synaptic cleft
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width of MO-injected 48 hpf fish (n = 15 per treatment). **P ≤0.01, dashed line=mean;
straight line=median.  (f) Whole-cell current clamp recordings EPPs and (g) quantification
of mean EPP frequencies in ventral fast muscle cells of control (n = 12), smn (n = 10),
ncald (n = 11) and smn+ncald (n = 12) morphants under control conditions or NMDA
induction. White bar parts reflect the mEPP frequencies, grey bar parts reflect the
frequency of the TTX-sensitive large EPPs. **P ≤0.01; ***P ≤0.001. (h) C. elegans
neuromuscular function was assessed based on pharyngeal pumping rates during feeding.
Arrow indicates the pharyngeal grinder, which moves during each pumping event. (i, j)
Quantification of pharyngeal pumping in wt or mutant smn-1 worms fed with control or ncs-
1 RNAi KD (i) or with an ncs-1(qa401) mutant allele (j). For every determination n ≥25.
Mean ± SEM is shown; * P ≤ 0.05, ** P ≤ 0.01. See also Supplementary Fig. 3.
Fig. 4 Heterozygous Ncald KO improves axonal outgrowth, proprioceptive input and NMJ
size in severe SMA mice. (a) Western blot and quantification of NCALD and ACTB (loading
control) in spinal cord and hippocampus of P10-old wt and Ncaldko/wt mice. *P ≤ 0.05. (b)
Representative images and quantification of NMJ area [µm2] in TVA muscle from P10-old
mice stained with antibodies against NF and SV2 (green) and Bungarotoxin (magenta).
NMJ area was analyzed with ImageJ software (n = 3, 100-120 NMJs/mouse). ***P ≤ 0.001.
Scale bar, 10 µm. (c) Representative images and quantification of proprioceptive inputs
(VGLUT1, green) on MN soma (CHAT, magenta) in lumbar spinal cord sections from P10-
old mice. Mean input number within 5 µm of MN soma was analyzed (n = 3, 100-120
MNs/mouse). ***P ≤ 0.001. Scale bar, 25 µm. (d) Representative merged images of 6 DIV
MNs isolated from E13.5 embryos and stained with DAPI (blue) and antibodies against
HB9 (green) and Tau (red). The longest axon and axonal branches were quantified with
ImageJ (n = 3-5, 20-40 axons per mouse). Scale bar, 25 µm. Each box plot covers values
from 25-75% with line at median and dotted outliers at <5% and >95% CI. For each
experiment, image analysis was double-blinded. n.s. not significant; *P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001. See also Supplementary Fig. 4.
Fig. 5 NCALD reduction improves motoric function, NMJ size, and NMJ architecture in
SMA+ASO mice. (a) Breeding scheme to produce mixed50 SMA and HET mice. All mixed50
offspring were injected with 30 µg SMN-ASO at P1. (b) Kaplan-Meier curves of uninjected
mixed50 mice show no differences in survival between SMA (17 days, n = 7) and SMA-
Ncaldko/wt (16.5 days, n = 12). Injection of 30 µg SMN-ASO on P1 increases survival to
>180 days for both SMA+ASO (n = 10) and SMA-Ncaldko/wt+ASO (n = 12) mice. (c)
Righting reflex test shows improvement in SMA-Ncaldko/wt+ASO, but not SMA+ASO mice
during P2-P6 (n ≥12 per genotype). Error bars represent SEM. n.s. not significant, **P ≤
0.01, ***P ≤ 0.001. (d) Grip strength test performance at P73 reveals enhanced strength
for SMA-Ncaldko/wt+ASO mice compared to SMA+ASO mice (n ≥12 per genotype).  Error
bars indicate SEM.  *P ≤0.05, **P ≤ 0.01, ***P ≤ 0.001. (e) Representative images of NMJs
of ASO-treated mixed50 mice at P21 stained with the antibody against NF (green, for
presynaptic terminal) and Bungarotoxin (magenta, for postsynaptic terminal). Scale bar,
20µm. Box plot shows quantification of NMJ area in µm2 in TVA muscle which was
analyzed and represented as in Fig. 4 (b). Bar graph shows percentage of immature NMJs
in TVA muscle (mean ± SD). N = 3 mice per genotype; n = 60-100 NMJs per mouse. n.s.
not significant, *P ≤0.05, **P ≤0.01, ***P ≤ 0.001. See also Supplementary Fig. 5.
157Appendix
Fig. 6 Interconnection between SMN, NCALD, voltage-dependent Ca2+ influx, endocytosis
and SMA. (a) Measurement of I-V relations of Ca2+ tail currents in differentiated NSC34
cells treated with respective siRNAs and depolarized for 5 ms to 60 mV, in 5 mV
increments, at holding potential -80 mV. Currents were not different between wildtype (n
= 7), control siRNA (n = 33) and Ncald KD (n = 13) and were significantly reduced upon
Smn KD (n = 15) and Smn+Ncald KD (n = 12) at current pulses above -35 mV. *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001. (b) Western blot of co-immunoprecipitation experiment. NCALD
interacts with clathrin in the absence of Ca2+ (EGTA addition) but not in presence of Ca2+.
Interaction between NCALD and SMN was not observed. (c) Quantification of endocytosis
by FITC-dextran uptake in fibroblasts from SMA (N = 10), controls (N = 3) and
asymptomatic individuals (N = 5); n = 50 per cell line and time point. Mean ±SD.*P≤ 0.05,
**P ≤ 0.01. (d) Quantification of FM1-43 intensity at presynaptic terminals in TVA muscles
under low frequency stimulation (5 Hz, 1s). N = 3 per genotype, n ≈100 per mouse. Mean
±SEM. n.s. not significant; ***P ≤ 0.001. (e) Quantification of MN axon phenotype of
zebrafish embryos treated with sub-phenotypical doses of smn MO (2 ng), ncald MO (2
ng) and the endocytosis inhibitors Pitstop2 and Dynasore, respectively. Dashed lines
highlight the synergistic effect of smn MO and Pitstop2 and the effect of Dynasore on axon
truncation. Additional ncald MO injection ameliorates the truncation defect. ***P ≤ 0.001.
Motor axons per treatment: Pitstop2: n ≥100, Dynasore: n ≥150. (f) Proposed mode of
action of NCALD in synaptic vesicle recycling in normal, SMA, and asymptomatic
presynaptic terminals. See also Supplementary Fig. 6.
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ONLINE MATERIAL
Patient DNA, fibroblast cell lines and lymphoblastoid cell lines. Informed written
consent was obtained from each subject or their legal guardians for all biological samples
according to the Declaration of Helsinki. The study has been approved by the Ethical
Committee of University of Cologne (04-138). Human fibroblast and EBV-transformed
lymphoblastoid cell lines (LCL) from SMA patients, carriers and asymptomatic individuals
used in this work are listed in Supplementary Table 3. DNA was extracted from EDTA
blood samples, primary fibroblast cell lines and LCL using standard protocols. SMN1 and
SMN2 copy number were determined by qRT-PCR or MLPA analysis (MRC Holland) as
described (Arkblad et al. 2009). For haplotype analysis, polymorphic markers Ag1-CA
(D5S1556), C212 (D5F149S1/S2), VS19A (D5S435) and MIT-I105 (D5S351) were
analyzed as described (Zerres et al. 1997). SMN2 coding region was sequenced in qRT-
PCR products obtained from LCL-isolated RNA as described (Sun et al. 2005). PLS3 RNA
expression was analyzed as described (Oprea et al. 2008). All cell lines used were tested
for mycoplasma contamination.
Genome-wide linkage analysis. Genome-wide scan was performed in 14 individuals of
the Utah family using Affymetrix GeneChip Human Mapping 10K Array 2.0, which
comprises total 10,024 SNPs with a mean intermarker distance of 258kb, equivalent to
0.36cM (Affymetrix). Parametric linkage analysis was performed by ALLEGRO program
assuming autosomal dominant inheritance with full penetrance and 0.0001 disease allele
frequency. Haplotypes were reconstructed with ALLEGRO and presented graphically with
HaploPainter. All data handling was performed with ALOHOMORA user interface.
Transcriptome analysis. For expression profiling, 400ng total RNA were amplified and
biotinylated using Illumina® TotalPrepTMRNA Amplification Kits (Ambion) according to
manufacturer’s protocol. Human HT-12v3 bead arrays (Illumina) were hybridized with
750ng cRNA for 18h at 58°C according to Illumina® Whole-Genome Gene Expression
with IntelliHyb SealSystem Manual. Arrays were washed with E1BC buffer, High-Temp
Wash Buffer and 100% ethanol, stained with streptavidine-Cy3 and washed with E1BC
buffer. Fluorescence intensities were recorded on BeadArray Reader GX (Illumina).
Average signal intensities without background correction (Dunning et al. 2008) were
performed with BeadStudio3.1 (Illumina). All data analysis steps were performed in the
statistical environment R (version 2.10-0; www.r-project.org) with several bioconductor
packages (version 2.6.1; www.bioconductor.org). Signal intensities were normalized with
VSN and non-informative probes were removed based on p-values. Signals were
averaged for individual subgroups and a linear model was designed capturing the
influence of the patient group on gene expression levels (Wettenhall and Smyth 2004).
Differences between subgroups were extracted as contrasts and analyzed with the
moderated F-test (empirical Bayes method) including a correction step for multiple testing
with 5%-FDR-based method (Benjamini and Hochberg 1995). To attribute significant
regulations to individual contrasts, a decision matrix was generated based on the function
“decide tests” within the “limma” package, where significant up- or downregulations are
represented by values of 1 or -1, respectively.
Targeted resequencing. To identify a potential variant regulating differential NCALD
expression, complete NCALD locus ±1Mb (chr8:101,505,353-104,404,346) was deep-
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sequenced from gDNA of family members 9129, 9124, 9128, 9119, 9165 at Radboud
University Medical Center Nijmegen using a 5500xl sequencing instrument (Life
Technologies). ~3Mb genomic DNA from chromosome 8 were captured using a 385K
NimbleGen SequenceCapture Array (Roche).
On average, we obtained 2.7Gb of mappable sequence data/individual. Reads were
mapped to the hg19 reference genome with LifeTechnologies BioScope software 1.3. On
average, 94% of bases originated from the target region (mean 544-fold coverage). 99.8%
of the targeted region was covered ≥20 times. Single-nucleotide variants were
subsequently high-stringency called by the DiBayes algorithm. Small insertions and
deletions were detected using the Small IndelTool. Variants were annotated using an in-
house analysis pipeline.
On average 2,723 variants were called per sample. Based on previous haplotype data, we
filtered for heterozygous variants shared between individuals 9129, 9124, 9128, 9119 but
absent in 9165. This yielded 43 variants (21 previously annotated SNPs), none of which
were in NCALD coding region. Only the SNP rs147264092 in intron1 with a minor allele
frequency=0.1079 (1000Genome database) was located in NCALD UTR (Supplementary
Table 2). Subsequent Sanger sequencing of potential variants in 50 unrelated SMA
patients identified several symptomatic individuals carrying the same alleles, thus refuting
a protective role of the respective variant (Supplementary Fig. 1). ~600kb upstream of
NCALD we identified a 17bp deletion (nt103783522-38, rs150254064; MAF=0.056 in
1000Genome database) linked to the modifier haplotype, adjacent to an H3K27AC block
(http://genome.ucsc.edu/ENCODE). Sanger sequencing of this variant in the family
showed co-segregation with the modifier haplotype. As the 17bp deletion was present in
8/50 independent SMA patients, we excluded it as a sole cause.
Microscopy. Unless indicated otherwise, all microscopic experiments were performed
with a fully motorized fluorescence microscope AxioImager M2 (Zeiss) equipped with an
ApoTome. All quantitative measurements were performed using Zen software (Zeiss) and
ImageJ and evaluated with indicated statistical packages.
Cell culture
Quantitative RT-PCR. RNA was extracted from cell lines using RNeasy kit (Qiagen).
150ng RNA was reversely transcribed to cDNA (Quantitect Reverse Transcription Kit,
Qiagen). For NCALD cDNA measurements, 9ng cDNA was used for RT-PCR (LightCycler,
Roche). RT-PCR was performed in triplicates according to manufacturer’s protocol
(annealing temperature 68°C, NCALD cDNA primers: 5’-
GGAATGCCCAGAGCCCCAGTGT-3’; 5’-GCCCCAACCCCCGAGTCTTACG-3’).
Standard curve-based absolute transcript quantification was performed using Excel
(Microsoft). For statistical evaluation, the Student´s t-test was applied. For quantitative
measurements of SMN and PLS3, previously described protocols were used(Oprea et al.
2008).
Western blot analysis. Cells were lysed on ice in RIPA buffer (Sigma) containing
protease inhibitors (Complete Mini, Roche). Following primary antibodies were used: anti-
beta-actin (A5316, Sigma), anti-SMN (MANSMA7, Hybridoma Bank; 610646, BD
Biosciences), anti-NCALD (12925-1-AP, Proteintech) and clathrin heavy chain (C1860,
Sigma). Signal was detected with HRP conjugated-secondary antibodies and
Chemiluminescence reagent (Thermo Scientific) according to manufacturer´s protocol.
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siRNA-mediated RNA knockdown. For all siRNA experiments NSC34 (CLU140)32 and
PC12(Greene and Tischler 1976) cells were transfected with Dharmafect1 (Thermo
Scientific) according to manufacturer´s protocol. siTOX (Dharmacon) and AllStars
Negative Control (Qiagen) siRNA were used as controls. siRNAs sequences: mmu-Smn:
5’-AAGAAGGAAAGTGCTCACATA-3’; mmu-Ncald 5’-CAGGTGATTCACCCATTATAA-3’;
rn-Smn 5’-CCCGACCTGTGAAGTAGCTAA-3’; rn-Ncald 5’-
AGAGACTTCCTAGCAATTTAA-3. After incubation, cells were harvested for protein
isolation or imaging. Every experiment was performed at least in triplicates.
Transient overexpression. Human NCALD cDNA was cloned into pcDNA™3.1⁄CT-GFP
TOPO using primers NCALD-FWD 5’-ATGGGGAAACAGAACAGCAAG-3’ and NCALD-
REV 5’-GAACTGGCCGGCACTGCTC-3’ (IDT) and manufacturer’s protocol (Invitrogen).
To overexpress human NCALD-GFP, NSC34 cells were transfected with Dharmafect1
according to manufacturer´s protocol.
NCALD co-immunoprecipitation. NSC34 cells transiently transfected with
pcDNA™6⁄FLAG-His-NCALD or control vector were lysed in the following buffer: 50mM
Tris/HCl, 5% (w/v) glycerol, 270mM sucrose, 0.5%(v/v) Tween 20, 0.1%(v/v) β-
mercaptoethanol, pH7.5, with protease inhibitor cocktail (Complete Mini, EDTA-free,
Roche). Immunoprecipitations were performed in 1mM EGTA/1mM EDTA or in the
presence of 100µM free Ca2+. Cell lysates were immunoprecipitated with FLAG-M2 affinity
beads (Sigma) under gentle agitation overnight at 4°C. Bound proteins were eluted in
laemmli buffer (240mM Tris-HCl, pH6.8, 6% SDS, 30% (v/v) glycerol, 0.06% bromophenol
blue (w/v), 16%(v/v) β-mercaptoethanol) and analyzed by Western blots were performed
as described above.
Primary motor neuron culture. Spinal cords were dissected from E13.5 mouse
embryos(Hsieh-Li et al. 2000). Neurons were singularized with trypsin (Worthington) and
DNAse (Sigma), sieved, plated on poly-D-lysine/laminin (Sigma) coated coverslips and
cultured in neurobasal medium with B27 supplement, 2mM L-glutamine, 1x pen-strep
(Invitrogen) containing 50ng/µl, BDNF, 50ng/µl GCNF and 50ng/µl CNTF (Peprotech) at
37C in a humidified incubator with 5%CO2.
Immunocytochemistry. Cells were cultured on laminin-coated coverslips, washed with
PBS, fixed in 4%PFA/4%sucrose (AppliChem), permeabilized in PBS-T
(PBS/0.2%Tween20 (AppliChem)) and blocked in blocking solution (PBS-T/5%BSA
(Sigma)/5%FCS (Biochrom)). Cells were incubated with blocking solution containing
primary antibodies (α-HB9 (1:100), AB2145209, Hybridoma Bank; α-Synaptic vesicle 2,
AB2315387, (SV2-c), Hybridoma Bank; α-Neurofilament, AB2314897, (2H3-c), Hybridoma
Bank; α-Choline Acetyltransferase (CHAT), AB144P, Millipore; α-Tau, sc-390476, Santa
Cruz; α-NCALD) overnight at 4°C. After washing in PBS, cells were incubated with
secondary antibodies labelled with AlexaFluor488, AlexaFluor647 or AlexaFluor568
(Invitrogen) in PBS, optionally with phalloidin-AlexaFluor568 (Invitrogen). Cells were
washed and mounted on objects slides with Mowiol (Sigma) for imaging.
Endocytosis Assay. Fibroblasts were plated in DMEM (Invitrogen) and starved for 10min
in starvation media (DMEM transparent (HEPES), 2%FKS) prior to FITC-Dextran
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treatment (5mg/ml, Sigma) for respective time periods at 37°C. Subsequently, cells were
washed with ice-cold PBS and fixed in 4%PFA for 10min. After washing, cells were stained
with phalloidin-AlexaFluor568 and DAPI (Invitrogen) and mounted with Mowiol for imaging.
Flow Cytometry Analysis. NSC34 cells were transfected with indicated siRNAs for 48h
prior to 6h starvation and incubation with 5mg/ml FITC-Dextran (Sigma) for 20min at 37°C.
Cells were trypsinized (Trypsin, Sigma) on ice and washed with PBS. Uptake of FITC-
Dextran was measured with FACS Calibur (BD Biosciences) and analyzed with Cyflogic
software (www.cyflogic.com). Dead cells were excluded by propidium iodide staining
(10µg/ml, Sigma).
Ca2+ current recordings in NSC34 and PC12. Whole-cell recordings were performed at
24°C.  Electrodes (tip resistance 2.5-3 MΩ) were made of borosilicate glass (0.86mm OD,
1.5mm ID, Science Products) with a temperature-controlled pipette puller (PIP5, HEKA
Elektronik) and filled with solution containing (in mM) 133 CsCl, 1 CaCl2, 2 MgCl2, 10
HEPES and 10 EGTA, adjusted to pH7.2 and osmolarity of 415mOsm. During
experiments, cells were constantly superfused with saline solution containing (in mM) 84
NaCl, 20 CsCl, 2.5 KCl, 10 CaCl2, 2 MgCl2, 10 HEPES and 30 glucose, adjusted to pH7.3
and osmolarity of 310mOsm. To isolate Ca2+ currents, a combination of pharmacological
blockers and ion substitution were used. Transient voltage-gated Na+ currents were
blocked by tetrodotoxin (10-6M TTX, T-550, Alomone). 4-Aminopyridine (4AP, 4×10-3M,
A78403, Sigma) blocked transient K+ currents (IA) and tetraethylammonium (TEA, 2×10-
3, Sigma) blocked sustained K+ currents (IK(V)) and Ca2+-activated K+ currents (IK(Ca)). The
pipette solution did not contain potassium. Whole-cell voltage-clamp recordings were
made with EPC10 patch-clamp amplifier (HEKA Elektronik) controlled by Patchmaster
program (V2x53, HEKA-Elektronik). Electrophysiological signals were low-pass filtered at
2.9kHz (3pole Bessel filter). Data were sampled at 50µs intervals (20kHz). The offset-
potential and capacitance were compensated using ‘automatic mode’ of EPC10 and liquid-
junction potential between intracellular and extracellular solution of 2.5mV (calculated with
Patcher’s PowerTools plug-in, http://www.mpibpc.gwdg.de/abtei-
lungen/140/software/index.html (WaveMetrics)) was compensated. Whole-cell
capacitance was determined using EPC10 capacitance compensation (C-slow). To
remove uncompensated leakage and capacitive currents, p/6 protocol was
used(Armstrong and Bezanilla 1974). Voltage errors due to series resistance (RS) were
minimized using RS compensation of EPC10 to 70-80% with 100µs time constant (τ).
Animal models
Zebrafish experiments. All experiments were performed with the transgenic line tg(mnx1-
GFP)ml2TG (Flanagan-Steet et al. 2005)and approved by the local animal protection committee
(LANUV NRW; reference number 84-02.04.2012.A251).
Zebrafish injection and analysis. Morpholinos (MO) were designed against the
translational start codons of respective genes (Gene Tools, LLC). smn-MO: 5’-
CGACATCTTCTGCACCATTGGC-3’; ncaldb-MO: 5’-
GGAGCTTGCTGTTTTGTTTTCCCAT-3’; control-MO: 5’-
CCTCTTACCTCAGTTACAATTTATA-3’. For NCALD mRNA injections, human NCALD
cDNA was cloned into pCS2+ mRNA expression vector and transcribed in vitro using
162
mMESSAGE mMACHINE® SP6 Transcription Kit (Ambion) according to manufacturer’s
protocol. Embryos from TL/EK wildtype and TL/EK-hb9-GFP (Flanagan-Steet et al. 2005)
crossings were used to visualize the MN phenotype. Embryos were injected with the
respective dose of MOs or mRNA in aqueous solution containing 0.05% PhenolRed and
0.05% Rhodamine-Dextran (Sigma). 6h after injection embryos were sorted according to
homogeneity of the rhodamine fluorescence signal.
Immunohistochemistry for motor axon quantification. 34hpf zebrafish were manually
dechorionated, fixed in 4% PFA-PBS and permeabilized by collagenase digest of the
whole animal. To visualize the primary motor axons, zebrafish were incubated at 4°C
overnight in PBS-T/1%DMSO/10%FCS containing znp-1 antibody (AB2315626,
Hybridoma Bank) and stained in PBS-T/1%DMSO/10%FCS containing donkey anti-
mouse secondary antibody labelled with AlexaFluor488 (Invitrogen) after all-day washing
in PBS-T/1%FCS/1%BSA (changing solution hourly) and stored in 80% glycerol/20% PBS
in the dark at 4°C or embedded in low-melting agarose microslides for microscopy
analysis. The structure of first ten motor axons posterior to the yolk was analyzed, rated
as: 1) normal, 2) truncated (truncation ventral from midline), 3) severely truncated (shorter
than midline), 4) branched I (branching ventral from midline), 5) branched II (branching at
midline), or 6) branched III (branching dorsal from midline).
Western blot analysis of zebrafish. 48hpf dechorionated embryos were gently spinned-
down, sacrificed by incubation on ice and lysed in RIPA buffer (Sigma) containing protease
inhibitors (Complete Mini, Roche). Following primary antibodies were used for overnight
incubation: anti-beta-actin (zebrafish) (553399, Anaspec), anti-SMN and anti-NCALD.
Signal detection was performed as described above.
Transmission electron microscopy of zebrafish. 48hpf zebrafish were ﬁxed in 4%PFA
for 30min and postﬁxed in 0.6% glutaraldehyde for another day. Samples were prepared
and embedded in resin as previously described (Ackermann et al. 2013). The thickness of
semi-thin and ultra-thin sections was 0.5 and 0.1mm, respectively. For immunogold
stainings, pre-stained sections were blocked, incubated with primary antibodies (anti-
clathrin, anti-NCALD), washed in PBS and stained with gold-labelled secondary antibodies
(donkey-anti-mouse 6nm gold, ab39616, goat-anti-rabbit 20nm gold, ab27237; Abcam).
Image acquisition was performed with TEM CM10 (Philips) microscope, Orius SC200W 1
Gatan camera and the Digital Micrograph software.
Motor behaviour analysis of zebrafish. 30 zebrafish treated with respective MOs were
placed in 10cm petri dish containing embryo medium. To trigger a swimming response,
zebrafish were stimulated with an electrical impulse (60V; delay: 60ms, duration: 4ms,
frequency: 6pps (SD9 Stimulator)). Swimming behaviour was recorded with 120
frames/second using a high-speed camera (FC-100, Casio). Swimming velocity and
distance were analyzed using LoliTrack software (Loligo Systems).
Endocytosis inhibitor treatment. Dynasore (dynamin inhibitor) and Pitstop2 (clathrin
inhibitor) (Abcam) were dissolved as stock solutions (50mM) in DMSO. Zebrafish were
dechorionated and incubated with the respective inhibitors in the medium starting at 16hpf
at 28°C on a rocking platform (20rpm) until fixed in 4%PBS-PFA at 34hpf. Subsequent
zebrafish immunohistochemistry was performed as described above.
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Electrophysiology. 72hpf zebrafish (control, smn-, ncald-, and smn+ncald-morphants)
were anesthetized with 0.02% tricaine (in saline; Sigma) for 1-2min and rinsed with saline
containing (in mM): 134 NaCl, 2.9 KCl, 2.1 CaCl2, 1.2 MgCl2, 10 HEPES, 10 glucose
adjusted to pH7.8. Zebrafish were decapitated and pinned under saline in a Sylgard-
coated (Dow Corning) recording chamber (~3ml volume). Skin was removed using a
tungsten pin and forceps; preparation was incubated in 3M formamide (in saline; Carl
Roth) for 2min to prevent muscle contractions. After rinsing the preparation, the superficial
layer of ventral slow muscle cells was removed by scratching with a tungsten pin to expose
deeper fast skeletal muscle cells and remaining superficial slow muscles were removed
with a low resistance pipette (~2 MΩ). The preparation was continuously superfused with
saline at a flow rate of ~2ml/min1. Experiments were carried out at ~24°C. Muscle cells
were visualized with a fixed-stage upright microscope (Zeiss Axio Examiner, Zeiss), using
a 40x water immersion objective (Zeiss) with infrared-differential interference contrast and
fluorescence optics. Fast muscle cells were identified by their orientation to the spinal cord
and ability to generate action potentials.
Caenorhabditis elegans experiments. Caenorhabditis elegans strains. LM99 smn-
1(ok355)I/hT2(I;III)(Briese et al. 2009), HA1981 +/hT2(I;III), HA2530 +/hT2(I;III);ncs-
1(qa401)X, HA2531 smn-1(ok355)I/hT2(I;III);ncs-1(qa401)X, HA2599 +/hT2(I;III);uIs72,
HA2623 smn-1(ok355)I/hT2(I;III);uIs72, were maintained at 20°C under standard
conditions. +/hT2 strains used as control for genetic background; RNAi studies were
undertaken in a sensitized background (transgene uIs72) expressing the SID-1 dsRNA
channel in neurons (Calixto et al. 2010).
C. elegans pharyngeal pumping. Pharyngeal grinder movement in any axis was scored
as a pumping event. Average pumping rates (±SEM) were combined from at least three
independent trials (n ≥ 25 animals in total). For RNAi knockdown, animals were reared for
two generations (F2) on either control vector L4440 or C44C1.3/ncs-1(RNAi) in HT115.
ncs-1 RNAi clone contains genomic DNA amplified by primers 5’-
AAATCGTCTAGCTGTAGTGTCGC-3’ and 5’-TTGTGCTCCCTACACTTTGTTTT-3’
inserted into L4440. Clone was verified by sequencing.
Mouse experiments. All mouse experiments were approved by LANUV NRW (reference
number 9.93.2.10.31.07.186 and 84-02.04.2014.A 126). The Taiwanese SMA mice
(FVB.Cg-Tg(SMN2)2Hung Smn1tm1Hung/J, Stock Number:005058) and heterozygous
Ncaldko/wt (B6N(Cg)-Ncaldtm1.1(KOMP)Vlcg/J, Stock Number:018575) were purchased from
Jackson Laboratory. The severe SMA (SMA) mouse model and the corresponding
heterozygous (HET) mice were produced as previously described (Hsieh-Li et al. 2000,
Riessland et al. 2010). The breeding scheme and genotypes for SMA-Ncaldko/wt and HET-
Ncaldko/wt are similar to SMA+ASO treated mice (Fig. 5a), except that all animals were on
congenic C57Bl/6N and untreated.
Primers used for mouse genotyping: mmu SmnKOfw: ATAACACCACCACTCTTACTC;
mmu SmnKOrev1: 5`-AGCCTGAAGAACGAGATCAGC-3`; mmu SmnKOrev2: 5`-
TAGCCGTGATGCCATTGTCA-3`; hsa SMN2fw: 5`-
CGAATCACTTGAGGGCAGGAGTTTG-3`; hsa SMN2rev 5`-
AACTGGTGGACATGGCTGTTCATTG-3`; mmu NcaldKOfw: 5`-
CGGTCGCTACCATTAC-3`; mmu NcaldKOrev: 5`-GCATGTGTGACAACAG-3`.
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A mild SMA mouse model was produced by suboptimal subcutaneous injection of severe
SMA mice (50% FVB/N: 50% C57BL6/N) on P1 with 30µg of SMN-ASO (IONIS
Phamaceuticals) using a MICROLITER syringe (Hamilton). The SMN-ASO was diluted as
previously described19. SMA-Ncaldko/wt+ASO and HET-Ncaldko/wt+ASO were produced
using the breeding scheme in Fig. 5a. Unless stated otherwise, all mouse experiments
were performed double-blinded.
Mouse motoric tests. Righting reflex test was performed as previously described (El-
Khodor et al. 2008). Righting time scores were evaluated as followed: 0-2s=1; 3-4s=2; 5-
6s=3; 7-8s=4; 9-10s=5; ≥11s=6. Muscle strength was assessed in P73 SMN-ASO injected
mixed50 background mice by the animal’s grasp of a horizontal metal bar mounted to a
high-precision force sensor (Grip strength meter, TSE Systems). Muscle force was
recorded in pounds and converted to Newton [N].
Quantification of proprioceptive inputs. Analysis of proprioceptive input on MN soma
was performed as described (Hosseinibarkooie et al. 2016). The spinal cord was dissected
from euthanized mice and fixed in 4% PFA overnight. The lumbar L4-L5 region was rinsed
in PBS, embedded in tissue freezing medium (Jung) after cryoprotection (first day: 20%
sucrose, second day: 30% sucrose) and sliced into 100µm sections (cryostat, Leica).
Samples were permeabilized, blocked in PBS/4% BSA/1% Triton/PBS for 1h and
incubated with anti-CHAT and anti-VGLUT1 (135303, Synaptic Systems) antibodies
overnight. Samples were washed and incubated with secondary antibodies (donkey anti-
rabbit AlexaFluor488, donkey anti-goat AlexaFluor568) and mounted in Mowiol. Images
were taken in Z-stacks of 30-60 slices of 0.3µm interval. Proprioceptive input numbers on
MN and MN soma size were quantified using the ImageJ software.
Quantification of NMJ size and maturity. The TVA muscle was prepared at the indicated
time points, fixed in 4%PFA for 20min and stained with anti-Neurofilament M (Hybridoma-
Bank), secondary goat-anti mouse AlexaFluor488 and Bungarotoxin (Invitrogen, labeled
with AlexaFluor555). Surface area of Bungarotoxin-positive post-synapse was measured
by ImageJ with threshold set to the method established by Li. NMJ immaturity index was
analyzed as described previously(Bogdanik et al. 2015): NMJs exhibiting ≥ 3 perforations
were evaluated as mature, NMJs with < 3 perforations as immature.
FM1-43 endocytic uptake at NMJ under electrical stimulation. FM1-43 endocytic
uptake at NMJ under electrical stimulation was undertaken as recently described
(Hosseinibarkooie et al. 2016). Three animals per genotype and stimulation set were used.
Imaging was performed as described above. All imaging processes and analyses were
performed double-blinded. Images were analyzed with ImageJ using a macro setting and
Li threshold method applied to the postsynaptic terminals to delineate the area of interest
in the presynaptic site.
Statistical analysis. If not mentioned otherwise, all statistical analyses were performed
using software programs Excel 2013 (Microsoft), GraphPad Prism 6 (GraphPad Software)
and Sigma Plot 11 (Systat Software); ANOVA, Mann-Whitney U-test, Fisher´s exact test
or unpaired two-tailed Student’s t-tests were applied. All data are represented as
mean±SEM/SD. Significance of RNA expression and protein levels was tested using a
directional student's t-test for uncorrelated samples. For experiments performed in
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C.elegans, Mann-Whitney-U test analysis was performed. Significance in the differences
of mouse behavioral analyses, NMJ and muscle fiber surface area size, motor axon length,
proprioceptive inputs on MNs, NSC34 neurite length and width of the synaptic cleft was
determined by the use of 1-way ANOVA or directional student's t-test for uncorrelated
samples. Survival was analyzed using Kaplan-Meier method by log rank test.
For all studies using mice, animals numbers were calculated prior to experiments by power
calculation using the G*Power 3.1.7 software (Power=0.8 and alpha-error=0.05). Endpoint
criteria for mouse experiments were defined in animal application prior to experiments.
Animal samples were processed equally and allocated to experimental groups post-
analysis. For all other experiments, sample size was estimated based on the known
variability of the assay.
Values of P<0.05 were considered significant. In all cases, three levels of statistical
significance were distinguished: *P<0.05, **P<0.01 and ***P<0.001.
Specific statistical tests, sample size and P-values are indicated in the Fig. legends.
Statistical analysis of electrophysiology. Data were analyzed using Spike2 and
statistical analysis was performed in GraphPad Prism 5.05 (GraphPad Software). All
calculated values are expressed as mean±SEM. The EEP frequencies for each cell were
measured as mean frequencies over 30s intervals. Frequencies before and during NMDA
application were compared by a paired t-test for each group. A Kruskal-Wallis test followed
by Dunns multiple comparisons was used to compare EPP frequencies in different groups.
A significance level of P<0.05 was accepted for all tests.
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SUPPLEMENTAL FIGURES AND LEGENDS
Supplementary Figure 1 Pedigree showing of Utah family segregation of identified
variants. (CT insertion in intron1 of NCALD and 17 bp deletion upstream of NCALD) on
chromosome 8.
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Supplementary Figure 2. NCALD downregulation restores neurite outgrowth in SMN-
deficient neuronal cells, NCALD overexpression induces membrane blebbing. (a)
Representative images and quantification of neurite outgrowth of NSC34 cells treated with
respective siRNAs (50nm) and differentiated with retinoic acid (1µm RA). 4 days after
siRNA transfection and 3 days after RA treatment Smn siRNA cells showed neurite
outgrowth defects. Smn+Ncald siRNA cells showed a phenotype rescue and an outgrowth
comparable to control siRNA cells. Cells were stained with Phalloidin-Alexa Fluor 568.
Scale bar, 200 µm. N = 100 cells per treatment; ***P <0.001; dashed line = mean (control
siRNA: 138.32 µm; Smn siRNA: 101.35µm; Ncald siRNA: 185.9 µm; Smn+Ncald siRNA:
150.36 µm), line=median (control siRNA: 122.5 µm; Smn siRNA: 87.5 µm; Ncald siRNA:
165 µm; Smn+Ncald siRNA: 135 µm). (b) Representative image of an NSC34 cell
overexpressing GFP or NCALD-GFP. Significant membrane blebbing is present only in
the NCALD-GFP overexpressing cell. Inset shows detail of membrane blebbing. Scale bar,
10 µm. (c) Quantification of neurite outgrowth length of NSC34 cells transfected either with
GFP or NCALD-GFP and treated with 1µm RA for 3 days and stained with Phalloidin-
rhodamine. NCALD-GFP cells showed reduced neurite length. N = 100; ***P < 0.001.
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Supplementary Figure 3. Overview of motor neuron phenotype after downregulation or
overexpression of NCALD and characterization of electrophysiological properties of
zebrafish muscles and swimming behavior of zebrafish. (a) Representative overview of
motor axon outgrowth phenotype of 34 hpf morphants (including pictures from main Figure
3). Significant truncation phenotype of smn morphants is corrected by additional ncald KD.
Scale bar, 100 µm. (b) Representative overview of motor axon outgrowth phenotype of 34
hpf zebrafish after human NCALD mRNA injection. Quantification shows the dose-
dependent truncation phenotype of zebrafish overexpressing NCALD. Scale bar, 100µm.
First 10 motor axons posterior to the yolk were evaluated in every fish. n ≥200 motor axons
per mRNA injection. (c) Fluorescence image of the recording situation. A wild-type ventral
fast muscle cell was filled with rhodamine dextran (red) during a whole-cell patch-clamp
recording. The muscle cell (m) is innervated by GFP-labeled motor neurons (green)
indicated by the arrowhead. The muscle cell spans one myotome. Scale bar, 20 µm. (d)
Whole-cell current clamp recordings of zebrafish muscles. Diagram shows original whole-
cell current clamp recordings of mEPPs: at rest, during 1 µM TTX, -and during
simultaneous TTX- and 100 µM NMDA-application. NMDA application failed to increase
muscle action potentials in the presence of TTX. mEEP amplitude and frequency are not
TTX-sensitive. (e) Means of 30 EPPs in the absence or presence of 1 µM TTX. (f) Bar
graph of high-speed camera swimming velocity measurement of 48 hpf zebrafish embryos
(N = 30 per treatment). After LoLitracker software evaluation, mean swimming velocity is
given in arbitrary units.
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Supplementary Figure 4. Characterization of NCALD KD in SMA mice: survival, weight
progression and proprioceptive inputs on motor neurons: NCALD KD ameliorates the input
number but not cell size. (a) Mean survival of SMA mice on pure C57BL/6N: SMA =
12.9±3.2 days, N = 28, SMA-Ncaldko//wt = 13.1±5.3 days, N = 22. (b) The weight of SMA
and SMA-Ncaldko/wt mice is reduced significantly from P5 onwards when compared to HET
and HET-Ncaldko/wt. Error bars indicate SD. N >20 for each genotype. (c) The MN cell
volume [µm3] of SMA and SMA-Ncaldko/wt is significantly smaller in comparison to HET. (d)
Analysis of proprioceptive inputs on spinal MN relative to cell volume: individual values of
input number were plotted against cell volume and linear regression was drawn. The
number of proprioceptive inputs in SMA-Ncaldko/wt MN is increased independently of cell
volume and input number/cell volume ratio was similar in SMA-Ncaldko/wt and HET-
Ncaldko/wt MN. N = 3/genotype, n = 100-120 MN/animal. ***P < 0.001. Box plots defined in
Figure 5.
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Supplementary Figure 5 SMN-ASO functionality testing, tail length and weight
progression in the SMA+ASO mouse model. (a) Western blot of spinal cord, brain and liver
lysates of P4-old control-ASO or SMN-ASO injected mixed50 HET or SMA mice. SMN
levels were increased in the liver, but not in the brain or spinal cord after SMN-ASO
injection. Beta-Actin (ACTB) was used as loading control. (b) Tail length of SMN-ASO
injected mixed50 mice was measured weekly; tail necrosis in SMA+ASO (N = 7) and SMA-
Ncaldko/wt+ASO (N = 9) mice started between the 6th and 8th week after birth. Control mice:
HET+ASO (N = 9); HET-Ncaldko/wt+ASO (N = 10). Error bars indicate SD. (c) Weight of
female (F) and male (M) of SMN-ASO injected mixed50 mice was measured weekly.
SMA+ASO (F = 7, M = 5), SMA-Ncaldko/wt+ASO (F = 4, M = 9), HET+ASO (F = 7, M = 9),
HET-Ncaldko/wt+ASO (F = 8, M = 9). Error bars indicate SD.
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Supplementary Figure 6 Voltage induced Ca2+ dynamics of cells treated with Smn siRNA
or Smn+Ncald siRNA; impact of Ca2+ on endocytosis. (a) Ratiometric Ca2+ imaging with
fura-2 in differentiated PC12 cells showed that the increase in cytosolic Ca2+, which is
triggered by KCl-induced, is reduced in SMN depleted cells (N = 3, n = 41) compared to
control cells (N = 3, n = 38); P<0.001. (b) Immunogold staining of NMJs of 48 hpf control
zebrafish embryos. Ncald is visualized by secondary antibody labelled with 20 nm gold
particle (big black dots) and clathrin with 6 nm gold particle (small black dots). Ncald (white
arrows) is localized to synaptic vesicles and the active zone (az) of the presynapse and
clathrin is localized to some synaptic vesicles (black arrows); white arrowheads mark the
colocalization of Ncald and clathrin at synaptic vesicles. M = muscle fiber, T = nerve
terminal, scale bar, 100 nm. (c) Representative images of fibroblasts derived from Utah
family members, SMA patients and controls after endocytosis assay. After starvation cells
were incubated for 20 min with FITC-dextran (green), fixed and counterstained with
phalloidin-AlexaFluor 568 (red). The FITC signal is higher in asymptomatic cells. Scale
bar, 50 µm. For quantification see also Figure 6c. (d) Representative images of endocytic
FM1-43 uptake at the presynaptic terminals on P10 in TVA muscles under low frequency
stimulation (5 Hz, 1s). Postsynaptic receptors staining (BTX-Alexa647) was used to define
the area to analyze the FM1-43 uptake (orange) at the presynaptic terminals. Scale bar,
10 µm. For quantification see also Figure 6d. (e) Quantification of the FM1-43 mean
intensity at the presynaptic terminals on P10 in TVA muscles under high frequency
stimulation (20 Hz, 1s). For each genotype 3 animals and ~100 NMJs were analysed. Error
bars represent SEM. n.s. non-significant; ***P <0.001. (f) FACS-based quantification of
FITC signal in NSC34 cells treated with respective siRNA. Ncald KD resulted in elevated
FITC-dextran endocytosis. Smn KD decreased endocytosis (*P <0.05), which was fully
restored by additional Ncald KD (Smn siRNA vs. Smn+Ncald siRNA: **P <0.01 control
siRNA vs. Smn+Ncald siRNA: n.s.). N=6 biological replicates per siRNA treatment,
individual sample n=50.000 cells. (g) Quantitative analysis of motor axon phenotype of 34
hpf zebrafish, subjected to the respective treatment: 1 = ncald MO (2 ng), 2 = smn+ncald
MO (2 ng), 3 = ncald MO + Pitstop2 (12.5 µM),  4 = control +  Pitstop2 (25 µM), 5 = smn
MO + Pitstop2 (25 µM), 6 = smn MO+ncald MO + Pitstop2 (25 µM), 7 = ncald MO +
Dynasore (25 µM). Note the rescue effect of ncald MO injection on the truncation
phenotype of smn MO and 25 µM Pitstop2 treated zebrafish (bars 5 and 6).
175Appendix
SUPPLEMENTAL REFERENCES
57. Arkblad, E., Tulinius, M., Kroksmark, A.K., Henricsson, M. & Darin, N. A
population-based study of genotypic and phenotypic variability in children with
spinal muscular atrophy. Acta Paediatr 98, 865-872 (2009).
58. Armstrong, C.M. & Bezanilla, F. Charge movement associated with the opening
and closing of the activation gates of the Na channels. The Journal of general
physiology 63, 533-552 (1974).
59. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing [Royal Statistical Society, Wiley] 57, 289-
300 (1995).
60. Calixto, A., Chelur, D., Topalidou, I., Chen, X. & Chalfie, M. Enhanced neuronal
RNAi in C. elegans using SID-1. Nat Methods 7, 554-559 (2010).
61. Dunning, M.J., Barbosa-Morais, N.L., Lynch, A.G., Tavare, S. & Ritchie, M.E.
Statistical issues in the analysis of Illumina data. BMC Bioinformatics 9, 85 (2008).
62. El-Khodor, B.F., et al. Identification of a battery of tests for drug candidate
evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp
Neurol 212, 29-43 (2008).
63. Greene, L.A. & Tischler, A.S. Establishment of a noradrenergic clonal line of rat
adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl
Acad Sci U S A 73, 2424-2428 (1976).
64. Sun, Y., et al. Molecular and functional analysis of intragenic SMN1 mutations in
patients with spinal muscular atrophy. Hum Mutat 25, 64-71 (2005).
65. Wettenhall, J.M. & Smyth, G.K. limmaGUI: a graphical user interface for linear
modeling of microarray data. Bioinformatics 20, 3705-3706 (2004).
66. Zerres, K., Wirth, B. & Rudnik-Schoneborn, S. Spinal muscular atrophy--clinical
and genetic correlations. Neuromuscul Disord 7, 202-207 (1997).
176
9 Publications, talks, poster presentations and scholarships
Publications:
*Kaczmarek A, *Schneider S, Wirth B, Riessland M
Investigational therapies for the treatment of spinal muscular atrophy. 2015, Expert
Opinion on Investigational Drugs 24, 867-881. *authors contributed equally to this work
Hosseinibarkooie SM, Peters M, Torres-Benito L, Rastetter RH, Hupperich K, Hoffmann
A, Mendoza-Ferreira N, Kaczmarek A, Janzen E, Milbradt J, Lamkemeyer T, Rigo F,
Bennett CF, Guschlbauer C, Büschges A, Hammerschmidt M, Riessland M, Jeong MK,
Clemen CS, Wirth B
The power of human protective modifiers: PLS3 and CORO1C unravel impaired
endocytosis in spinal muscular atrophy and rescue SMA phenotype. 2016, American
Journal of Human Genetics 99, 647-665.
*Riessland M, *Kaczmarek A, *Schneider S, Swoboda KJ, Löhr H, Bradler C, Grysko V,
Dimitriadi M, Hosseinibarkooie SM, Torres-Benito L, Peters M, Upadhyay A, Biglari N,
Kröber S, Hölker I, Garbes L, Gilissen C, Hoischen A, Nürnberg G, Nürnberg P, Walter M,
Rigo F, Bennett FC, Kye MJ, Hart AH, Hammerschmidt M, Kloppenburg P, Wirth B
Neurocalcin delta suppression rescues spinal muscular atrophy species. Nature
Medicine, under review. *authors contributed equally to this work
Talks:
24.09.2014 Symposium Shaping cells and Organisms, Universität zu Köln, Cologne,
Germany
Kaczmarek A, Schneider S, Grysko V, Swoboda KJ, Riessland M, Wirth B
Investigation of ASO-mediated protective effect of modifier genes in mouse models of
spinal muscular atrophy (SMA)
23.06.2016 10th International Motoneuron Meeting, Koc University, Istanbul, Turkey
Kaczmarek A, Schneider S, Torres-Benito L, Grysko V, Upadhyay A, Riessland M,
Swoboda KJ, Wirth B
SMA modifier MOD2 improves motor neuron length and neuromuscular junction size
06.10.2016 6th Annual Human Genetics Meeting, Universität zu Köln, Cologne, Germany
Kaczmarek A, Schneider S, Torres-Benito L,Grysko V, Riessland M, Swoboda K, Wirth B
177Publications, talks, poster presentations and scholarships
Reduction of potential SMA modifier NCALD improves axonal length in vitro and
proprioceptive inputs on motoneuron soma and neuromuscular junction size in vivo
Poster presentations:
13.05.2011 3rd Annual Human Genetics Meeting, Universität zu Köln, Cologne, Germany
Kaczmarek A, Riessland M, Förster A, Swoboda KJ, Wirth B
Genetic studies of NCALD as a potential modifier in SMA
12.07.2012 1st GSfBS Alumni Day, Universität zu Köln, Cologne, Germany
Kaczmarek A, Riessland M, Swoboda KJ, Wirth B
Genetic and functional studies of MOD2 as potential modifier for SMA
29.11.2012 4th Annual Human Genetics Meeting, Universität zu Köln, Cologne, Germany
Kaczmarek A, Riessland M, Förster A, Swoboda K, Wirth B
Genetic and functional studies of neurocalcin delta (NCALD) as potential modifier for SMA
14.06.2013 17th Annual SMA Conference, Anaheim, California, USA
Kaczmarek A, Riessland M, Garbes L, Hölker I, Gilissen C, Hoischen A, Swoboda KJ,
Wirth B
Generation of a Doxycycline inducible shRNA-mediated Mod2 knockdown mouse to
analyze the protection effect on SMA
24.05.2014 5th Annual Human Genetics Meeting, Universität zu Köln, Cologne, Germany
Kaczmarek A, Riessland M, Schneider S, Wirth B
Investigation of the protective effect of NCALD downregulation on the SMA phenotype in
mice
Scholarships:
Sep 2010 - Aug 2013 Graduate scholarship from the International Graduate
School “Disease, Health and Development”
12 - 14.06.2013 Scholarship from the Initiative SMA to participate in the
17th Annual SMA Conference, Anaheim, California, USA
29.06 – 04.07.2014 Elke-Fresenius-Scholarship to participate in the 64th Lindau
Nobel Laureate Meeting
19.-23.06.2016 Scholarship from FAZIT Stiftung to participate in the 10th
International Motoneuron Meeting, Istanbul, Turkey

IXAcknowledgements
Acknowledgements
My first words of gratitude go to Prof. Brunhilde Wirth for giving me the opportunity to work
in her group on this interesting and challenging project and for generously supporting me
to learn and grow as a scientist; I am especially grateful for her help during the final stage
of this thesis.
I thank Prof. Aleksandra Trifunovic for kindly agreeing to review my thesis and Prof. Peter
Kloppenburg for taking the chair of the exam committee.
I would like to first thank Dr. Markus Rießland, the initiator of the NCALD project, for being
the best teacher, colleague and a real friend. I also thank Dr. Min Jeong Kye for motivating
me in the end phase of my thesis and keeping up my faith in science. I am very grateful to
my “older” colleagues who welcomed me in the Wirth lab: Bastian Ackermann, Anja
Förster, Lutz Garbes, Mohsen Hosseini, Irmgard Hölker, Kristina Hupperich, Miriam
Jakubik, Sandra Kröber, Lilian Martinez Carrera and Markus Storbeck – you have been
great role models and someone to look up to. Many thanks to my “younger” colleagues:
Eva Janzen, Miriam Peters, Natalia Mendoza-Ferreira, Janine Milbradt and Andrea Delle
Vedove – I have truly enjoyed working next to all of you. My special thanks go to the
“NCALD group”: Vanessa Grysko, who I was honoured to call “my” technician, and Svenja
Schneider (this would not be possible without you two), Laura Torres-Benito and Aaradhita
Upadhyay – you all are my favourite people and have a very special place in my heart.
I would also like to thank all the colleagues from other groups at the Institute of Human
Genetics, Cologne: AG Kye, AG Wollnik, AG Beck, AG Schreml and AG Netzer, as well
as our wonderful Dr. Uwe Becker.
I would like to acknowledge our numerous collaborators on the NCALD project at the
University of Cologne and beyond: Prof. Kathryn Swoboda, Prof. Peter Kloppenburg and
his group, Prof. Matthias Hammerschmidt and his group, and especially our collaborators
from Ionis Pharmaceuticals, who have always generously provided me with ASOs. I thank
Dr. Ralf Kühn for providing me the ES cells and plasmids for mouse generation. My
gratitude goes to Peter Zentis and Dr. Astrid Schauss for their assistance with image
analysis. My work has also been greatly supported by the animal caretakers at the Centre
for Mouse Genetics at the Institute of Genetics, University of Cologne.
The following words go to my family who have supported me throughout all these not so
easy years with their love and faith: Mimo że byliście daleko, sercem byliście zawsze ze
mną i Wasze wsparcie było dla mnie bezcenne. Dziękuję Wam za to i bardzo Was kocham.
Finally, my deepest gratitude goes to my dear Bartosz “Pablo” Kaczmarek, who has been
there for me every step of the way. You are my beloved husband and my best friend and
I am looking forward to the rest of our lives together.
XErklärung
Ich versichere, dass ich die von mir vorgelegte Dissertation selbstständig angefertigt, die
benutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit –
einschließlich Tabellen, Karten und Abbildungen – die anderen Werken im Wortlaut oder
im Sinn nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich gemacht habe;
dass diese Dissertation noch an keiner anderen Fakultät oder Universität zur Prüfung
vorgelegen hat; dass sie noch nicht veröffentlicht worden ist sowie, dass ich eine solche
Veröffentlichung vor Abschluss des Promotionsverfahrens nicht vornehmen werde. Die
Bestimmungen dieser Promotionsordnung sind mir bekannt. Die von mir vorgelegte
Dissertation ist von Prof. Dr. Brunhilde Wirth und Prof. Dr. Peter Kloppenburg betreut und
in der Arbeitsgruppe von Prof. Dr. Brunhilde Wirth durchgeführt worden.
Teilpublikationen liegen nicht vor.
Ich versichere, dass ich alle Angaben wahrheitsgemäß nach bestem Wissen und
Gewissen gemacht haben und verpflichte mich, jedmögliche, die obigen Angaben
betreffenden Veränderungen, dem Promotionsausschuss unverzüglich mitzuteilen.
…………………………………… …………………………………..
Datum Unterschrift
XILebenslauf
Lebenslauf
 Persönliche Daten
Name Kaczmarek
Familienname Koper
Vorname Anna
Geburtsdatum 17.06.1985
Geburtsort Sucha Beskidzka, Polen
Nationalität Polnisch
 Schulausbildung
1991 – 1999 Henryk-Sienkiewicz-Grundschule Nr. 1, Makow
Podhalanski, Polen
1999 – 2003 Bartlomiej-Nowodworski-Lyzeum Nr. 1, Krakow, Polen,
mit dem Abschluss des Abiturs (Mai 2003)
 Akademische Ausbildung
Okt 2003 – Juli 2009 Studium der Angewandten Linguistik an der Adam-
Mickiewicz-Universität, Poznan, Polen
Akademischer Abschluss: Master of Arts
Masterarbeit: Institut für Angewandte Linguistik, unter Anleitung
von Prof. Dr. Alicja Sakaguchi
Titel: Analyse der Bezeichnungen und Attributen Gottes in
deutschen und polnischen religiösen Texten
Okt 2004 – Juli 2009 Studium der Biotechnologie an der
Naturwissenschaftlichen Universität, Poznan, Polen
Akademischer Abschluss: Master of Science
Masterarbeit: Department of Genetics and Animal Breeding, unter
Anleitung von Dr. Ewelina Warzych-Plejer
Titel: Evaluation of the developmental competence of
swine oocytes based on the transcript analysis of
genes ATP5A1 and EEF1A1
XII
 Praktikum
August 2009 – Mai 2010 DAAD-Stipendium am Institut für
Humangenetik, Universität Leipzig, unter
Anleitung von Prof. Dr. med. Ursula Froster
Forschungsprojekt: Evaluierung der HRMA (High Resolution
Melting Analysis) als Verfahren zur Mutation-
Screening bei APC- und BRCA 2-Genen
 Dissertation
Sep 2010 – Aug 2013 Stipendium der International Graduate
School for Disease, Health and Development
Sep 2013 – Okt 2016 Wissenschaftlicher Mitarbeiter an der
Uniklinik Köln
Dissertation Institut für Humangenetik, unter der
Anleitung von Prof.Dr.rer.nat. Brunhilde Wirth
Titel Analysis of reduced Neurocalcin delta
(NCALD) as a protective modifier in mouse
models of Spinal Muscular Atrophy (SMA)
Köln, den 10.10.2016 Anna Kaczmarek
